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The investigation of human imprinting disorders has provided important insights into 
the role of genomic imprinting in normal health and development. Beckwith-
Wiedemann syndrome (BWS) is a congenital overgrowth disorder associated with 
abnormal function of 11p15.5 imprinted genes that’s result, most commonly, from 
the epimutation (loss of maternal allele methylation) at the imprinting centre 
KCNQ1OT1:TSS-DMR (BWS_IC2). In contrast, Silver-Russell syndrome (SRS) is 
characterised by pre- and postnatal growth retardation and, most commonly, 
epimutations (loss of paternal allele methylation) at H19/IGF2:IG-DMR. Using 
Infinium 450K methylation array, I performed methylation profiling at 46 imprinted 
differentially methylated regions in 90 BWS and 21 SRS patients. I report 
epimutations at other imprinting centres outside of chromosome 11p15.5 in 40% of 
BWS_IC2 but not in SRS_IC1. The investigation of the potential underlying causes 
of this multilocus methylation disturbances (MLID) epigenotype in BWS_IC2 
individuals indicated that several factors might contribute to the BWS phenotype and 
MLID epigenotype. Although not a universal finding, the use of assisted reproductive 
technology was significantly associated with MLID in my cohort of BWS_IC2 
patients. Furthermore, using whole-exome sequencing strategy, I describe new 
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The term epigenetics was first coined by Waddington in 1942 (Waddington 1942). 
Originally, it referred to the complex mechanisms at work that link genotype to 
phenotype. Since then, the term has changed in meaning and the most widely 
accepted definition designates every mechanism that results in reversible heritable 
(via meiosis or mitosis) changes altering gene expression without alterations to the 
DNA sequence itself (Probst et al. 2009). 
 
The epigenetic mechanisms capable of switching genes from an ON to OFF state 
are initiated and sustained by at least three systems. This includes not only DNA 
methylation, which is the most broadly studied and well-characterised epigenetic 
modification, but also the post-translational modification of histone proteins and 
RNA-mediated gene silencing. These systems are highly interactive with each other 
in order to maintain efficient gene expression regulation (Figure 1.1). Any 
unscheduled compromise at any of these levels can have dramatic effects on gene 





Figure 1.1. Interaction between RNA, histone modification and DNA 
methylation in heritable gene silencing. 
Chromatin condensation resulting from histone deacetylation or the methylation of 
the lysine 9 within histone H3 residues can lead to transcriptional repression. The 
post-translational modification of histones can also attract and trigger the DNA 
methylation machinery (DNA methyltransferases) which in turn can reinforce the 
transcriptional silencing initiated by the histone modification patterns. RNA 
interference could also trigger chromatin remodelling through the modification of 
histones or the methylation of DNA and therefore results in gene silencing. (Adapted 
from Egger et al. 2004). 
 
 
1.1.1 DNA methylation 
The methylation of DNA is a heritable epigenetic mark referring to the covalent 
transfer of a methyl group from S-adenosyl-L-methionine to the fifth carbon of a 
cytosine. Consequently, this modification results in a 5-methylcytosine (5-mC) 
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in symmetrical cytosine-phosphate-guanine (CpG) context, although rare non-CpG 
(CpH, where H is adenine, thymine or cytosine) methylation occurs (Ramsahoye et 
al. 2000; Ziller et al. 2011). 
 
In somatic cells, DNA methylation generally affects 70-80% of all CpG sites. Highly 
methylated sequences are found at repetitive genomic regions, including satellite 
DNA, long interspersed transposable elements (LINEs) and short interspersed 
transposable elements (SINEs), at non-repetitive intergenic DNA and at exons of 
genes. In contrast, CpG islands (CGI), which are on average 1000 base pairs long 
GC-rich regions with high CpG density, are generally unmethylated. CGI are found 
predominantly at sites of transcription initiation including the gene promoters of 
approximatively 60% of human genes (Bird 2002; Deaton and Bird 2011; E. Li and 
Y. Zhang 2014). 
 
Historically, DNA methylation has been linked to transcriptional repression but other 
critical roles in the control of genomic imprinting (Bartolomei and Ferguson-Smith 
2011; Ferguson-Smith 2011) (see section 1.2 - Genomic imprinting) and the 
inactivation of the X chromosome in females (Sharp et al. 2011) or the maintenance 
of the genome integrity (Eden et al. 2003) have been described. 
 
1.1.1.1 Life cycle 
In the life cycle of an individual, the genome undergoes several dynamic changes in 
DNA methylation (Figure 1.2). These modifications take place at different times and 
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involve different pathways. During the maturation of the primordial germ cells (PGCs) 
of an embryo, DNA methylation is erased through genome-wide demethylation 
event. Following sex determination, the male (blue line) and female (red line) germ 
cells acquire new gametic methylation profile via global de novo DNA methylation. 
This process takes place at different times between the male and female germ cells. 
In the male embryo, the de novo DNA methylation is established during 
prospermatogonia and is completed before birth. In the female embryo, the de novo 
DNA methylation is established after birth during oocytes growth. In the zygote, a 
second wave of epigenetic reprogramming occurs. During the pre-implantation 
period, genome-wide DNA methylation marks from the paternal and maternal 
genome are erased. This mechanism takes place at different times for both parental 
genomes. After implantation, the embryo re-acquires a new epigenetic profile, which 
is associated with cell differentiation, through genome-wide de novo methylation. 
The DNA methylation in genomic imprinted regions escapes this second global 





Figure 1.2. Dynamic changes in DNA methylation during PGCs maturation, 
fertilisation and embryo development. 
(From Smallwood and Kelsey 2012). 
 
 
1.1.1.2 The machinery 
1.1.1.2.1 De novo DNA methylation 
In mammals, DNA methylation is catalysed by DNA methyltransferase (DNMT) 
enzymes. The methylation patterns are established during embryonic development 
by the de novo methylating enzymes DNMT3A and DNMT3B (Okano et al. 1998; 
Okano et al. 1999) and the non-catalytic activating co-factor DNMT3L (Bourc'his et 
al. 2001; Bourc'his and Bestor 2004) (Figure 1.3). The deletion of mouse Dnmt3b 
results in substantial global loss-of-methylation and embryonic lethality (E. Li et al. 
1992; Okano et al. 1999; Bostick et al. 2007). Similarly, the Dnmt3a knockout mice 
lack methylation but are, for a few weeks, partially viable (Okano et al. 1999). Finally, 
Dnmt3L knockout mice are viable, but lack de novo methylation in the germline 
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associated with male sterility and embryonic lethality of maternal null-derived 
embryos (Bourc'his et al. 2001; Hata et al. 2002; Bourc'his and Bestor 2004). 
 
 
Figure 1.3. De novo methylation mechanism. 
De novo methylation is catalysed by the DNA methyltransferases DNMT3A, 
DNMT3B and supported by the non-catalytic DNMT3L. 
 
 
1.1.1.2.2 DNA methylation maintenance 
During replication, the maintenance methylating enzyme DNMT1 localises at the 
replication fork on the parental methylated strand and restores methylation to the 
newly synthesised unmethylated strand (Leonhardt et al. 1992). For the faithful 
DNMT1-mediated reproduction of the methylation profile that is present in the parent 
cell, the maintenance mechanism also requires the protein UHRF1 (ubiquitin like 
with PHD and ring finger domains 1; also known as NP95 or ICBP90) which 
recognises and targets DNMT1 to hemi-methylated CpG residues (Figure 1.4). The 
deletion of mouse Dnmt1 or Uhrf1 results in substantial global loss-of-methylation 





Figure 1.4. DNA methylation maintenance mechanism. 
The DNA methyltransferase DNMT1, supported by UHRF1, maintains the DNA 
methylation at hemi-methylated CpG during DNA replication 
 
 
1.1.1.2.3 DNA demethylation 
DNA demethylation can be achieved by one of two mechanisms; a passive 
replication-dependant process or an active enzyme-catalysed and replication-
independent process. 
 
1.1.1.2.3.1 Passive DNA demethylation 
Global loss of 5-mC in mitotic cells can be achieved through the gradual passive 
dilution of the methylation mark over subsequent cleavage division due to DNA 
replication. Additionally, the gradual loss of 5-mC is performed in the absence or 
exclusion of both de novo and maintenance DNA methylase activity, including 
DNMT1, DNMT3A, DNMT3B and DNMT3L, and the key cofactor UHRF1 (P.A. 




1.1.1.2.3.2 Active DNA demethylation 
Loss of 5-mC can also be achieved via indirect and active mechanisms. Active 
genome-wide DNA demethylation is mostly achieved by the iterative oxidation of 5-
mC to 5-hydroxymethylcytosine (5-hmC) and further to 5-formylcytosine (5-fmC) and 
5-carboxycytosine (5-caC) by the ten-eleven translocation enzymes, TET1 and 
TET2 (He et al. 2011; Inoue et al. 2011; Ito et al. 2011; Hackett et al. 2013). 5-hmC, 
5-fmC and 5-caC marks are then lost during replication since it is inefficiently 
recognised by DNMT1 (Inoue et al. 2011; Hashimoto et al. 2012) (Figure 1.5-bottom 
panel, red arrow). Alternatively, an enzyme-catalysed DNA demethylation 
mechanism involves the deamination of 5-mC to thymine by the DNA deaminases 
AID (activation-induced cytidine deaminase) and APOBEC1 (apolipoprotein B 
mRNA editing enzyme, catalytic polypeptide 1). The thymine base resulting from the 
resulting T:G mismatch is recognised and removed by the thymine-DNA glycosylase 
(TDG) or the methyl-CpG-binding domain protein 4 (MBD4). The base excision 
repair (BER) machinery recognises the abasic site and reinstates an unmodified 
cytosine, effectively resulting in removal of the methyl mark (Morgan et al. 2004; 
Maiti and Drohat 2011) (Figure 1.5-top panel, red arrow). Finally, it is also suggested 
that TDG, MBD4 or a yet unidentified glycosylase can directly recognise and remove 
the 5-hmC, 5-fmC and 5-caC marks. The BER pathway will then repair the resulting 
abasic site and reinstate an unmodified cytosine (He et al. 2011; Inoue et al. 2011; 
Maiti and Drohat 2011; Shen et al. 2013; Messerschmidt et al. 2014) (Figure 1.5-





Figure 1.5. DNA demethylation mechanism. 
Passive DNA methylation is achieved via absence of DNMT and UHRF1 during 
subsequent round of cell division (middle panel, blue arrow). Possible active DNA 
demethylation mechanisms: AID/APOBEC1 can deaminate 5-mC to thymine, which 
in return can be excised by TDG/MBD4 and repaired by BER (top panel, red arrows). 
Alternatively, 5-mC can be lost via the TET-mediated oxidation of 5-mC to 5-hmC/5-
fC/5-caC. The iterative oxidised 5-mC is then lost during replication or removed by 
TDG/MBD4 and repaired by BER (bottom panel, red arrows). 
 
 
1.1.2 DNA methylation and transcriptional regulation 
Several lines of evidence demonstrated that DNA methylation can regulate gene 




1.1.2.1 Direct regulation 
DNA methylation can mediate gene silencing through the direct inhibition of the 
binding of specific transcription factors to their targets (Figure 1.6). This was first 
demonstrated in HeLa cells in which the binding of the transcription factor MLTF 
(major late transcription factor) to DNA was affected by DNA methylation, hence 
leading in the silencing of the adenovirus major late promoter (Watt and Molloy 
1988). The investigation of additional transcription factors, including CREB (cAMP 
response element-binding protein), c-Myc and E2F (E2 factor), further validated the 
model (Iguchi-Ariga and Schaffner 1989; Prendergast and Ziff 1991; Campanero et 
al. 2000). 
 
1.1.2.2 Indirect regulation 
DNA methylation mediated gene silencing can also be achieved indirectly through 
the recruitment of methyl-CpG-binding domain (MBD) proteins, including MeCP2 
(methyl-CpG-binding proteins 2), MBD1, MBD2, MBD3 and MBD4, at methylated 
promoter regions. In return, MBD proteins recruit at methylated sites additional 
repressor complexes associated with the remodelling of chromatin and the covalent 
modification of histones. Finally, this mechanism results in the compaction of the 
chromatin (i.e. heterochromatin state) leading to transcriptional repression (E. Li and 
Y. Zhang 2014) (Figure 1.6-a). Several lines of evidence have validated this model. 
The protein MeCP2 recruits the co-repressor molecule SIN3A (transcriptional 
regulator, SIN3A) and the histone deacethylases (HDAC) HDAC1 and HDAC2 at 
CpG methylated sites. The consequent transcriptional repression is then achieved 
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via HDAC-mediated chromatin remodelling (P.L. Jones et al. 1998; Nan et al. 1998). 
Furthermore, the protein MBD2 was shown to recruit the nucleosome remodelling 
and deacetylase (NuRD) co-repressor complex, which comprises HDAC enzymes 
and large ATP-dependent chromatin remodelling proteins CHD3 (chromodomain 
helicase DNA binding protein 3) and CHD4 (chromodomain helicase DNA binding 
protein 4), at CpG methylated sites. This results in the deacetylation of histone 
proteins, the compaction of chromatin and consequently to gene silencing (Feng and 
Y. Zhang 2001). Finally, the protein MBD1 was shown to recruit the histone lysine 
methyltransferase SETDB1 (SET domain bifurcated 1) during the S phase of the cell 
cycle when DNA replication occurs. Subsequently, SETDB1 methylates the lysine 9 
of the histone H3 (H3K9me) hence resulting in transcriptional repression (Sarraf and 
Stancheva 2004). 
 
DNA methylation can also indirectly mediate gene silencing through the DNA 
methylation-dependant binding of the insulator protein CTCF (CCCTC-binding 
factor) (Bell et al. 1999; Bell and Felsenfeld 2000; Hark et al. 2000; Murrel et al. 
2004; Kurukuti et al. 2006). The absence of methylation allows the protein CTCF to 
bind to the DNA. The binding of CTCF can lead to the formation of chromatin loops 
and the establishment of an active chromatin domain that could include genes, gene 
promoters and enhancers and an inactive chromatin domain that could include 
genes and gene promoters, away from enhancers. The interactions between gene 
promoters located in the inactive chromatin domain and their enhancers located in 
the active chromatin domain are blocked by the CTCF insulating activity. This 
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mechanism results in genes silencing (Figure 1.6-b, left panel). In contrast, DNA 
methylation prevents the protein CTCF to bind to the DNA and the creation of the 
associated chromatin boundaries. Gene promoters previously located within the 
inactive chromatin domain are now free to interact with their enhancers, hence 
leading to gene expression (Figure 1.6-b, right panel). 
 
Figure 1.6. DNA methylation-mediated gene silencing. 
(a) DNA methylation inhibits binding of transcription factors, hence leading to gene 
silencing. Alternatively, DNA methylation can recruit MBD proteins which in turn 
associate with histone modification proteins, hence inducing chromatin remodelling 
and gene silencing. (b) The absence of DNA methylation allows the binding of the 
insulator protein CTCF which in turn blocks interaction between gene promoters and 
enhancers, hence leading to genes silencing. DNA methylation inhibits the binding 
of CTCF which in turn allows interaction between gene promoters and enhancers, 
hence leading to genes expression. Chromatin looping is the proposed mechanism 
by which CTCF boundary elements separate active and silent and active chromatin 
domains (grey area). 
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1.2 Genomic imprinting 
Mammals are diploid organisms whose cells possess two matched sets of 
chromosomes, one inherited from the mother and one from the father. Thus, 
mammals have two copies of every gene. In usual physiological state, most genes 
are biallelically expressed which means that both of the maternal and paternal allele 
of the gene is active. A minority of genes, probably numbering 100 in humans and in 
mice, are subject to genomic imprinting and show differences in expression 
according to the parental origin of the allele (Catalogue of Parent of Origin Effects, 
http://igc.otago.ac.nz/home.html (Morison et al. 2001)). 
 
The machinery regulating genomic imprinting must fulfil different properties. It must 
influence transcription via the deliberate silencing of one allele of specific genes 
according to whether the allele comes from the father or the mother. The imprinting 
marks need to be placed onto parental inherited chromosomes at a time they are not 
in the same nucleus (i.e. during gametogenesis). Subsequently, following fertilisation 
the marks needs to be transmitted to the somatic lineages of the male and female 
offspring. Finally, an erasure mechanism must ensure that the imprinting marks are 
removed and replaced in the new female or male germline (Bartolomei and 
Ferguson-Smith 2011; Ferguson-Smith 2011). Considering these properties, DNA 
methylation fulfils these criteria and is described as one of the main mechanisms 
regulating genomic imprinting. However, other mechanisms including allele-specific 
RNA transcription, antisense transcripts, histone modifications and differences in 
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replication timing are also thought to be involved in the genomic imprinting regulatory 
machinery (Barlow and Bartolomei 2014). 
 
1.2.1 Historical overview 
The notion of genomic imprinting was first described in a series of experiments 
aiming to understand the inheritance of the maize kernel coloration (Kermicle 1970). 
The author noted that the maize kernels were solidly coloured when the R allele (i.e. 
the allele responsible for the coloration) was carried by the female gametes but, 
surprisingly, were mottled when carried by the male gametes. The author suggested 
that the R allele might function differently accordingly to the parental origin of the 
carrier (Kermicle 1970). 
 
In 1974, genetic studies on mice demonstrated that the maternal-inheritance of a 
deletion at the Tme (T-associated maternal effect) locus located on chromosome 17 
resulted in death at birth or in utero. In contrast, the paternal-inheritance of the 
deletion resulted in less abnormal and viable embryos (Johnson 1974). This 
suggested a differential contribution between the maternal and paternal allele. 
 
Around that time, the researchers studying familial cases with Beckwith-Wiedemann 
Syndrome (BWS; see 1.3 - Beckwith-Wiedemann Syndrome) noted that BWS 
affected male and female offspring were born from female carriers only. These 
observations supported the idea that a parent-of-origin effect was associated with 
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the familial BWS phenotype (Lubinsky et al. 1974). 
 
In the 1980’s, pronuclear transplantation in newly fertilised mouse eggs aiming to 
remove and replace the paternal pronucleus with a second maternal one (i.e. 
generating a parthenogenic conceptus) and vice versa (i.e. generating an 
androgenic conceptus), resulted in the failure of embryos to develop normally. The 
parthenogenic mouse embryos developed tissues predominantly of embryonic origin 
but failed to develop the extra-embryonic lineages. In contrast, the androgenic 
mouse embryos developed predominantly extra-embryonic lineages but lacked, or 
had very underdeveloped, embryonic components. Consequently, it was suggested 
that mammalian genomes possess some genes that may be imprinted in different 
ways on the two parental genomes, making the presence of both maternal and 
paternal genome essential for normal embryonic development (McGrath and Solter 
1983; Surani and Barton 1983; McGrath and Solter 1984; Surani et al. 1984). 
 
In 1985, mouse genome engineering aiming to create regions of uniparental disomy 
by the introduction of reciprocal translocations resulted in mice with anomalous 
phenotypes which depart from normal in opposite directions. The discrete regions 
involved in the anomalous phenotypes were suggested to be subject to parent-of-
origin effects (Cattanach and Kirk 1985). Interestingly, the study of non-Mendelian 
human disorder showed very similar inheritance to phenotypes seen in the disomic 
mice. As an example, paternally-inherited deletion of a region encompassing 
chromosome 15q11q13 results in Prader-Willi syndrome whereas the maternal-
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inheritance of the deletion results in a very different clinical disorder, Angelman 
syndrome. This suggested that the paternal and maternal contribution of a gene or 
genes in region 15q11q13 were required for normal human growth and development 
(Nicholls et al. 1989). 
 
In the early 1990’s, several research groups identified three endogenous imprinted 
genes (Igf2r, Igf2 and H19) in mice. The Igf2r gene encodes for the insulin-like 
growth factor 2 receptor and is located within the Tme locus previously described to 
be subject to a parental-origin effect (see above). Igf2r was found to be maternally 
expressed and paternally silenced (Barlow et al. 1991). The Igf2 gene encodes for 
the insulin growth factor 2 and was identified as a paternally expressed imprinted 
gene and maternally silenced (DeChiara et al. 1991; Ferguson-Smith et al. 1991). 
Finally, the H19 gene (imprinted maternally expressed transcript) encodes for a long 
non-coding RNA that may have a tumour suppressor activity (Hao et al. 1993; 
Yoshimizu et al. 2008). H19 was identified as maternally expressed and paternally 
silenced (Bartolomei et al. 1991). Additionally, H19 is located 90 kb downstream of 
the Igf2 imprinted gene, hence supporting the idea that imprinted genes can be 
clustered together. Finally, it was shown that the imprinting status of a gene may also 
be tissue-specific. The biallelic expression of Igf2 has been described in the choroid 
plexus and leptomeninges of the brain whilst, as mentioned above, it is exclusively 
expressed from the paternally-inherited chromosome in the embryo (DeChiara et al. 
1991). Similarly, the imprinted gene Dlk1 (Delta-like homologue 1), normally 
expressed from the paternally-inherited chromosome, has been described to be 
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biallelicaly expressed in the postnatal neurogenic niche (Ferrón et al. 2011). 
 
Finally, not long after the identification of the first endogenous imprinted genes it was 
shown that both parental genomes were differentially marked by DNA methylation at 
imprinting regions (Bartolomei et al. 1993; Ferguson-Smith et al. 1993; Stöger et al. 
1993). In these reports, the imprinted differentially methylated regions (DMRs), 
mainly known as imprinting centres (ICs) or imprinting control regions (ICRs), were 
shown to be cis-acting elements controlling the expression of nearby or distant 
cluster of imprinted genes (Figure 1.7). Imprinted DMRs can be classified in germline 
imprinted DMRs and somatic (or secondary) imprinted DMRs. Germline imprinted 
DMRs exhibit differences in methylation states between the sperm and the egg. 
These differences are maintained post-fertilisation. In contrast, at somatic imprinted 
DMRs the DNA methylation is acquired after fertilisation but is still parent-of-origin 
specific (Woodfine et al. 2011). The parental-specific DNA methylation pattern at ICs 
is essential to maintain genomic imprinting and the disruption of the normal 
methylation pattern leads to aberrant imprinted gene expression (E. Li et al. 1993) 




Figure 1.7. Genomic imprinting. 
Gene X, Y and Z are imprinted genes and their gene expression is regulated by a 
cis-acting imprinting centre (blue oval). Methylation at the maternal imprinting centre 
leads to the expression of Gene Y and silencing of Gene X and Gene Z. On the 
paternal chromosome, the imprinting centre is unmethylated which leads to 
expression of Gene X and Gene Z but silencing of Gene Y. 
 
 
1.2.2 Life cycle of genomic imprinting 
The life cycle of genomic imprinting in mammals consists of three major steps: 






Figure 1.8. Life-cycle of genomic imprinting. 
In the primordial germ cells, global methylation, including at imprinted regions, is 
erased via active and passive demethylation. Once devoid of methylation, the DNA 
methyltransferases DNMT3A, DNMT3B, further enhanced by DNTM3L, ensure re-
methylation of the genome, including imprinted regions, via de novo methylation 
activity. After fertilisation, ZFP57, DPPA3 and DNMT1 protect the imprinting 
methylation marks against the epigenetic reprogramming events that take place 
during the pre-implantation (genome-wide demethylation) and post-implantation 
(genome-wide de novo methylation) period. (From Sanchez-Delgado et al. 2016). 
 
 
1.2.2.1 Imprinting erasure 
Erasure of imprinting methylation occurs in primordial germ cells (PGCs) at an early 
stage during differentiation of the female and male germlines. This global 
demethylation ensures the somatic cell epigenetic profile is completely erased. This 
epigenetic reprogramming is also required for the pluripotency of future germ cells, 
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imprinting switching and for the prevention of the inheritance of epigenetic defects 
(Morgan et al. 2005). The methylation erasure is achieved in a two-step process 
involving both passive (see section 1.1.1.2.3.1 - Passive DNA demethylation) and 
active (see section 1.1.1.2.3.2 - Active DNA demethylation) demethylation. Initially, 
PGCs proliferate actively, ensuring replication-dependent global passive 
demethylation (Kagiwada et al. 2013). This mechanism is further enhanced by the 
transcriptional silencing of the DNA methyltransferases Dnmt1, Dnmt3a, Dnmt3b 
and Dnmt3L and the key cofactor Uhrf1 (P.A. Jones and Taylor 1980; Kurimoto et al. 
2008; Seisenberger et al. 2012; Kagiwada et al. 2013). A second wave of global 
active demethylation takes place during the migration of the PGCs to the genital 
ridge which are the precursors of the gonads (Hajkova et al. 2002; J. Lee et al. 2002). 
This active second epigenetic event involves the deamination of 5-mC to thymine by 
AID/APOBEC1, followed by the thymine excision by TDG or MBD4 and finally the 
repair of the resulting abasic site by the BER pathway (Morgan et al. 2004; Hajkova 
et al. 2010; Maiti and Drohat 2011). Alternatively, the TET enzymes can catalyse the 
oxidation of 5-mC to 5-hmC/5-fC/5-caC (He et al. 2011; Inoue et al. 2011; Ito et al. 
2011; Hackett et al. 2013). The resulting oxidised products can be lost and replaced 
by unmodified cytosine through DNA replication (Inoue et al. 2011; Hashimoto et al. 
2012) or via excision by TDG, MBD4 or an un-identified glycosylase followed by 
repair by the BER pathway (He et al. 2011; Inoue et al. 2011; Maiti and Drohat 2011; 





1.2.2.2 Imprinting establishment 
Once devoid of methylation, the PGCs undergo global genome re-methylation to 
acquire the gametes new epigenetic states. This includes the establishment of 
germline sex-specific methylation at imprinted loci. The timing of acquisition of 
imprinting methylation marks is different between the male and female germline. In 
the male germline, the DNA methylation imprint is established prenatally in 
prospermatogonia (Davis et al. 1999; Ueda et al. 2000; J.-Y. Li et al. 2004). In the 
female germline, the DNA methylation imprint is established asynchronously at 
different loci but in all cases completed postnatally during the oocyte growth (by the 
metaphase II) (Lucifero et al. 2002; Lucifero et al. 2004). The de novo DNA 
methyltransferase DNMT3A, helped by the enzymatically inactive DNA 
methyltransferase DNMT3L to stimulate its activity and stabilise its binding to the 
unmodified lysine 4 of histone 3 (H3K4me0), gives rise to the methylation profile of 
the gametes including the sex-specific germline imprints (Bourc'his et al. 2001; 
Kaneda et al. 2004; Suetake et al. 2004; Ooi et al. 2007). Additional mechanisms 
also take part to this de novo DNA methylation establishment. In the oocytes, the 
acquisition of methylation at the maternal imprinted DMR Gnas (GNAS (guanine 
nucleotide binding protein, alpha stimulating) complex locus) requires the active 
transcription of the Nesp transcript, which initiates furthest upstream in this imprinted 
domain (Chotalia et al. 2009). This relationship between transcription and 
establishment of DNA methylation in the oocytes is not exclusive to the imprinted 
Gnas locus. Intragenic methylated CpG islands are enriched at active transcription 
units compared to intragenic unmethylated CpG islands. Additionally, methylated 
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promoter CpG islands are more frequently found at overlapping transcript regions 
compared to unmethylated promoter CpG islands (Smallwood et al. 2011). Besides 
an active transcription, the presence of the histone H3K4 demethylase KDM1B 
(lysine demethylase 1B) is also required during oogenesis for the acquisition of DNA 
methylation at a subset of imprinted loci (Cicconne et al. 2009). The establishment 
of DNA methylation failed at the maternal imprinted DMRs Mest (mesoderm specific 
transcript), Grb10 (growth factor receptor bound protein 10), Plagl1 (pleiomorphic 
adenoma gene-like 1) and Impact (impact, RWD domain protein) in KDM1B-deficient 
oocyte whilst the acquisition of DNA methylation at the maternal imprinted DMRs 
Kcnq1ot1 (KCNQ1 overlapping transcript 1), Snrpn (small nuclear ribonucleoprotein 
N) and Igf2r are not affected by the absence of KDM1B. In the sperm, the PIWI-
interacting RNA machinery is required for the establishment of DNA methylation at 
the paternal imprinted DMR Rasgrf1 (RAS protein-specific guanine nucleotide-
releasing factor 1) but not at other imprinted paternal loci (Watanabe et al. 2011). 
 
1.2.2.3 Imprinting maintenance 
The paternal and maternal epigenetic imprints established in the germline are 
transmitted to the zygote through fertilisation and maintained faithfully throughout  
development and adulthood. Furthermore, the maintenance mechanism also 
protects the imprint against global embryonic epigenetic reprogramming events that 
take place before and after implantation. During pre-implantation, global epigenetic 
remodelling takes place and consists of erasing the epigenetic information presents 
on parental genomes. Global methylation is lost via the fast-active demethylation of 
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the paternal genome (Oswald et al. 2000) and the subsequent slow passive 
demethylation of both paternal and maternal genomes (Rougier et al. 1998; Santos 
et al. 2002). However, the newly established methylation marks at imprinted regions 
is strikingly fully resistant to the reprogramming. Several proteins are involved in this 
protection and maintenance mechanism. This includes the maternal and zygotic 
DNA methyltransferase DNMT1 (Howell et al. 2001; Hirasawa et al. 2008), the 
developmental pluripotency-associated protein 3 DPPA3 (also known as STELLA or 
PGC7) (T. Nakamura et al. 2007) and the Krüppel-associated box (KRAB) domain 
and 7 zinc fingers protein ZFP57 (X. Li et al. 2008). After implantation, the differential 
methylation at genomic imprinting regions is maintained by both DNMT1 and UHRF1 
(Bostick et al. 2007; Sharif et al. 2007). In parallel, the unmethylated imprinted alleles 
escape another global epigenetic change that takes place at that time. This global 
epigenetic event consists of a wave of global de novo DNA methylation resulting in 
the hypermethylation of many genes including the totipotency, pluripotency and 
germ-cell specific genes (Messerschmidt et al. 2014). The insulator protein CTCF, 
the pluripotency transcription factor POU5F1 (POU class 5 homeobox 1; also known 
as OCT4) and the permissive histone modification H3K4me2/3 were shown to be 
involved in this protection pathway (N. Engel et al. 2006; Demars et al. 2010). 
 
1.2.3 Consequences of aberrant genomic imprinting 
It is widely believed that imprinted genes that are paternally expressed are 
associated with promoting the foetal growth, which would increase the chance of the 
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offspring to survive and reproduce. In contrast, it seems that imprinted gene that are 
maternally expressed are more likely to be associated with restricting the foetal 
growth by limiting access to the mother’s nutrients and resources, which would 
increase her chance to survive and to have future offspring (Moore and Haig 1991). 
To support this theory, the knockout in mice of paternally expressed genes, such as 
Igf2, mesoderm-specific transcript (Mest) and paternally expressed gene 3 (Peg3), 
leads to foetal growth restriction (DeChiara et al. 1990; Lefebvre et al. 1998; L. LI et 
al. 1999). In contrast, the knockout in mice of maternally expressed genes, such as 
Igf2r, H19 and Grb10, is associated with foetal overgrowth (Lau et al. 1994; Leigthon 
et al. 1995; Charalambous et al. 2003). Consistently, several evidences from the 
mouse and rare human imprinting disorders suggest that imprinting predominantly 
occur in genes influencing foetal growth, brain function and neurological behavioural 
traits (Smith et al. 2006, Ishida and G. E. Moore. 2013, G.E Moore et al. 2015). 
 
As suggested above, genomic imprinting failures can have dramatic consequences 
on the normal growth and development of the embryo. Several epigenetic and/or 
genomic alterations in imprinted gene clusters and in ICs have been associated with 
a number of human diseases including cancer and imprinting disorders (IDs). The 
over expression of the growth promoting gene IGF2 and the low-level expression of 
the candidate tumour suppressor H19 have been described in the aetiology of 
various tumour types including colon, liver, lung, ovarian cancer and Wilms tumour. 
Loss-of-imprinting is also associated with IDs which are a group of ten rare but 
probably underdiagnosed congenital diseases mainly characterised by growth, 
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metabolic and neurological abnormalities. These include Angelman syndrome (AS; 
OMIM n°105830), Prader-Willi syndrome (PWS; OMIM n°176270), transient 
neonatal diabetes mellitus type 1 (TNDM1; OMIM n°601410), 
pseudohypoparathyroidism type Ib (PHP1B; OMIM n°603233), Silver-Russell 
syndrome (SRS; OMIM n° 180860), Beckwith-Wiedemann syndrome (BWS; OMIM 
n°130650), Temple syndrome (TS; OMIM n°616222), Kagami-Ogata syndrome 
(KOS; OMIM n°608149), maternal uniparental disomy of chromosome 20 syndrome 
and precocious puberty syndrome (European Network of Human Congenital 
Imprinting Disorders, http://www.imprinting-disorders.eu). In the molecular aetiology 
of IDs, the deregulation of the genomic imprinting machinery, and consequently the 
aberrant expression of imprinted genes, is achieved by four different mechanisms: 
paternal or maternal uniparental disomy (UPD), genomic imbalances 
(duplications/deletions), epimutations (disturbed methylation) or point mutations in 










Figure 1.9. Molecular mechanisms leading to imprinting disorders. 
The four different mechanisms leading to the deregulation of imprinted gene 
expression and ultimately to imprinting disorders (adapted from Eggermann et al. 
2015). 
 
1.3 Beckwith-Wiedemann Syndrome 
Beckwith-Wiedemann syndrome is a paediatric overgrowth condition firstly 
described in 1963-64 by Dr. J. Bruce Beckwith (Beckwith 1963) and independently 
by Dr. H.E. Wiedemann (Wiedemann 1964). BWS occurs once in approximately 
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every 15,000 births (Eggermann, Perez de Nanclares, et al. 2015), and is associated 
with an increased risk of various tumour types during childhood (DeBaun et al. 1998). 
 
The clinical phenotype of BWS is highly variable and while some children are 
relatively mildly affected, others have a wider range of physical problems. The 
syndrome is most commonly associated with pre- and/or postnatal overgrowth, 
macroglossia and abdominal wall defects. Additional features include visceromegaly 
(particularly kidneys, liver and pancreas), neonatal hypoglycaemia, 
hemihyperplasia, genitourinary abnormalities and placental mesenchymal dysplasia. 
Embryonal tumours such as Wilms tumour (the most frequent), hepatoblastoma, 
neuroblastoma, adrenal carcinoma and rhabdomyosarcoma, are observed in 
approximatively 7.5% of BWS patients (J.R. Engel 2000; Bliek et al. 2001; Weksberg 
et al. 2010). The vast majority of patients, with adequate treatment following 
diagnosis, survive infancy and develop normally. 
 
1.3.1 Molecular defects in BWS aetiology 
Analyses of rare chromosome 11p15 rearrangements have identified three regions, 
BWSCR1, BWSCR2 and BWSCR3, believed to play a role in BWS (Figure 1.10). 
BWSCR1 is the most frequent and most documented breakpoint and maps to a 
region of several imprinted genes including IGF2, H19, CDKN1C (cyclin dependent 
kinase inhibitor 1C) and KCNQ1OT1 (KCNQ1 opposite strand/antisense transcript 
1) (Hoovers et al. 1995). Genetic and/or epigenetic abnormalities within BWSCR1 
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can disrupt the imprinted gene expression and lead to BWS. The less frequent 
breakpoints, BWSCR2 and BWSCR3, are located 5 and 7 Mb centromeric to 
BWSCR1 respectively (Redeker et al. 1995). BWSCR2 is defined by two breakpoints 
and may be associated with BWS (Alders et al. 2000). Two zinc finger genes, 
ZNF214 and ZNF215, have been identified within BWSCR2. The ZNF215 gene is 
imprinted in a tissue-specific manner and is expressed preferentially from the 
maternal allele, whereas ZNF214 is not imprinted (Alders et al. 2000; Sofos et al. 
2011). Both BWSCR2 breakpoints disrupt two of the five alternatively spliced 
ZNF215 transcripts and parts of the 3-prime end of these splice forms are transcribed 
from the antisense strands of ZNF214. These data supported a role for ZNF215, and 
possibly for ZNF214, in the aetiology of BWS. 
 
Through a number of different mechanisms, the primary epigenetic alterations or the 
genetic alterations resulting in the disruption of the imprinting of several genes 





Figure 1.10. Localisation of the three breakpoints associated to BWS at 
chromosome 11p15. 
The more telomeric breakpoint, BWSCR1, includes IGF2, H19, CDKN1C and 
KCNQ1OT1 imprinted genes. The more centromeric breakpoints, BWSCR2 and 
BWSCR3, are respectively located 5 and 7 Mb from BWSCR1. BWSCR2 includes 
the tissue-specific imprinted gene ZNF215 and not imprinted gene ZNF214. 





Figure 1.11. Linear map of the BWS locus on 11p15.5. 
(a) Linear schematic representation of the normal parent of origin-specific imprinted 
allelic expression. (b) H19/IGF2:IG-DMR gain-of-methylation, (c) KCNQ1OT1:TSS-
DMR loss-of-methylation, (d) CDKN1C mutations and (e) H19/IGF2:IG-DMR and 
KCNQ1OT1:TSS-DMR paternal UPD. Mat, maternal; pat, paternal; OT1, refers to 
KCNQ1 antisense transcript, KCNQ1OT1. (Adapted from Choufani et al. 2010).  
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1.3.1.1 Disturbances at H19/IGF2:IG-DMR region 
The telomeric imprinting centre H19/IGF2:IG-DMR (also known as IC1, ICR1 or H19-
DMR) controls the IGF2 and H19 imprinted gene expression. H19/IGF2:IG-DMR is 
located within 2kb upstream of H19. Both IGF2 and H19 imprinted genes interact 
with the same enhancer located downstream of H19 in an enhancer-competition 
manner. The IGF2 gene encodes an embryonic foetal growth factor essential for 
normal development. IGF2 is normally paternally expressed and maternally silenced. 
H19 is a maternally expressed gene that encodes for a non-coding RNA that may 
function as a tumour suppressor (Hao et al. 1993) and is also implicated in growth 
restriction (Guo et al. 2008).  
 
H19/IGF2:IG-DMR controls the allele-specific imprinted gene expression of IGF2 
and H19 in two distinct ways. IGF2 gene expression is regulated by the methylation-
sensitive insulator activity of the protein CTCF that can bind to several CTCF binding 
sites within the H19-IGF2 imprinted domain. That includes at the H19/IGF2:IG-DMR 
imprinted centre, at a site upstream to the IGF2 gene, at a centrally conserved region 
between IGF2 and H19 and at a site downstream of the enhancer (Figure 1.11-a). 
Once bind to the DNA, CTCF recruits the protein complex cohesin and each of the 
resulting CTCF/cohesin complexes interact with each other, hence forming 
chromatin loops and generate aboth active and inactive chromatin domain (Figure 
1.11-a and Figure 1.12). The H19 gene expression is regulated by a secondary 
DMRs located within the H19 promoter. The methylation of the secondary DMR is 
acquired somatically and is mediated by H19/IGF2:IG-DMR (Hark et al. 2000; Bell 
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and Felsenfeld 2000; Srivastava et al. 2000; Murrel et al. 2004; Nativio et al. 2011) 
(Figure 1.11-a and Figure 1.12). 
 
In normal conditions, H19/IGF2:IG-DMR is unmethylated on the maternal allele and 
methylated on the paternal allele. The absence of methylation on the maternal 
H19/IGF2:IG-DMR allows the insulator protein CTCF to bind to its target within 
H19/IGF2:IG-DMR, which in turn recruits the cohesin protein complex. The newly 
formed CTCF/cohesin complex at H19/IGF2:IG-DMR can then interact with the other 
CTCF/cohesin sites located upstream to the IGF2 gene and downstream to the 
enhancer. This leads to the formation of chromatin loops that isolate IGF2 and its 
promoter to an inactive chromatin domain away from the enhancer. As a result, the 
IGF2 gene promoter can’t interact with the enhancer and IGF2 is silenced. H19 and 
the enhancer are located within the same active chromatin loop and they are free to 
interact. This interaction and the absence of methylation at the H19 secondary DMR 
lead to H19 gene expression (Figure 1.11-a and Figure 1.12). In contrast, the 
presence of DNA methylation on the paternal H19/IGF2:IG-DMR prevents the 
insulator protein CTCF to bind to CTCF binding sites within H19/IGF2:IG-DMR. This 
results in the exclusion of H19/IGF2:IG-DMR from the CTCF/cohesin interacting 
region. The exclusion of H19/IGF2:IG-DMR results in IGF2 and its promoter to locate 
in an active chromatin domain near to the enhancer. This allows the interaction 
between IGF2 promoter with its enhancer and consequently leads to IGF2 gene 
expression. The methylation at H19 promoter inhibits H19 gene expression and this 
gene silencing is reinforced by the loss of interaction between H19 promoter and its 
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enhancer (Hark et al. 2000; Bell and Felsenfeld 2000; Srivastava et al. 2000; Murrel 
et al. 2004; Nativio et al. 2011) (Figure 1.11-a and Figure 1.12). 
 
Figure 1.12. Proposed model for the monoallelic expression of IGF2 and H19. 
 (Adapted from Nativio et al. 2011). 
 
In BWS, the biallelic expression and the upregulation of IGF2 gene play a critical role 
in the molecular aetiology of BWS (Maher and Reik 2000) and sporadic tumours 
(Tycko 2000; Schofield et al. 2001). The primary isolated epigenetic alteration or in 
association with an underlying genomic alteration resulting in the gain-of-methylation 
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(GOM) of H19/IGF2:IG-DMR (i.e. both paternal and maternal H19/IGF2:IG-DMR are 
methylated) is responsible for the disruption of IGF2 and H19 imprinted gene 
expression (Figure 1.11-b). The main genomic alterations associated with the GOM 
of H19/IGF2:IG-DMR are variable length maternally inherited microdeletions 
removing a subset of the CTCF binding sites within the IC (Sparago et al. 2004; 
Prawitt, Enklaar, Gärtner-Rupprecht, et al. 2005; De Crescenzo et al. 2011; Beygo, 
Citro, et al. 2013). In addition, OCT4/SOX2 binding sites located within H19/IGF2:IG-
DMR have been found to be important to maintain the unmethylated profile of the 
maternal allele (Poole et al. 2012). Accordingly, maternally-inherited point mutations 
disrupting conserved OCT4/SOX2-binding motif located in H19/IGF2:IG-DMR have 
been described in familial cases with BWS. 
 
1.3.1.2 Disturbances at KCNQ1OT1:TSS-DMR region 
The centromeric imprinting centre KCNQ1OT1:TSS-DMR (also known as IC2, ICR2 
or KvDMR1) controls the CDKN1C and KCNQ1OT1 gene expression. The CDKN1C 
(cyclin-dependent kinase inhibitor 1C; also known as p57Kip2) gene encodes for a 
negative regulator of cell proliferation (M.H. Lee et al. 1995; Tsugu et al. 2000). In 
human, CDKN1C is imprinted and primarily expressed from the maternal allele, 
though some expression (5 to 30%) is observed from the paternal chromosome 
(Chung 1996; Hatada et al. 1996). KCNQ1OT1 is a paternally expressed non-coding 
RNA with antisense transcription to KCNQ1 (potassium voltage-gated channel 
subfamily Q member 1). The 5’ end of KCNQ1OT1 transcript overlaps with the 
differentially methylated imprinting centre KCNQ1OT1:TSS-DMR (M.P. Lee et al. 
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1999; Smilinich et al. 1999; Cerrato et al. 2002) (Figure 1.11-a). 
 
The expression of the imprinted genes located at the KCNQ1OT1:TSS-DMR locus 
are controlled by the KCNQ1OT1 non-coding RNA negative regulator of gene 
expression activity and the CTCF enhancer blocking activity. On the paternal allele, 
KCNQ1OT1:TSS-DMR is unmethylated and results in the expression of 
KCNQ1OT1. Consequently, a nuclear compartment is established in the vicinity of 
the KCNQ1OT1 locus and a KCNQ1OT1 non-coding RNA-mediated bidirectional 
(i.e. downstream and upstream) gene silencing occurs. Several imprinted genes and 
enhancers are affected by this negative regulation, including CDKN1C and its 
respective enhancer (Pandey et al. 2008). This repressor activity is further facilitated 
by the binding of the insulator protein CTCF to the unmethylated paternal 
KCNQ1OT1:TSS-DMR. Similarly to the H19/IGF2:IG-DMR, the binding of CTCF to 
the unmethylated IC represses the interactions between CDKN1C and its enhancer 
located downstream of KCNQ1OT1:TSS-DMR. This results in the CDKN1C gene 
silencing. In contrast, the maternal KCNQ1OT1:TSS-DMR is methylated and results 
in the silencing of KCNQ1OT1. Subsequently, the absence of the KCNQ1OT1 
transcript leads to CDKN1C gene expression. CDKN1C gene expression is further 
enhanced by the lack of the enhancer blocking activity associated with the absence 
of CTCF binding (Algar et al. 2011) (Figure 1.11-a). 
 
KCNQ1OT1 biallelic expression and CDKN1C biallelic silencing play critical role in 
BWS. The primary loss-of-methylation (LOM) of KCNQ1OT1:TSS-DMR (i.e. both 
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paternal and maternal KCNQ1OT1:TSS-DMR are unmethylated) results in the 
disruption of KCNQ1OT1 and CDKN1C imprinting. Consequently, this epimutation 
leading to the biallelic expression of KCNQ1OT1 and the biallelic silencing of 
CDKN1C results in BWS phenotype (Figure 1.11-c). Chromosome 
deletion/duplication affecting the KCNQ1OT1:TSS-DMR is rarely associated with 
BWS. However, the rare maternal inherited deletions occurring just in 
KCNQ1OT1:TSS-DMR (Niemitz et al. 2004; Algar et al. 2011) or encompassing a 
larger locus including CDKN1C (Zollino et al. 2010) have been reported. Finally, loss-
of-function mutations of the maternally-inherited CDKN1C allele are also 
documented in the aetiology of BWS (Hatada et al. 1997; Lee et al. 1997; Milani et 
al. 2014) (Figure 1.11-d). 
 
1.3.1.3 Disturbances at both H19/IGF2:IG-DMR and KCNQ1OT1:TSS-DMR 
regions 
Segmental paternal uniparental disomy (pUPD) affecting chromosome 11p15.5 is 
also described in BWS aetiology. The reported BWS cases with pUPD show somatic 
mosaicism with over expression of IGF2 due to the GOM at H19/IGF2:IG-DMR and 
biallelic silencing of CDKN1C due to the LOM at KCNQ1OT1:TSS-DMR (Henry et 
al. 1993; Slatter et al. 1994; Cooper et al. 2007) (Figure 1.11-d). 
 
1.3.1.4 Abnormality detection rate in BWS 
The LOM at KCNQ1OT1:TSS-DMR contributes to approximatively 50% of BWS 
cases. The paternal UPD of chromosome 11p15 is described in approximatively 20% 
 
38 
of cases. The GOM at H19/IGF2:IG-DMR contributes for approximatively 5 to 10% 
of BWS cases. Genetic mutations altering the maternal CDKN1C function accounts 
for approximatively 10% of cases (40 to 50% of familial BWS cases). Chromosomal 
aberrations (i.e. duplications, translocations, inversions) affecting chromosome 
11p15 are described in a minority of BWS cases (<2-4%). Finally, in 13-15% of BWS 
cases the molecular defects are yet to be elucidated (Weksberg et al. 2010; 
Eggermann, Perez de Nanclares, et al. 2015) (Figure 1.13). 
 
Figure 1.13. Enrichment of the type of abnormalities describe in the molecular 
aetiology of BWS. 
 
1.4 Silver-Russell Syndrome 
Silver-Russell syndrome is a paediatric growth retardation condition first described 
in 1953 by Dr. Silver (Silver et al. 1953) and independently by Dr. Russell in 1954 
(Russell 1954). SRS occurs once in approximatively every 75,000 to 100,000 births 
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(Eggermann, Netchine, et al. 2015). Most cases are sporadic although a few familial 
cases have been reported (Duncan et al. 1990). 
 
The clinical presentation of SRS is variable but the disease is most commonly 
associated with pre- and/or post-natal growth failure, relative macrocephaly at birth, 
a frontal bossing in early life, body asymmetry, problems feeding and/or a low body 
mass index at 2 years. Additional features include clinodactyly of the fifth finger, 
syndactyly of the second and third toes and shoulder dimples. Finally, congenital 
malformations are also associated with the disease. These include genital 
abnormalities (cryptorchidism, hypospadias, Müllerian agenesis), renal and cardiac 
defects (Netchine et al. 2007; Eggermann, Netchine, et al. 2015). 
 
1.4.1 Molecular defects in SRS aetiology 
SRS and BWS are very similar diseases in the sense that both syndromes are the 
clinical mirror to the other. Unlike BWS the exact genes causing SRS are currently 
unknown. However, several lines of evidence indicate that (epi)genetic alterations 
leading to the deregulation of the imprinted genes IGF2, CDKN1C, MEST 
(mesoderm expressed transcript; also known as PEG1) located on chromosome 
7q32 and GRB10 (growth factor receptor bound protein 10) located on chromosome 
7p11.2-p13 may be responsible for the disorder. Finally, a few SRS cases were also 
reported with abnormalities at chromosomes other than chromosome 7 and 11, 
suggesting that other genes might be involved in SRS molecular aetiology. In some 
 
40 
of these patients, additional and atypical features are also described (Abu-Amero et 
al. 2008). 
 
1.4.1.1 Disturbances at chromosome 11p15.5 
As discussed above (see section 1.3.1.1 - Disturbances at H19/IGF2:IG-DMR 
region), the expression of IGF2 is controlled by the imprinting centre H19/IGF2:IG-
DMR. IGF2 is preferentially expressed from the paternally-inherited allele and is 
maternally silenced. In mirror to BWS, the biallelic silencing of IGF2 is described in 
SRS aetiology. The LOM at the paternal H19/IGF2:IG-DMR resulting in a 
concomitant decrease in IGF2 expression was identified in SRS individuals (Gicquel 
et al. 2005). Other mechanisms leading to the IGF2 biallelic silencing have also been 
described. These very rare genetic defects include the mosaic maternal UPD of 
chromosome 11 (Bullman et al. 2008), the maternal duplication of chromosome 
11p15 encompassing both H19/IGF2:IG-DMR and KCNQ1OT1:TSS-DMR domains 
(Eggermann et al. 2005; Eggermann et al. 2010) or KCNQ1OT1:TSS-DMR domain 
only (Schönherr et al. 2007), the paternal deletions of the H19/IGF2 enhancer region 
(Grønskov et al. 2011) and the paternally-inherited IGF2 loss-of-function mutation 
(Begemann et al. 2015). 
 
Another imprinted gene located at chromosome 11p15.5 has been described in SRS 
aetiology. Gain-of-function mutations in the imprinted gene CDKN1C are normally 
associated with the IMAGe (Intrauterine Growth Restriction, Metaphyseal Dysplasia, 
Adrenal Hypoplasia Congenita, and Genital Anomalies) syndrome (OMIM n°614732) 
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which is a severe growth retardation condition overlapping with SRS. Interestingly, a 
rare maternally-inherited gain-of-function mutation in the CDKN1C gene has been 
identified in familial cases with SRS. It was subsequently suggested that the 
mutation was responsible for the SRS phenotype (Brioude et al. 2013). 
 
1.4.1.2 Disturbances at chromosome 7 
The identification of several SRS individuals with maternal UPD of chromosome 7 
(Kotzot et al. 1995; Eggermann et al. 1997; Preece et al. 1997) raised the hypothesis 
that maternally transcribed imprinted genes with predicted growth suppression 
activity or paternally transcribed imprinting gene with predicted growth promoting 
activity were located on chromosome 7 and consequently were likely to be 
responsible for the observed SRS phenotype. Key candidate genes including the 
MEST and GRB10 imprinted gene have since been proposed as causative genes. 
 
The MEST gene encodes for a member of the alpha/beta hydrolase superfamily with 
unknown function. MEST is an imprinted gene preferentially expressed from the 
paternally-inherited allele. Mest knockout mice show pre- and postnatal growth 
restriction when the mutant gene is transmitted from the father (Lefebvre et al. 1998). 
Due to the high phenotypic similarity between Mest knockout mice and maternal 
UPD 7 SRS cases, the MEST imprinted gene was suggested to be responsible for 
the disease. In one SRS patient, the identification of a 35 Mb segmental maternal 
UPD at chromosome 7q31-qter, including MEST, further supported the hypothesis 
that MEST was involved in SRS aetiology (Hannula et al. 2001). However, despite 
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this evidence, no conclusive reports indicating a clear pathogenic role of MEST has 
been found and, consequently, a MEST relevant role in SRS aetiology is 
questionable. Genetic mutations (e.g. paternal loss-of-function) leading to the 
deregulation of MEST expression have yet to be reported in SRS individuals 
(Riesewijk et al. 1998). Furthermore, the methylation analysis at the IC controlling 
MEST imprinting, MEST:alt-TSS-DMR, didn’t reveal epimutations that could 
deregulate MEST expression in SRS (S. Kobayashi et al. 2001; Schöherr et al. 
2008). 
 
The GRB10 gene encodes for a growth factor receptor-binding protein. The SH2 
(Src Homology 2) domain of human GRB10 was shown to inhibit the insulin receptor 
and insulin-like growth-factor receptor mediated mitogenesis activity. Therefore, 
GRB10 has growth suppressing activity (F. Liu and Roth 1995; O'Neill et al. 1996). 
The GRB10 gene is imprinted in an isoform and tissue specific manner. In human 
foetal brain, the parental specific gene expression is exclusively derived from the 
paternally-inherited allele. In contrast, the imprinted GRB10 isoform γ1 is maternally 
expressed in skeletal muscle. However, biallelic expression of all GRB10 isoforms 
was found in several other foetal tissues including intestine, kidney and liver 
(Blagitko et al. 2000; Hitchins et al. 2001). Several pieces of evidence suggested 
that GRB10 is a strong candidate in SRS molecular aetiology. Mice with maternal 
disomy encompassing the mouse orthologous Grb10 (located on chromosome 11) 
showed prenatal growth failure whilst the reciprocal paternal disomy resulted in the 
opposite phenotype, consisting of prenatal overgrowth (Cattanach and Kirk 1985). 
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The disruption of Grb10 imprinting via maternally inherited Grb10 mutation results in 
a disproportionate mice overgrowth phenotype with an Igf2-independent mechanism 
(Charalambous et al. 2003). Finally, the genetic investigation of SRS individuals 
revealed maternally inherited duplication at chromosome 7p11.2-p13, 
encompassing the GRB10 region, hence suggesting that GRB10 over-expression 
might be involved in SRS aetiology (Joyce et al. 1999; Monk et al. 2000; Monk et al. 
2002). However, despite this evidence, conclusive reports involving GRB10 have yet 
to be reported in SRS. The methylation analysis of the IC regulating GRB10 
expression, GRB10:alt-TSS-DMR, showed no significant changes that would 
deregulate GRB10 imprinted gene expression (Arnaud 2003; Monk et al. 2003). 
Furthermore, genetic alterations leading to GRB10 over-expression (e.g. maternal 
duplication) or biallelic expression (e.g. paternal gain-of-function) have not been 
reported in SRS individuals (Yoshihashi et al. 2000; Hitchins et al. 2001). 
 
1.4.1.3 Disturbances at other chromosome 
Copy number variations and UPD affecting chromosomes other than chromosome 
7 and 11 have been identified in cohorts of clinically diagnosed SRS patients with, in 
some individuals, additional and atypical clinical features. The majority of these rare 
defects were identified in single cases and the associated prevalence is yet to be 
determined (Abu-Amero et al. 2008). 
 
More recently, the hypomethylation of ICs located at chromosome 14, 
MEG3/DLK1:IG-DMR and MEG3:TSS-DMR, has been identified in three SRS 
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compatible individuals with no known defects at chromosome 7 or 11 (Azzi et al. 
2015; Kagami et al. 2015). These ICs control the imprinted gene expression of DLK1 
(delta like non-canonical Notch ligand 1) and MEG3 (Maternally expressed gene 3). 
In mice, the low-level expression of Dlk1 has been implicated in growth retardation 
and accelerated adiposity (Moon et al. 2002; Cleaton et al. 2016). The imprinted 
gene MEG3 is suggested to be a tumour suppressor and the loss of MEG3 
expression has been found in various types of human tumours and tumour cell lines 
(Zhou et al. 2012). These new findings at chromosome 14 imply that the maternal 
UPD of chromosome 14 and the epigenetic abnormalities affecting MEG3/DLK1:IG-
DMR and MEG3:TSS-DMR constitute a rare, but potentially important, underlying 
factors leading to SRS. Furthermore, it was interesting to note that the LOM of both 
ICs is mostly associated with Temple syndrome (TS), which is an imprinting disorder 
sharing a high degree of phenotypic overlap with SRS. Consequently, this raises the 
question if TS individuals that fit the SRS description should be classed as SRS.  
 
1.4.1.4 Abnormality detection rate in SRS 
In the general population, the LOM at H19/IGF2:IG-DMR contributes for more than 
38% of SRS cases and the maternal UPD of chromosome 7 is described in 
approximatively 10% of cases. The other mechanisms leading to SRS are very rare. 
The copy number variations (deletion/duplication) affecting H19/IGF2:IG-DMR and 
KCNQ1OT1:TSS-DMR imprinted loci, the maternal UPD of chromosome 11 and the 
genomic abnormalities affecting chromosomes other than chromosome 7 and 11 are 
responsible for less than 1-2% of SRS cases. An IGF2 loss-of-function mutation has 
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been identified in one case only. Similarly, a CDKN1C gain-of-function mutation has 
been reported in a single family with SRS. Finally, the molecular defects are yet to 
be identified for the remaining SRS cases (approximatively 40-50%) (Abu-Amero et 




Figure 1.14. Enrichment of the type of abnormalities describe in the molecular 
aetiology of SRS. 
 
1.5 Imprinting disorders and multilocus methylation 
disturbances. 
Genomic imprinting disorders are individually rare and at a clinical level they are 
usually considered distinct disorders. However, clinical features such as disordered 
 
46 
growth are common to several disorders. In some cases, a similar clinical phenotype 
may result from different types of disordered imprinting. Thus, SRS has been 
associated with epimutations at H19/IGF2:IG-DMR (SRS_IC1) on chromosome 
11p15.5 but also with maternal uniparental disomy of chromosome 7 (SRS_UPD7) 
(see section 1.4 - Silver-Russell Syndrome). Occasionally a patient may present with 
a clinical diagnosis of a specific ID but molecular investigation reveals an epigenetic 
abnormality that is associated with a clinically distinct disorder. Thus, several studies 
have reported rare patients referred with a clinical diagnosis of BWS who have LOM 
of the paternal H19/IGF2:IG-DMR allele at 11p15.5, which is characteristically 
associated with SRS (Tee et al. 2013). By opposition, rare patients were referred 
with a clinical diagnosis of SRS but have LOM of the maternal KCNQ1OT1:TSS-
DMR allele, which is characteristically associated with BWS (Azzi et al. 2009). Such 
epigenotype-phenotype inconsistencies may result from the observation that a 
subset of patients with an ID have epimutations at multiple ICs (Rossignol et al. 2006; 
Bliek et al. 2008; Mackay et al. 2008; Azzi et al. 2009; Lim et al. 2009; Turner et al. 
2010; Court et al. 2013; Poole et al. 2013; Tee et al. 2013; Maeda et al. 2014; Mackay 
et al. 2015). This phenomenon is also known as multilocus imprinting disturbances 
(MLIDs). 
 
The first evidence of MLID was reported in individuals clinically diagnosed with 
TNDM1 and carrying not only a LOM at the PLAGL1:alt-TSS-DMR, epimutation 
accounting for approximatively 20% of TNDM1 cases, but also hypomethylation at 
KCNQ1OT1:TSS-DMR, which is the main epimutation associated with BWS (Arima 
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2005; Mackay et al. 2006) (see section 1.3 - Beckwith-Wiedemann Syndrome). 
Since then, MLID has been identified in approximatively 50% of TNDM1 individuals 
with LOM at PLAGL1:alt-TSS-DMR (Mackay et al. 2008), in approximatively 25% of 
BWS with LOM at KCNQ1OT1:TSS-DMR (Rossignol et al. 2006; Bliek et al. 2008; 
Azzi et al. 2009; Court et al. 2013; Poole et al. 2013; Tee et al. 2013; Maeda et al. 
2014), in approximatively 10% of SRS individuals with LOM at H19/IGF2:IG-DMR 
(Azzi et al. 2009; Turner et al. 2010) and in approximatively 12.5% of PHP1B 
individuals carrying isolated epimutation at the GNAS imprinting region (Perez-
Nanclares et al. 2012; Court et al. 2013; Maupetit-Méhouas et al. 2013). Though the 
MLID phenomenon has now been documented in several IDs, the causes and 
clinical significance of MLID are, in most cases, not well defined (Eggermann, Perez 
de Nanclares, et al. 2015; Mackay et al. 2015). 
 
1.6 General summary of this project  
DNA methylation is a heritable epigenetic mark that is, for historical reasons, mainly 
associated with transcriptional repression. However, it is now well established that 
DNA methylation also play critical roles in other mechanisms such as the 
maintenance of the genome integrity, the inactivation of the X chromosome in female 
or in the regulation of genomic imprinting. 
 
Genomic imprinting is an epigenetic phenomenon that results in the deliberate 
silencing of one copy (allele) of specific genes, according to whether the allele comes 
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from the father or the mother. Those genes, known as imprinted genes, are currently 
believed to be mainly associated with foetal growth, brain development, and 
neurological behavioural traits. 
 
At imprinted domains, both parental genomes are differentially marked by DNA 
methylation (i.e. methylated on the paternal allele but unmethylated on the maternal 
allele). These imprinted differentially methylated regions, known as imprinting 
centres or imprinted DMRs, are cis-acting elements controlling the expression of 
nearby or distant cluster of imprinted genes. The parent-specific DNA methylation 
marks found at imprinted centres can be established during the development of 
parental germ cells into egg or sperm. The methylation marks at these germline 
imprinted centres are maintained post-fertilisation but are erased and then replaced 
by a new one during the new generation of germ cells. Alternatively, secondary 
imprinted DMRs are imprinted loci that acquire their parent-specific methylation 
marks post-zygotically. 
 
Genomic imprinting is essential for normal growth and development and its 
deregulation, for example through aberrant methylation at imprinting centres, is 
associated in with number of human diseases such as the imprinting disorders BWS 
and SRS. BWS is a paediatric overgrowth condition caused by epigenetic or genetic 
alterations at the imprinted gene cluster located on chromosome 11p15.5. In 
contrast, SRS is a paediatric growth restriction condition caused by epigenetic or 
genetic alterations at imprinted gene clusters located on chromosome 7 and 11. 
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Interestingly, in a subset of BWS patients associated with a LOM at 
KCNQ1OT1:TSS-DMR or SRS patients associated with a LOM at H19/IGF2:IG-
DMR, multiple epimutations (MLIDs) occuring at imprinted loci other than 
KCNQ1OT1:TSS-DMR (for BWS) and H19/IGF2:IG-DMR (for SRS) are also 
described. These aberrant MLID epigenotypes are not exclusively found in BWS and 
SRS individuals. MLIDs are also describe in patients diagnosed with other imprinting 
disorders, including TNDM1 and PHP1B. However, in most cases, the causes, 
nature, frequency and clinical significance of MLID is currently not well defined yet. 
 
1.7 Aims of this project 
The principal aim of my thesis was to perform the methylation profiling of imprinted 
loci in BWS and SRS individual. The resulting comprehensive analysis would have 
helped to define the nature, frequency and range of MLID in these cohorts. It also 
would have provided valuable informations on the possible clinical significance of 
these widespread imprinting failures in BWS and SRS. Additionally, I also aimed to 
decipher the possible underlying causes that could be responsible for the abnormal 
MLID epigenotype. 
 
To that aim, I first sought to develop an affordable and highly sensitive high-
throughput method to assess the methylation at imprinted loci in both cohorts. 
Following the unsuccessful attempt to develop the assay, I carried out the 
comprehensive methylation profiling using methylation array and my own 
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bioinformatic methodology. I studied the significance of the use of assisted 
reproductive technologies in BWS_IC2 individuals with MLID and, using whole-
exome sequencing, I investigated the possibility that genetic alterations may be 
responsible for the widespread imprinting methylation disturbances. Finally, by using 
functional assays, I sought to know if a novel candidate gene variant found in siblings 
with BWS and LOM at KCNQ1OT1:TSS-DMR could be responsible for MLID. 
 
Taken together, the work undertaken during my thesis could improve not only our 
knowledge about the molecular aetiology of BWS and SRS, but also our 








2.1 Buffers recipe 
2.1.1 1X Transfer buffer 
192 mM glycine, 25 mM Tris, 10% pure methanol, adjust volume with dH₂O if 
needed. 
 
2.1.2 1X PBS-Tween 20 (PBST) 
137 mM NaCl, 12 mM Phosphate, 2.7 mM KCl, 0.1% Tween 20, pH 7.4, adjust 
volume with dH₂O if needed. 
 
2.1.3 Blocking buffer 
5 g non-fat milk, 100 ml PBST  
 
2.1.4 4X Laemmli sample buffer 
240 mM Tris/HCl pH 6.8, 8% SDS, 40% glycerol, 0.04% bromophenol blue, 5% beta-
mercaptoethanol, adjust volume with dH₂O if needed. 
 
2.1.5 RIPA 
50 mM Tris-HCL pH 8.0, 150 mM NaCl, 1% Igepal, 0.5% sodium deoxycholate, 0.1% 





2.1.6 2X SSC 
300 mM NaCl, 30 mM sodium citrate, adjust volume with dH₂O if needed. 
 
2.1.7 1X TAE 
40 mM Tris, 20 mM acetic acid, 1 mM EDTA, adjust volume with dH₂O if needed. 
 
2.2 DNA purification 
DNA was purified using the QIAquick PCR Purification Kit (QIAGEN). 5 volumes of 
Buffer PB was added to 1 volume of sample and mixed by pipetting. To bind DNA to 
the membrane, the sample was loaded into a QIAquick spin column placed in a 2 ml 
collection tube and centrifuged a 10,000 x g for 30-60 seconds. The flow-through 
was discarded and the collection tube was reused. To wash the DNA, 750 µl of Buffer 
PE was added to the QIAquick spin column and the column was centrifuged at 
10,000 x g for 30-60 seconds. The flow-through was discarded and the collection 
tube was reused. The column was centrifuged again for 1 minute to remove residual 
ethanol from Buffer PE. To elute the DNA, the column was transferred in a 1.5 ml 
tube, 50 µl of Buffer EB (or water) was added to the centre of the Qiaquick 
membrane, let to incubate for 1 minute and the column was centrifuged at 10,000 x 
g for 1 minute. The purified DNA was used immediately or stored at -20 °C for later 
use. 
 
Alternatively, DNA purification was done by ethanol precipitation. In a 15 ml tube, 2.5 
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volumes of 100% ethanol and 0.1 volume of 3M NaOAc (pH 5.2 or 5.5) were added 
to 1 volume of sample. The mixture was mixed well and left at -80 °C for at least 30 
minutes. To precipitate the DNA, the tube was centrifuged at 3,000 rpm (or maximum 
speed) for 30 minutes at 4 °C. After centrifugation, the supernatant was carefully 
discarded and 800 µl of cold 75% ethanol was added to the tube. Using a 1 ml tip 
(with tip pre-cut) the DNA pellet was transferred to a 1.5 ml tube and the tube was 
centrifuged at 14,000 rpm for 5 minutes. The supernatant was carefully discarded 
and the pellet was let to air dry for 3-5 minutes. To resuspend the DNA, 10-150 µl of 
double distilled water (pre-incubated at 37 °C) was added to the pellet and mixed 
well by pipetting up and down several times. The purified DNA was used immediately 
or stored at -20 °C for later use. 
 
2.3 DNA quantification 
2 μl of DNA was loaded on NanoDrop® ND-1000 (Thermo Scientific) and the 
measured absorbance at 260 nm was used to calculate the DNA concentration. The 
presence of proteins in DNA samples was evaluated with the measurement of 
absorbance at 280 nm. A ratio of sample absorbance at 260 nm and 280 nm 
(A260/A280) greater than 1.8 suggested DNA samples exempt from proteins. 
Similarly, salt and organic compounds contaminations were evaluated with the 
measurement of absorbance at 230 nm. A ratio of sample absorbance at 260 nm 
and 230 nm (A260/A230) greater than 1.5, ideally close to 1.8, suggested minimal 
or non existant contaminants carryover. 
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DNA concentration was determined by the measurement of absorbance at 260 nm 
and 280 nm. 2 µl of DNA was loaded on NanoDrop® ND-1000 (Thermo Scientific) 
and DNA concentration was obtained with the ratio of sample absorbance at 260 nm 
and 280 nm (A260/A280). 
 
Alternatively, DNA concentration was determined by fluorescent dyes method using 
Qubit® dsDNA HS Assay Kit (Thermo Fisher Scientific). For samples with expected 
DNA concentration below 100 ng/µl, 2 µl of sample DNA was mixed with 198 µl of 
Qubit® dsDNA HS Reagent diluted in 1:200 in Qubit® dsDNA HS Buffer. Samples 
fluorescence intensities were measured with Qubit® 2.0 Fluorometer and DNA 
concentration was calculated from the fluorescence intensities of provided low and 
high standard (10 μl of low or high Qubit® standard was mixed with 190 µl of Qubit® 
dsDNA HS Reagent diluted in 1:200 in Qubit® dsDNA HS Buffer). For samples above 
100 ng/µl, DNA was first diluted in distilled water to bring concentration below 100 
ng/µl and then processed as above. 
 
2.4 Sodium bisulfite treatment 
Genomic DNA (gDNA) was quantified with NanoDrop® ND-1000 (see section 2.3 - 
DNA quantification) and 500 ng of DNA was bisulfite treated using EZ DNA 
Methylation-Lightning™ Kit (Zymo Research). Bisulfite treatment was done as 
follows: first gDNA was mixed with 130 µl of Lightning Conversion Reagent and then 
incubated in a thermal cycle with the following programme: 98 °C for 8 minutes, 54 
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°C for 60 minutes, 4 °C for up to 20 hours. Sample was then mixed with 600 µl of M-
Binding Buffer, loaded into a Zymo-Spin™ IC Column placed into a provided 
Collection Tube and centrifuged at full speed for 30 seconds. To remove conversion 
reagent 100 µl of M-Wash Buffer was added to the column and centrifuge at full 
speed for 30 seconds. Complete methylated cytosine to uracil conversion was 
achieved by adding 200 µl of L-Desulphonation Buffer to the column and let stand at 
room temperature (20-30 °C) for 15-20 minutes. To stop the desulphonation reaction 
the tubes were centrifuged at full speed for 30 seconds and then washed twice in 
200 µl of M-Wash Buffer with centrifugation at full speed for 30 seconds after each 
wash steps. Elution step was done by adding 15 µl of M-Elution Buffer to the column 
and centrifuged at full speed for 30 seconds. Recovered bisulfite treated DNA 
(bisDNA) was used immediately or stored at -20 °C for later use. 
 
2.5 Infinium HumanMethylation450 BeadChip 
Genomic DNA was quantified with Qubit® dsDNA HS Assay Kits (see section 2.3 - 
DNA quantification) and 500 ng of gDNA was processed on the Infinium 
HumanMethylation 450K BeadChips (HM450K) (Illumina). This robust platform can 
interrogate the methylation status of more than 485,000 CpG across the genome. 
Processing of the samples on the HM450K array were performed at the Cambridge 
Genomic Services (Cambridge, UK), according to the manufacturer’s protocol 
(Infinium HD Assay Methylation Protocol Guide). In brief, gDNA was sodium bisulfite 
converted, denatured, neutralised and whole-genome amplified. Amplified bisulfite 
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treated gDNA was then enzymatically fragmented, purified by isopropanol 
precipitation and the resulting fragmented purified DNA was hybridized to BeadChip. 
The chip was then washed to remove all unhybridized and nonspecifically hybridized 
DNA. Using the capture DNA as template, specific fluorophore labels were added at 
CpG sites query by single-base extension. Staining detection was done by recording 
high resolution images of the light emitted from the fluorophore of the single-base 
extension products after laser excitation. GenomeStudio software (Illumina) was 
used to extract signal intensities for each probe and generate raw ‘idat’ files. The 
resulting raw data files were imported and analysed in R. 
 
2.6 Analysis software 
Unless stated otherwise, data handling, processing and statistical analysis were 
performed in R v3.3.0 and in Microsoft Excel v15.24. 
 
2.7 DNA fragments analysis of DNA libraries 
Bioanalyzer High Sensitivity DNA Kit (Agilent) was used to analyse DNA fragments. 
 
2.7.1 Setting up the chip priming station 
A new syringe was placed in the chip priming station, the plate base was inserted in 




2.7.2 Loading the gel dye mix 
Protected from light, the gel-dye mix was put at room temperature for 30 minutes 
before use. After equilibration at room temperature, 9 µl of gel-dye mix was pipetted 
at the bottom of the well located on the fourth column and third row of the DNA chip. 
The DNA chip was then placed into the chip priming station. The chip priming station 
was closed and the plunger of the syringe that was previously positioned at 1 ml was 
pressed down until held by the clip. The plunger was kept down for exactly 60 
seconds and then released. The plunger was inspected that it moved back to the 0.3 
ml mark and after 5 seconds it was slowly pull back to the 1 ml position. Finally, the 
chip priming station was opened and 9 µl of gel-dye mix was loaded in the three 
wells located on the fourth column and first, second and fourth row. 
2.7.3 Loading the marker 
5 µl of High Sensitivity DNA marker was pipetted into the wells with a ladder symbol 
and into each of the 11 sample wells. 
 
2.7.4 Loading the ladder and the samples 
1 µl of High sensitivity DNA ladder was pipetted in the well marked with the ladder 
symbol. 1 µl of sample was pipetted in each of the 11 sample wells. The chip was 
placed horizontally in the adapter of the IKA vortex mixer and vortex for 60 seconds 
at 2400 rpm. Finally, the DNA chip was placed into the Agilent 2100 Bioanalyzer (with 




2.7.5 Starting the chip run 
Using the 2100 Expert software, the appropriate assay was selected from the Assay 
menu located in the instrument context tab. Then the sample information’s were 
inserted into the sample name table. Finally, the button start was pressed to start the 
run. 
 
2.7.6 Data analysis 
Results were analysed directly using the 2100 Expert software built-in analysis 




Development of a novel next generation sequencing 
strategy for the genomic imprinting methylation profiling 




3.1.1 What is NGS? 
Next-generation sequencing (NGS), also known as high-throughput sequencing or 
deep sequencing, is a generic term used to describe a number of different modern 
sequencing technologies. Examples include (i) sequencing-by-synthesis technology 
used by Illumina in its commercially available sequencers MiSeq, HiSeq, NextSeq 
and NovaSeq (see section 3.1.2 - Sequencing-by-synthesis; an Illumina technology); 
(ii) pyrosequencing used by Roche 454 Life Sciences in the now discontinued 
Genome Sequencer FLX and GS Junior sequencers; (iii) sequencing-by-ligation 
used by ThermoFisher Scientific in the ABI SOLID sequencers; and (iv) detection of 
pH changes that follow the release of a hydrogen ion used by ThermoFisher 
Scientific in the Ion Proton, Ion PGM and Ion S5 sequencers. 
 
NGS platforms are reliable methods to sequence DNA and have many significant 
advantages when compared to classical Sanger sequencing. (i) It is quicker. NGS 
allows the sequencing of 300 Gb of DNA in a single run whilst a single read of 1 kb 
can be sequenced in a single reaction with Sanger sequencing. (ii) It is cheaper. 
Nowadays the sequencing of whole human genome with NGS may cost £3,000 or 
less whilst the predicted cost using Sanger sequencing could be approximatively 
£6M. (iii) It is more accurate and reliable. In a single NGS reaction, each portion of 
DNA can be covered by many short overlapping DNA fragments that are sequenced 
multiple times, hence resulting in reliable base calling. In contrast many time 
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consuming Sanger sequencing reactions will be required to achieve the same level 
of coverage. (iv) It needs less DNA. Approximatively 5 µg of genomic DNA would be 
required for the sequencing of the whole human genome using NGS. In contrast, 
Sanger sequencing of a small genomic region of 1 kb will required approximatively 
20 ng of genomic DNA. 
 
3.1.2 Sequencing-by-synthesis; an Illumina technology 
The sequencing-by-synthesis technology used by Illumina relies on several steps. 
Using the appropriate method, sequencing libraries are prepared from genomic DNA 
(Figure 3.1- step 1). In the 5’ to 3’ order, the libraries consist of a P5 adaptor, possibly 
index 1 (i5) barcode, sequencing primer for read 1, DNA insert, sequencing primer 
for read 2, possibly index 2 (i7) barcode and P7 adaptor sequences. Once prepared 
and ready for sequencing, the double-stranded libraries are denatured and loaded 
onto the flow cell. The DNA molecules attach through the attachment of either the 
P5 or P7 adapter of the libraries to the surface of the flow cell (Figure 3.1- step 2). 
In parallel, the other end that did not attach to the flow cell anneals to a dense lawn 
of complimentary oligonucleotides that coat the surface of the flow cell, hence 
forming a kind of bridge (Figure 3.1- step 3). The single-stranded DNA molecules 
that are now in a bridge shape are double-stranded through the addition of 
unlabelled nucleotides, primers, buffer and polymerase enzyme (Figure 3.1- step 4). 
The double-stranded molecules are denatured and the original strands are washed 
away, leaving behind the strands that had been synthesised and covalently bonded 
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to the flow cell surface in a mixture of orientations (Figure 3.1- step 5). Step 3 to 5 
are repeated multiple times to create clusters of DNA molecules that contains 
thousands of identical copies of the same sequence (in a mixture of orientations) 
(Figure 3.1- step 6). Prior to sequencing cycles, the P5 region is then cleaved, 
resulting in clusters containing only fragments which are attached by the P7 adaptor 
region. This is to ensure that all copies are in the same direction. Sequencing 
primers, polymerase, fluorescently labelled nucleotides with reversible terminator 
(one fluorescent colour for each base) and buffer are then added to the flow cell. The 
primers anneal to the P5 end of the fragments, which leads to the incorporation of 
the first base and therefore begins the sequencing-by-synthesis procedure (Figure 
3.1- step 7). After the incorporation of the first locked base, the flow cell is washed, 
hence resulting in removing unincorporated nucleotides and excess of primers. The 
sequencer starts the acquisition of the clear fluorescent signals and records the 
identity of the first base that was added to each clusters (Figure 3.1- step 8). The 
terminator dye and the fluorescent dye of the first base are removed, ultimately 
resulting in an unblocked and non-fluorescent nucleotide. Subsequently, a new 
sequencing chemistry cycle is initiated to determine the second base. Sequencing 
primers, polymerase, fluorescently labelled nucleotides with reversible terminator 
and buffer are added to the flow cell, which result in the incorporation of another 
fluorescently labelled nucleotide (Figure 3.1- step 9). The flow cell is then washed 
and the sequencer acquires the fluorescent signals and records the identity of the 
second base that was incorporated (Figure 3.1- step 10). The terminator dye and the 
fluorescent dye are removed which allows the start of a new sequencing cycle. This 
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sequencing procedure is repeated multiple times which leads to the identification of 
each base of a cluster (Figure 3.1- step 11). Finally, all the acquired sequencing 





Figure 3.1. Sequencing-by-synthesis technology used in Illumina. 





3.1.3 What is bisulfite sequencing? 
DNA methylation plays a critical role in normal growth and development and aberrant 
DNA methylation changes can cause a number of human disorders, including cancer 
and imprinting disorders. Consequently, it is crucial to characterise methylome states 
during normal development and under pathological conditions. 
 
Bisulfite-sequencing (Frommer et al. 1992) is one of the most reliable methods to 
characterise DNA methylation within a genomic region. It relies on the treatment of 
a single stranded DNA with a chemical compound, sodium bisulfite, and results in 
the deamination of unmodified cytosine residues to uracil. In contrast, 5-mC (and the 
iterative oxidised form 5-hmC/5-fC/5-caC), is protected against the bisulfite 
treatment. Consequently, cytosine residues that survive the bisulfite treatment are 
indirectly identified as methylated, whilst cytosines that are converted to thymines 
after polymerase chain reaction are identified as unmethylated (Figure 3.2). Used in 
combination with NGS, it constitutes nowadays the method of choice for the high-






Figure 3.2. Principle of sodium bisulfite treatment. 
Unmethylated cytosine residues are deaminated to uracil whereas methylated 
cytosine residues are unaffected. After polymerase chain reaction and sequencing, 
all cytosines that survive the treatment were methylated cytosine. 
 
 
3.1.4 NGS based methods for DNA methylation profiling 
The status of DNA methylation of a genomic region can be analysed by many 
different methods that rely on three basic principles: (i) the enzymatic digestion of 
methylated and unmethylated DNA with a restriction enzyme; (ii) the enrichment of 
methylated DNA using anti-methylcytosine antibodies or methyl-binding domain 
proteins; (iii) the sodium bisulfite conversion of genomic DNA which results in the 
conversion of unmodified cytosine to thymine whereas methylated cytosines remain 
unchanged. These principles have been integrated into high-throughput analytical 




Several methods for the large-scale DNA methylation analysis that rely on bisulphite 
conversion of genomic DNA in combination with NGS have been developed (E.-J. 
Lee et al. 2013; Plongthongkum et al. 2014). This includes whole-genome bisulphite 
sequencing (WGBS) (Cokus et al. 2008; Lister et al. 2008; Lister et al. 2009), 
reduced-representation-bisulphite-sequencing (RRBS) (Meissner et al. 2008; Z.D. 
Smith et al. 2009; Gu et al. 2011; Boyle et al. 2012), methylated DNA 
immunoprecipitation sequencing (MeDIP-seq) (Down et al. 2008; Maunakea et al. 
2010; Taiwo et al. 2012) and targeted capture methods (Deng et al. 2009; Herrmann 
et al. 2011; Komori et al. 2011; E.-J. Lee et al. 2011; Diep et al. 2012; Guilhamon et 
al. 2013; Ivanov et al. 2013; Paul et al. 2014). 
 
Whole-genome bisulfite sequencing (WGBS) is the gold standard method for the 
single base-pair resolution complete mapping of cytosine methylation across the 
genome. It has made significant contributions to determine the methylome of 
individuals and especially in cancer cells (Hansen et al. 2011; Hon et al. 2012). 
However, despite undeniable advantages, it is an expensive approach especially 
when applied to a large set of samples. 
 
RRBS is a large-scale approach that uses CpG-specific restriction enzyme (e.g. 
MspI, which is methylation-insensitive) digestion to randomly enrich for regions of 
high CpG content, such as CpG islands and promoters in any genome (Meissner et 
al. 2008; Z.D. Smith et al. 2009; Gu et al. 2011; Boyle et al. 2012; Junwen Wang et 
al. 2013). The method allows the profiling of approximatively 10-20% of the human 
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CpG content and requires a very low amount of DNA (10-100 ng). However, due to 
the intrinsic principle of using restriction enzymatic digestion, many CpG-sparse 
regions could be left uncharacterised. Additionally, the use of a high output 
sequencer is recommended in order to obtain a good depth of sequencing coverage. 
 
MeDIP-seq is a large-scale approach that uses monoclonal antibodies directed 
against 5-mC to precipitate and enrich methylated DNA fragment (MeDIP; (Weber et 
al. 2005)) before sequencing. It was used to complete the first high resolution 
methylome of a mammalian (i.e. human) genome (Down et al. 2008). The method 
has now been refined and requires a low input of DNA (i.e. 50 ng) (Taiwo et al. 2012) 
for the characterisation of 60-90% of the human CpG content. Similarly to RRBS, 
sequencing following MeDIP will require a high output sequencer to obtain a good 
depth of sequencing coverage. 
 
Targeted capture methods may be designed to interrogate any region of the genome. 
First developed to conduct whole-exome sequencing at a low cost compared to 
whole-genome sequencing (Albert et al. 2007; Hodges et al. 2007; Okou et al. 2007; 
Porreca et al. 2007), these methods were gradually integrated with bisulfite 
sequencing. Several targeted bisulfite sequencing (TBS-seq) methods have been 
developed and rely on different capture technics, including bisulphite padlock probes 
(Deng et al. 2009; Diep et al. 2012) (see section 3.1.5 - DNA methylation profiling 
using the bisulfite padlock probes below), microdroplet-based PCR amplification 
coupled with NGS protocols (Herrmann et al. 2011; Komori et al. 2011; Guilhamon 
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et al. 2013; Paul et al. 2014), on array hybridisation (Hodges et al. 2009) or in solution 
hybridisation (E.-J. Lee et al. 2011; Ivanov et al. 2013; Allum et al. 2015). TBS-seq 
offers several advantages over WGBS, RRBS or MeDIP-seq: (i) they are scalable 
approaches that can adapt to the amount of targeted regions; (ii) they are designed 
in answer to the hypothesis in question; (iii) depending of the size of the project they 
can result in high depth of sequencing coverage (>1000x) even when sequenced 
with a benchtop sequencer (e.g. MiSeq); (iv) they are developed with the scope of 
processing many samples hence offering a high degree of throughput for sample 
processing and multiplexing and (v) they don’t require, for the majority, a large 
amount of input DNA (200-500 ng). However, TBS-seq has the disadvantage of (i) 
limiting findings to the captured targeted regions which consequently excludes 
possible new discoveries that are located out of these boundaries; (ii) for some 
methods, the design of capturing probes may be complicated by reduced sequence 
complexity (resulting from bisulfite treatment) and high GC-rich regions; (iii) they 
have a starting high cost (e.g. for probe synthesis) but they become much more 
affordable when used for the analysis of large set of samples. 
 
3.1.5 DNA methylation profiling using the bisulfite padlock 
probes 
Bisulfite padlock probes (BSPPs) have been suggested as a practical, flexible and 
cost-effective approach to interrogate the methylation profile of multiple regions of 
interest across a large set of samples (Ball et al. 2009; Deng et al. 2009; Diep et al. 
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2012). The method requires a very low amount of input DNA (e.g. 200 ng of bisulfite-
treated DNA) and is highly specific and reproducible. 
 
Historically, BSPP was firstly used to assess the methylation status of 66,000 CpG 
sites in 2,020 CGI on human chromosomes 12 and 20 (Deng et al. 2009). In the 
same year, another research group used BSPP to profile 7,000 CpG sites within the 
ENCODE pilot project regions (Ball et al. 2009). Both studies used approximatively 
30,000 padlock probes to capture the targeted regions and both showed that the 
method is highly specific and reproducible. More recently, a third group released an 
upgraded version of the protocol and demonstrated the high specificity of the 
technique by characterising the methylation profile of approximatively 500,000 CpG 
sites across 34 Mb of sequences. For this large-scale project, 330,000 padlock 
probes were designed, synthesised and used to capture the sequence of interest 
(Diep et al. 2012). Although the initial cost of BSPP is high, the cost per sample 
dramatically decreases with increased sample sizes (Diep et al. 2012). 
 
BSPP are long single stranded DNA oligonucleotides (100-150 mers) designed to 
hybridise to bisulfite converted genomic DNA targets in a horseshoe manner (Figure 
3.3-a). The targeted regions for sequence capture are the gap between the two 
hybridised and locus-specific arms of a padlock probe and their capture are done by 
filling the gap with a polymerase (Figure 3.3-b). Uncaptured linear DNA is digested 
(Figure 3.3-c) and the resultant circular DNA is enriched and amplified using the 
common linker sequence between the two ligation arms with primers containing 
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sequencer's adaptors and barcode (sequencing library preparation) (Figure 3.3-d). 
BSPP sequencing libraries are mainly designed to be sequenced on Illumina 







Figure 3.3. Bisulfite padlock probes. 
(a) Padlock probes bind to bisulfite converted genomic DNA. (b) The sequence of 
interest is captured through gap filling step. (c) Linear DNA is digested with nuclease 
and (d) circles DNA, which contain sequence of interest, are amplified by PCR with 
primers containing P5 and P7 Illumina sequencing adaptors and index sequences. 
Both primers are specific to a different portion of the BSPP common linker. (Adapted 




As discussed previously (see section 1.5 - Imprinting disorders and multilocus 
methylation disturbances), a subset of BWS and SRS individuals have been 
identified with MLID but the nature, frequency and clinical significance of such 
aberrant epigenotype has not been clearly defined yet. Additionally, the comparison 
of different studies of MLID in BWS and SRS is complicated by different strategies 
for detecting epimutations and different choices of ICs analysed. In order to 
undertake a comprehensive survey of the frequency and nature of MLID in patients 
with BWS and SRS I attempted to develop a NGS assay for a highly sensitive 
methylation profiling at 46 imprinting DMRs (Table 3.1) (Court et al. 2014). The assay 
was intended to fulfil a list of criteria that includes (i) a streamlined workflow for the 
processing of a large number of clinical samples; (ii) being cost-efficient; (iii) the 
characterisation of CpG methylation within the targets at a single base-pair 
resolution; (iv) a very high depth of sequencing coverage (e.g. > 500x); and (v) 
requires a low amount of input DNA (e.g. <500 ng). At the time of the project, this 
was one of the first attempt of genome-wide screening for alteration at multiple 
imprinted loci using NGS method and applied to a large cohort of BWS and SRS 
individuals (more than 100). Additionally, although the primary focus was to 
characterise DNA methylation at imprinting regions in BWS and SRS individuals, the 
NGS assay could also be used for the genomic imprinting methylation profiling of 




Table 3.1: List of imprinted DMRs. 




3.2 Materials and methods 
3.2.1 DNA purification 
See section 2.2 - DNA purification. 
 
3.2.2 DNA quantification 
See section 2.3 - DNA quantification. 
 
3.2.3 Sodium bisulfite treatment 
See section 2.4 - Sodium bisulfite treatment. 
 
3.2.4 Amplicon size selection 
Size selection of a pool of amplicons was done using E-Gel® SizeSelect™ 2% pre-
cast agarose gels (Thermo Fisher Scientific). 20-25 µl of sample was loaded in the 
top wells (lane 1 to 8) of the gel. 5-10 µl of diluted molecular weight markers was 
loaded into the small middle well (lane M) at the top of the gel. 25 µl of deionised 
water was loaded into all of the wells (lane 1 to 8) in the lower row and 5-10 µl of 
deionised water was loaded into the small well of the lower row (lane M). Following 
sample loading, the gel was inserted into the E-Gel® iBase™ Power System and the 
amber filter was put over the iBase™ device. For the electrophoresis, the program 
called ‘Run SizeSelect 2%’ was selected and an appropriate time (according to ‘Run 
Time Estimation Table’) was set to ‘Run Time to Reference’ (Run Time Estimation 
Table). Once set, the electrophoresis was run until the band of interest reached the 
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reference line. At that point the electrophoresis was paused, the collection wells were 
refilled to 25 µl of deionised water, the appropriate time listed under ‘Run Time from 
Reference Line to Collection Well’ from the ‘Run Time Estimation Table’ was entered 
and the electrophoresis was run. The migration of the band of interest was carefully 
monitored until it migrates into the Collection Well. At that point the run was stopped 
and the DNA of the appropriate size was collected from the Collection Well. The 
collected DNA was used immediately or stored at -20 °C for later use. 
 
3.2.5 Preparation of sequencing libraries using bisulfite padlock 
probes 
3.2.5.1 Bisulfite padlock probes design and synthesis 
ppDesigner software (Diep et al. 2012) was used to design bisDNA specific padlock 
probes within regions of interest (Table 3.1). In design 1 (see section 3.3.1 – First 
experimental design), overlapping probes were designed to cover as much as 
possible of the regions of interest and CpG inclusion within the probes was allowed. 
The probes were synthesised by LCSiences. In design 2 (see section 3.3.2 – Second 
experimental design), one probe was design for each of PPIEL:Ex1-DMR, 
ZDBF2/GPR1:IG-DMR, FAM50B:TSS-DMR, H19/IGF2:IG-DMR, KCNQ1OT1:TSS-
DMR, L3MBTL1:alt-TSS-DMR and SNU13:alt-TSS-DMR. CpG inclusion within the 





3.2.5.2 Bisulfite padlock probes production (for LCSciences only) 
The following amplification, nicking digestion and purification steps of the padlock 
probes were done for the one synthesised by LCSiences only (Figure 3.4). The 
quantity of probes synthesised by LCSiences was very low and consequently it was 
necessary to amplify them prior target capture step. On the contrary, the quantity of 
probes synthesised by Integrated DNA Technologies was high and therefore it was 
not necessary to amplify them prior target capture. 
 
3.2.5.2.1 Amplification (for LCSciences only) 
To overcome the low concentration of the padlock probes received from LCSciences, 
amplification primer site 1 (AP1) and amplification primer site 2 (AP2) were added at 
each end of all probes. The amplification of the single stranded padlock probes was 
done as previously described (Diep et al. 2012) (Figure 3.4-a). In brief, in 200 µl 
reaction volume, 1 nM of template oligonucleotides was mixed with 400 nM each of 
forward primer AP1_F and reverse primer AP2_R (Table 3.2), and 100 μL of KAPA 
SYBR fast Bio-Rad qPCR Master Mix (Kapa Biosystems). The mixture was placed 
in a thermocycler for PCR amplification and incubated at 95 °C for 30 sec, 5 cycles 
of 95 °C for 5 sec; 52 °C for 1 min; and 72 °C for 30 sec, 10-12 cycles of 95 °C for 5 
sec; 60 °C for 30 sec; and 72 °C for 30 sec, and 72 °C for 2 min. The resulting 
amplicons were purified using QIAquick PCR purification columns (QIAGEN) (see 
section 2.2 - DNA purification) and re-amplified by PCR in 32 reactions (100 μL each) 
with 0.02 nM first round amplicons, 400 nM each of AP1_F primer and AP2_R primer, 
and 50 μL of KAPA SYBR fast Bio-Rad qPCR Master Mix. For PCR amplification, 
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the mixture was incubated in a thermocycler at 95 °C for 30 sec, 13-15 cycles of 95 
°C for 5 sec; 60 °C for 30 sec; and 72 °C for 30 sec, and 72 °C for 2 min. The resulting 
double stranded amplicons were purified by ethanol precipitation and re-purified with 
QIAquick PCR purification columns (see section 2.2 - DNA purification). The purified 
amplicons were quantified by Nanodrop (see section 2.3 - DNA quantification) and 
immediately processed with next step or stored at -20 °C for later use. 
 
Table 3.2: List of primers used for the amplification of the padlock probes. 
 
 
3.2.5.2.2 Nicking digestion (for LCSciences only) 
Nicking digestion was used to remove the amplification primer sites AP_1 and AP_2 
from the double stranded amplicons (Figure 3.4-b). Approximately 4 μg of the 
purified amplicons were digested with 100 units of Nt.AlwI (100 U/μl, New England 
Biolabs, cleaves at 5’-GGATCNNNN/N-3’ only on one strand of a double stranded 
DNA) at 37°C for 1 h in NEBuffer 2 (New England Biolabs). The enzyme was heat 
inactivated at 80 °C for 20 min. The digested amplicons were then incubated with 
100 units of Nb.BrsDI (10 U/µl, New England Biolabs, cleaves at 3’-CGTTAC/NN-5’ 
only on one strand of a double stranded DNA) at 65 °C for 1 h. The resulting double 
stranded nicked DNA was purified by QIAquick PCR purification column (see section 
2.2 - DNA purification). The nicking digestion of the amplicons with Nt.AlwI and 
Nb.BrsDI resulted in a double stranded DNA with a 70 bp long top strand  (i.e. 
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equivalent to the padlock probes) and a 100 bp bottom strand (i.e. equivalent to the 
unwanted complementary strand). 
 
3.2.5.2.3 Denaturing PAGE purification (for LCSciences only) 
To discard the 100 bp complementary strands and to keep the 70 bp padlock probe 
strands the DNA molecules were purified using denaturing Novex® TBE-Urea Gels 
6% (Thermo Fisher Scientific) (Figure 3.4-c). In 100 µl final volume, 2 µg of nicked 
DNA was mixed with 2X Novex® TBE-Urea Sample Buffer in a 1:1 ratio volume. For 
the DNA ladder, in a 10 µl final volume 1 µg of 10 bp DNA ladder (Thermo Fisher 
Scientific) was mixed with 1X Novex® TBE-Urea Sample Buffer. The Novex® TBE-
Urea gel was put into XCell SureLock™ Mini-Cell Electrophoresis System (Thermo 
Fisher Scientific), the upper and lower chamber of the electrophoresis system was 
filled with 0.5X Novex® TBE Running Buffer (Thermo Fisher Scientific) and the gel 
was pre-run at 200 V for 10-15 minutes. At the same time, the DNA and DNA ladder-
loading dye mixtures were incubated at 75 °C for 8-10 minutes and then quickly 
cooled on ice for at least 1 minute. The wells of the Novex® TBE-Urea gel were 
flushed with a 1 ml pipette to remove residual urea. The DNA and DNA ladder-
loading dye mixtures were quickly loaded into the gel and the gel was run at 200 V 
for 30 minutes. Once the run finished, the gel was removed from the cassette and 
stained in 25-50 ml of 0.5X Novex® TBE Running Buffer and 1X SYBR Gold (Thermo 
Fisher Scientific) for 5 minutes and gentle shaking. The gel was then placed on a 
clean Saran wrap on a UV transilluminator (UVP). The area of the gel containing the 
band of approximately 70 bp was cut as close to the band using a clean scalpel (with 
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minimising exposing the gel to UV light). The cut gel was moved to a clean area and 
chop into small pieces with a scalpel. Two 0.5 ml tubes were pierced at their bottom 
with a 22G needle and then put into two 1.5 ml DNA LoBind tubes (Eppendorf). The 
chopped gel was transferred into the two 0.5 ml tubes and then centrifuged at 15,000 
rpm for 3 minutes at room temperature. The gel remaining in the 0.5 ml tube was 
transferred to the 1.5 ml tube below with a sterile pipette tip. 400 µl of 1X TAE buffer 
(see section 2.1.7 - 1X TAE) was then added to the tube, and the mixture was shake 
vigorously on vortex for at least 45 minutes at 37 °C. Once finished, the clear 
supernatant was transferred to a Nanosep column (Pall Corporation) and centrifuged 
at 15,000 rpm for 3 minutes. The lower layer of the flow-through was carefully (i.e. 
avoiding the large chunk of gel) transferred again to the Nanosep column and then 
centrifuged for an additional 3 minutes at 15,000 rpm. The supernatant was 
transferred to a fresh 1.5 ml tube and precipitated with ethanol (see section 2.2 - 
DNA purification). After ethanol precipitation, the DNA pellet was dissolved with 10-
15 µl of distilled water. All probes were pooled and the size of the probes and DNA 
concentration was estimated using 6% TBE-urea gel. The resulting bisulfite padlock 





Figure 3.4. Preliminary steps used for the probes syntghesised by LCSiences. 
(a) PCR amplification was used to increase bisulfite padlock probes quantity. (b) AP1 
and AP2 sites were removed from double stranded amplicons using nicking 
digestion. The enzymatic digestion resulted in a DNA molecules with 70 bp top 
strand and 100 bp bottom strand. (c) The unwanted bottom strand (i.e. 
complementary product) was removed using denaturing urea PAGE. 
 
3.2.5.3 Multiplex capture of bisulfite treated target regions 
500 ng of sample gDNA was quantified with Nanodrop (see section 2.3 - DNA 
quantification) and bisulfite treated (see section 2.4 - Sodium bisulfite treatment). In 
25 µl volume reaction, 50 nM of a pool of padlock probes, approximatively 500 ng of 
bisDNA and 1X Ampligase buffer (Epicentre) were mixed and incubated in a 
thermocycler using the following reaction conditions: 95°C for 10 min, gradual 
cooling at 70 °C (0.1 °C/sec), 70 °C for 30 min, gradual cooling at 65 °C (0.1 °C/sec), 
65 °C for 60 min, gradual cooling at 60 °C (0.1 °C/sec), 60 °C for 120 min, gradual 
cooling at 55 °C (0.1 °C/sec) and 55 °C for 20 h. The capture reaction was 
immediately processed with next step. 
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3.2.5.4 Circularisation of captured sequences 
2.5 µl gap-filling mix consisting of 100 µM dNTP, 10 U/µl Titanium Taq (Takara Bio 
USA), 0.5 U/µl Ampligase and 1X Ampligase buffer (Epicentre) was incubated at 95 
°C for 1 min, cooled at 55 °C and added to the previous capture reaction. Gap-filling 
and circularisation reactions were then performed by incubating the reaction at 55 
°C for 20 h. The gap-filled reaction was then cooled on ice and immediately 
processed with next step. 
 
3.2.5.5 Enzymatic digestion 
Linear DNA was digested by adding 4 µl of exonuclease mix (20 U exonuclease I 
and 200 U exonuclease III, 1X ampligase buffer; New England Biolabs) to the target 
capture reaction. The reaction was then incubated at 37 °C for 2 h followed by 
exonuclease inactivation at 95 °C for 2 min and hold at 4 °C indefinitely. Reaction 
was immediately processed with next step or stored at 4 °C or -20 °C for later use. 
 
3.2.5.6 Capture circle amplification 
Sequencing library was generated by amplifying the exonuclease treated circle DNA 
with barcoded primers. In 100 µl volume reaction, all of the circularised DNA was 
mixed with 400 nM of each forward AmpF_P5 and reverse AmpR_P7_Ind_001 
primer (for design 1) or forward SLXA_PE_MIPBC_FOR and 
SLXA_PE_MIPBC_REV_001 primer (for design 2) (Table 3.3), 50 µl of KAPA HiFi 
2x HotStart ReadyMix Taq (Kapa Biosystems) and PCR-grade water. The mixture 
was incubated in a thermocycler and PCR amplified using one of condition 1, 
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condition 2 or condition 3 programme (see below). The resulting barcoded 
sequencing library was processed immediately after with next steps consisting of 
fragment analysis using bioanalyzer (see section 2.7 - Fragment analysis of DNA 
libraries), size selection and purification using E-Gel® SizeSelect™ gels (see section 
Amplicon size selection), followed by DNA quantification using Qubit® dsDNA HS 
(see section 2.3 - DNA quantification). Finally, the libraries were again checked for 
correct size using bioanalyzer (see section 2.7 - Fragment analysis of DNA libraries). 
The libraries were used immediately after or stored at -20 °C for later use. 
 




Condition 1: 98 °C for 30 sec, 10 cycles of 98 °C for 15 sec; 50 °C for 20 sec; and 
72 °C for 20 sec, 20 cycles of 98 °C for 15 sec; 72 °C for 20 sec, and 72 °C for 3 
min, and hold at 4 °C. 
Condition 2: 98 °C for 30 sec, 25 cycles of 98 °C for 15 sec; 58 °C for 20 sec, and 
72 °C for 20 sec, and 72 °C for 3 min, and hold at 4 °C. 
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Condition 3: 98 °C for 30 sec, 25 cycles of 98 °C for 15 sec; 50 °C for 20 sec; and 
72 °C for 20 sec, 72 °C for 3 min, and hold at 4 °C. 
 
3.2.5.7 Sequencing 
The sequencing of the libraries was performed by the Stratified Medicine Core 
Laboratory (SMCL) Next Generation Sequencing facility. A MiSeq sequencer was 
used for the sequencing. The sequencing primer used are listed in Table 3.4. 
 




3.3.1 First experimental design 
3.3.1.1 Design requirements 
I designed BSPP with the following specific requirements: the capture insert size 
would be of 120-125 nucleotides; the maximum length of the two ligation arms would 
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be of 25 nucleotides; the maximum combined length of the two ligation arms would 
be of 40 nucleotides. The amplification primer site 1 (AP1) required for padlock 
probes amplification contains the nicking endonuclease Nt.AlwI sequence. Similarly, 
the amplification primer site 2 (AP2) contains the nicking endonuclease Nb.BrsDI 
sequence. The nucleotide composition of the common linker was dictated by the 
sequencing primer sequences. However, the choice of the sequencing primers to 
include in the common linker was complicated by several factors. The sequencing 
libraries were predicted to be sequenced using a MiSeq sequencer. One of the 
particularities of this sequencer is that it runs hotter (65 °C) than other Illumina 
sequencers, such as the HiSeq sequencer (55 °C), during the deblocking and 
extension stages. Consequently, custom sequencing primers have to have a melting 
temperature above 65 °C to prevent them from dissociating from the target. 
Additionally, the custom sequencing primers need to meet Illumina 
recommendations which are 33 bp long, 51.5% GC, with a Tm of 65.5 °C for 
sequencing primer for read 1 and 37 bp long, 59.5% GC with a Tm of 70.1 °C for 
sequencing primer for read 2. However, despite fulfilling these requirements, it is not 
guaranteed the custom sequencing primers will work properly. Finally, Illumina 
doesn’t provide technical support when custom sequencing primers are used. 
Consequently, I decided to incorporate a mixture of Illumina proprietary sequencing 
primers, Illumina Nextera sequencing primer for read 1 and Illumina TruSeq Small 
RNA sequencing primer for read 2, into the common linker. They are both natively 
recognised by the MiSeq sequencer and they have a limited impact on introducing 
additional Nt.AlwI and Nb.BrsDI restriction sites. 
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3.3.1.2 Padlock probes to synthetise 
Following the design criteria, 516 overlapping padlock probes were generated in 
silico using ppDesigner to capture 61.6 kb of DNA sequence, including the targeted 
regions. Analysis of the probes sequence revealed CpG sites inclusion within the 
ligation arms of 412 (80.5%) padlock probes. Therefore, to avoid binding bias 
towards the methylated allele, a second copy of each of the 412 probes was 
computed to be specific to the unmethylated allele, which resulted in the design of a 
total of 928 padlock probes. The pool of 928 oligonucleotides were checked to be 
free from additional Nt.AlwI and Nb.BrsDI recognition site sequences to avoid un-
wanted digestion. Out of 928, the procedure identified 19 (~ 2%) probes with 
additional Nt.AlwI and Nb.BrsDI recognition site sequences, which consequently 
were removed from the pool of padlock probes. This resulted in 909 padlock probes 
to be synthesised (Table 3.5). 
 
Table 3.5: Number of padlock probes to synthesise. 
 
 
3.3.1.3 Library preparation 
Quality control of the sequencing libraries before size selection by Bioanalyzer 
identified mainly two amplicons of different sizes. The amplicons with a length of 
approximatively 286 bp were predicted to be the expected sequencing libraries. The 
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amplicons with a length of approximatively 237 bp were predicted to be a truncated 
form of the sequencing libraries resulting from inneficient amplification (i.e. only one 
primer anneals to the DNA template) (Figure 3.5). 
 
The libraries were then size selected (retained product at approximatively 280-290 
bp) and cleaned-up. qPCR analysis indicated that the resulting libraries were of the 
correct size and were at an appropriate concentration for the sequencing reaction 
(data not show). 
 
Figure 3.5. BSPP sequencing library preparation (first design). 
Bioanalyzer analysis identified two kinds of amplicons in the sequencing libraries. 
One is predicted to be the full-length library construct whilst the other is predicted to 





The resulting sequencing libraries were sequenced on Illumina MiSeq sequencer. 
However, no sequencing reads were generated during the sequencing run. The 
quality control performed during the sequencing run, which mainly checks the cluster 
generation output, did not indicate any failures with the instrument. After 
investigation with the core sequencing facility, I formulated several hypothesis that 
may explain the unsuccessful sequencing. Firstly, balance A/C/G/T bases 
composition is required for the optimal differentiation of the different clonally 
amplified DNA molecules spatially separated in the flow-cell. My libraries were 
generated from bisulfite converted DNA, which meant that the A/C/G/T bases 
proportion was un-balanced and consequently could have been an issue for the 
sequencer. However, to avoid this problem, PhiX sequencing control was spiked into 
my libraries in sufficient quantity, hence resulting in a pool of libraries with a balanced 
A/C/G/T composition. Secondly, my custom paired-end, single-indexed libraries 
were pooled with paired-end, dual-indexed libraries, which were provided by other 
customers. It was conceivable that the mixture of libraries prepared by different 
methods could interfere with each other (e.g. cross-hybridization) and consequently 
lead to failure in sequencing. However, I was not able to verify this assumption. 
Another possible issue associated with the mix of sequencing libraries could 
originate from the different index 1 (i7) size length used in the different libraries. To 
achieve sample multiplexing I used a custom six nucleotides barcode for index 1 (i7) 
(barcode for index 2 (i5) has 8 nucleotides) whilst in the other libraries an eight 
nucleotides index 1 (i7) barcode was used. This could have impacted the whole 
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sequencing process via interference with the index sequencing read stage. It is 
possible that during the sequencing of index 1 (i7) the sequencer completed the first 
six sequencing cycles without problems but encountered an un-identified issue 
during the remaining two cycles. As a result, the sequencer could have interpreted 
the issue as a major malfunction and consequently discarded the already acquired 
sequencing data. I was not able to confirm this hypothesis. Alternatively, it is also 
possible that an issue arose from the demultiplexing procedure that takes place once 
the whole sequencing run is finished. The software used for the demultiplexing could 
have struggled to identify my six nucleotides-indexed samples. If it was the case, the 
acquired sequencing data consisting of sequencing artefacts or sequences that were 
not assign to a sample, mine included, would have been saved but placed into a 
‘garbage’ file. However, no sequences in relation to my target regions were present 
in that file. Finally, another source of failure may come from the failure of the 
sequencing primers to anneal to the DNA molecules. 
 
3.3.2 Second experimental design 
3.3.2.1 Design requirements 
The original BSPP design was modified to take into account and minimise the 
previously discussed possible sources of errors. 
i. Only seven oligonucleotides were designed to reduce the cost of the 
experiment. The chosen target regions were PPIEL:Ex1-DMR, 
ZDBF2/GPR1:IG-DMR, FAM50B:TSS-DMR, H19/IGF2:IG-DMR, 
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KCNQ1OT1:TSS-DMR, L3MBTL1:alt-TSS-DMR, SNU13:alt-TSS-DMR 
imprinting centres. 
ii. The padlock probes were ordered from Integrated DNA Technologies 
company, which allowed more freedom in the design. This included the 
synthesis of a higher oligonucleotides concentration, which meant avoiding 
the initial round of padlock probes amplification (no need for AP1 and AP2 
primer sites), digestion and purification; the design of a longer padlock probes 
(101-111 bp; 70 bp previously) which meant incorporating longer ligation arms 
(up to 70 bp combined; up to 40 bp previously) for more specificity during the 
target capture step, and longer common linker for more primers padding 
sequence during the capture circle amplification step. 
iii. The size of the target inserts was changed to be between 120 to 185 bp (120 
to 125 bp previously) which gave more flexibility to ppDesigner software to 
find regions that fit the design requirements. 
iv. Custom sequencing primers (Diep et al. 2012) were used in place of the 
proprietary ones from Illumina. Although this approach is not supported by the 
company, the custom oligonucleotides were previously reported to perform 
well with both the library preparation protocol and the sequencing with MiSeq 
(Diep et al. 2012). 
v. Different PCR amplification conditions were tested during the capture circle 
amplification step (see section 3.2.5.6 - Capture circle amplification for 
condition 1, 2 and 3 details). This may prevent the formation of non-specific, 
and truncated, products and increase the yield of enrichment. Therefore, this 
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may result in libraries with better quality, hence increasing the chance of 
optimal sequencing. 
 
3.3.2.2 Library preparation 
Condition 1, 2 and 3 were used to generate and enrich for the libraries. According to 
Bioanalyzer analysis performed before size selection and clean-up step, the 
condition 1 used to amplify the captured targets failed to generate amplicons, which 
suggested that the PCR condition was inadequate. Condition 2 and condition 3 had 
similar outcome. Both generated amplicons but the majority of them were likely to 
be non-specific product. Additionally, Bioanalyzer analysis also indicated that library 
concentration was within the pg/µl range, hence indicated poor yield during 
amplification (Figure 3.6). This could be explained by non-optimal PCR conditions 
during the capture circle amplification stage. Alternatively, this could also be 
explained by the fact that only seven regions were targeted and captured, as oppose 
of the hundreds in the previous design. 
 
The libraries were then size selected and cleaned-up. Bioanalyzer analysis failed to 
detect any product within the samples (data not shown). This suggested that size 
selection and clean-up procedures led to the complete or partial loss of samples. 
DNA quantification with Qubit High Sensitivity kit detected very low amount of DNA, 
hence confirming the size selection and clean-up procedures were, in part, 
responsible for the loss of samples (data not shown). However, whilst the 
concentration was too low for the Bioanalyzer detection threshold, it was still 
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Figure 3.6. BSPP sequencing library preparation (second design). 
Sequencing library preparation with second BSPP design and reviewed method. (a) 
The captured circle amplified with PCR condition 1 did not generate amplicons whilst 








The two libraries that were generated using condition 2 and condition 3 were 
sequenced using MiSeq sequencer. Unfortunately, the sequencing of the samples 
did not produce a successful outcome. Among the few reads that were acquired 
during the sequencing run, only a very few (<1%) aligned to my target regions whilst 
the vast majority (>99%) were either artefacts or garbage sequences that aligned to 
the common linker of the padlock probes. This was unexpected as the original single 
stranded free form of the oligonucleotides is expected to be digested during the 
exonuclease I and III enzymatic treatment. Furthermore, the design of the 
experiment was done in such way that even in the presence of carried over free form 
padlock probes, they should not be PCR amplified during the capture circle 
amplification step. The long primers used for library enrichment during the capture 
circle amplification step were designed to amplify specifically circle DNA that 
contains both the common linker of the padlock probes and the target regions but 
not single stranded linear padlock probes only. Finally, in the absence of 
amplification, the free form padlock probes should not contain any P5 and P7 
adaptor sequences, which are both required to bind to the flow-cell. Alternatively, the 
failed sequencing may have also originated from failure of the custom sequencing 
primers to bind to the libraries during read 1 or read 2 sequencing stages. However, 
according to previous reports that made use of them with success (Deng et al. 2009; 
Diep et al. 2012) it is unlikely that they were responsible for the failed sequencing. 
 
Taken together, the lack of reads aligning to target regions but instead aligning to 
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padlock probe common linker sequence suggested that the designed method failed 
to capture and enrich the targets prior to sequencing. Instead, it seems that non-




Padlock probes based assay have been used successfully in the past to complete 
large projects that include exome sequencing, RNA allelotyping, copy number 
variation analysis, and SNP identification (Porreca et al. 2007; J.B. Li, Gao, et al. 
2009; J.B. Li, Levanon, et al. 2009; K. Zhang et al. 2009; H Wang et al. 2010; Gore 
et al. 2011; Noggle et al. 2011; O'Roak et al. 2012; Carvill et al. 2013; Hiatt et al. 
2013; Nuttle et al. 2013; Yoon et al. 2015). The method has since been adapted for 
DNA methylation analysis and BSPPs were found to be highly specific and 
consistent in the characterisation of DNA methylation of a large number of CpG. 
Additionally, the method requires a low amount of DNA and can easily be scaled to 
adapt to the size of the genomic regions of interest and to the sample size of the 
project (Deng et al. 2009; Diep et al. 2012). Based on these reports, I decided to use 
BSPPs in the novel high-throughput genomic imprinting methylation assay I aimed 
to develop. 
 
Two types of padlock probes design (i.e. first and second design) were tested and in 
both cases several sequencing libraries were generated using different experimental 
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conditions. Quality control steps using bioanalyzer was performed before and after 
final size selection and the best candidate libraries (i.e. bioanalyzer profile closer to 
the theoretical end product, higher yield) for both padlock probes design was sent 
for sequencing. On overall, the method encountered several issues which led to 
unsuccessful target capture, enrichment of the targets, sequencing and methylation 
profiling. The absence of additional quality control steps throughout the method, 
such as after the target capture (Figure 3.3-a) and after the enzymatic digestion of 
circulised target sequences (Figure 3.3-c), has made troubleshooting difficult. 
However, based on several pieces of evidence I hypothesised that the failure of the 
assay could have originated from different factors: 
 
(i) In the first design, the size of the BSPPs may have been too short. This was a 
supplier constraint for which at the time of the project was not able to synthesise a 
pool of hundreds of oligonucleotides of more than 100 bp. The short size of BSPPs 
implied having two short locus-specific target recognition and hybridisation arms, 
hence resulting in a loss of specificity to recognise the bisulfite treated targeted 
regions. Additionally, the short BSPPs also meant that the common linker was also 
short (30 bp) and consequently it left little room to design annealing sequences for 
the two long (60 bp) primers used during the multiplex PCR amplification of capture 
circle DNA step (15 bp annealing sequence for each primer). The BSPPs size issue 
was addressed with the second experimental design in which longer 
oligonucleotides (i.e 100 bp versus 70 bp) were synthesised. However, I was not 




(ii) The sequencing primers may have been an issue during the sequencing library 
preparation and/or during sequencing. In the first design I opted for the use of a 
mixture of Illumina proprietary sequencing primers, hence avoiding possible 
incompatibility with the MiSeq sequencer. However, the downside of these primers 
was that their last 15 bp (i.e. the ones that anneal to the common linker) have a 
melting temperature difference of 5 °C, which meant possible loss of PCR efficiency 
during the capture circle amplification step and therefore a low efficiency to generate 
final sequencing libraries. This may have explained the presence of a non-specific 
amplicon in the pool of sequencing libraries. Alternatively, the mixture of Illumina 
sequencing primers may have interfered with the sequencing itself as in both 
sequencing primers are not meant to work in combination on the same sequencing 
library. To address this possible problem, I opted for the use of the published custom 
sequencing primers that were originally designed with BSPPs method and were 
compatible, to some extent, with the MiSeq sequencer (Diep et al. 2012). However, 
I was not able to assess how that benefited to the second design as it also failed. 
 
(iii) Finally, although originally not an issue, the 6 nucleotides index used in the first 
experimental design may have interfered with sequencing once my libraries were 
pooled with 8 nucleotides indexed sequencing libraries. The differences of index 
length may have led to sequencer malfunction or issue during demultiplexing. To 
avoid further complication, I included 8 nucleotides index in the second experimental 
design. However, I was not able to assess how that benefited to the second design 
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as it also failed. 
 
In conclusion, various factors that were hypothesised to be a possible source of 
problems in the first place were taken into account during a second experimental 
design. However, despite the taken measures, this resulted in an unsuccessful 
attempt. Whilst the exact causes of failures are still unknown, it is likely that a 
combination of mentioned and unknown parameters may have influenced the assay 









4.1.1 DNA methylation profiling using the Infinium 
HumanMethylation 450K BeadChips 
The Infinium HumanMethylation 450K BeadChips (HM450K) is an array-based 
method developed for the genome-wide profiling of DNA methylation. Whilst the 
platform is limited to the characterisation of a very small proportion of the human 
CpG content (~ 2%), it remains a popular choice in the analysis of large sample 
cohorts for which it represents an affordable approach to generate DNA methylome 
data (Rakyan et al. 2011; Y. Liu et al. 2013; Michels et al. 2013). Furthermore, the 
method requires a low amount of DNA input (500 ng) which make it suitable for 
studies in which DNA is a limiting factor. 
 
The HM450K platform contains more than 485,000 probes distributed throughout the 
genome. Of the pool of probes, 482,421 interrogate CpG sites (~ 2% of human CpG 
content), 3091 non-CpG sites and 65 interrogate random single-nucleotide 
polymorphism sites. They were selected from WGBS data and input from DNA 
methylation experts and they cover 99% of RefSeq genes with an average of 17 
probes per gene, 96% of CpG islands from the UCSC database, CpG island shores, 
DNAse I hypersensitive sites and regulatory elements such as enhancers (Bibikova 
et al. 2011). 
 
HM450K is constituted of two types of beads, Infinium I and Infinium II. Infinium I 
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beads were designed for the Infinium HumanMethylation27 BeadChip, which is the 
precursor of HM450K. The design of Infinium I beads consists of two probes per 
locus, one for the methylated allele and one for the unmethylated allele, and the base 
extension is the same for the methylated or unmethylated alleles (i.e. the fluorescent 
signal does not carry any information on the methylation status). Infinium II beads 
are specific for HM450K. The design of Infinium II beads consists of a single type of 
probe per locus, and the methylation information is obtained through dual channel 
single-nucleotide primer extension with labelled dideoxynucleotides on the 
methylation variable position of a CpG (Figure 4.1) (Bibikova et al. 2011; 
Dedeurwaerder et al. 2014; Morris and Beck 2015). 
 
Infinium I and Infinium II also differ in the reported derived methylation values, which 
for both is reported as beta-value (β = intensity of the Methylated allele (M) / (intensity 
of the Unmethylated allele (U) + intensity of the Methylated allele (M) + 100) and 
where β = 0 is equivalent to unmethylated and β = 1 is equivalent to 100% 
methylated. Infinium II probes were found to exhibit a much lower dynamic range of 
methylation values compared to Infinium I probes (0 to 0.922 for Infinium II versus 0 
to 0.971 for Infinium I) (Dedeurwaerder et al. 2011). Infinium II probes were also 
found to be less sensitive for the detection of extreme methylation values (i.e. 0 and 
1) and less reproducible than Infinium I (standard deviation = 0.029 for Infinium II 
versus 0.008 for Infinium I) (Dedeurwaerder et al. 2011). Therefore, it is important to 
normalise the data to correct for the Infinium I and Infinium II probe differences. 
Several methods have been developed to address these issues (Cazaly et al. 2016). 
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These include Subset-quantile Within Array Normalisation (SWAN) (Maksimovic et 
al. 2012), Dasen (Pidsley et al. 2013), Beta-MIxture Quantile dilation (BMIQ) 




Figure 4.1: Overview of the Infinium I and Infinium II bead types. 
(a) Infinium I and (b) Infinium II present on the HM450K. M, Methylated; U, 






Following the unsuccessful design of a novel NGS strategy for the methylation 
profiling of imprinting regions in BWS and SRS, I undertook the characterisation of 
the nature and frequency of MLID in a large cohort of BWS and SRS individuals 
using the robust HM450K platform. To that end, I developed a bioinformatic pipeline 
that can preprocess and handle large cohort methylation dataset and detect with 
accuracy epimutations at targeted regions, including imprinting DMRs (Table 3.1), in 
BWS and SRS individuals. Finally, I screened the patients methylomes to identify 
genomic regions that appeared to have an aberrant methylation profile and could 
possibly be involved in the molecular aetiology of the diseases. 
 
 
4.2 Materials and methods 
4.2.1 Patient blood DNA 
According to the criteria described in the literature (http://www.geneclinics.org), BWS 
was diagnosed in 90 screened patients and SRS was diagnosed in 21 screened 
patients. For BWS, the molecular diagnostic investigations undertaken in NHS 
laboratories identified GOM at H19/IGF2:IG-DMR (BWS_IC1) in 4 individuals, 
paternal UPD11 (BWS_UPD11) in 8 individuals and LOM at KCNQ1OT1:TSS-DMR 
(BWS_IC2) in 78 individuals. For SRS, the molecular diagnostic identified LOM at 
H19/IGF2:IG-DMR (SRS_IC1) in 15 individuals and maternal UPD7 (SRS_UPD7) in 
6 individuals. Written informed consent was obtained and ethical approval was 
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obtained from South Birmingham Research Ethics committee. For the 1472 healthy 
individuals that were included in my control group, 30 originated in-house whilst the 
remaining 1442 originated from collaborators.  
 
4.2.2 DNA quantification 
See section 2.3 - DNA quantification. 
 
4.2.3 Sodium bisulfite treatment 
See section 2.4 - Sodium bisulfite treatment. 
 
4.2.4 DNA methylation profiling using HM450K 
In order to obtain the genome wide methylation profiles, genomic DNA from patients 
with BWS (n=90) or SRS (n=21) and normal control individuals (n=1472; 30 
individuals in-house and 1442 individuals from collaborators) was bisulfite treated 
(see section 2.4 - Sodium bisulfite treatment), processed on the HM450K (see 
section 2.5 - Infinium HumanMethylation450 BeadChip) and analysed as described 
below (Figure 4.2). 
 
The sample preparation (i.e. DNA quantification and dilution prior HM450K) of the 
111 BWS and SRS patients and of 30 out of 1472 normal individuals was done by 
me. The methylation profiling of these individuals was then done at the Cambridge 
Genomic Services. The sample preparation of the remaining 1442 normal individuals 
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was done by collaborators and, of those, the methylation profiling of 1402 was also 
done at the Cambridge Genomic Services. The methylation profiling of the remaining 




Figure 4.2: Overview of the genome-wide methylation profiling workflow. 
 
 
4.2.4.1 Bioinformatic pipeline to analyse HM450K methylation dataset 
4.2.4.1.1 HM450K data preprocessing 
Data filtering and normalisation were performed in R with RnBeads (Assenov et al. 
2014). Samples with detection P-value > 0.01 were filtered out. Infinium probes 
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containing SNPs and sites with excessive missing values were filtered out. In 
addition, probes with detection P-value > 0.01 and probes that lack signal values in 
one or more of the DNA samples analysed were also filtered out. Probe intensities 
were then normalised with beta-mixture quantile (BMIQ) normalisation (Teschendorff 
et al. 2013). Finally, probes located on sex chromosomes and in a non-CpG context 
were removed to discard any bias within samples. β values (i.e. equivalent to the 
absolute DNA methylation levels) and M-value (i.e. logistically transformed β values) 
were then generated for each probes. The R script used to process the data is 
available in Appendix 1. 
 
4.2.4.1.2 HM450K data batch correction 
Methylation data were corrected for technical (e.g. array slides and array positions) 
and biological (e.g. age) effects. I used ComBat method (Johnson et al. 2007) 
included in the sva (Leek et al. 2012) R package to perform the correction. The R 
script used to process the data is available in Appendix 2. 
 
4.2.4.1.3 Epimutation methodology 
To define LOM and GOM, I extracted the methylation value (β -value) of each 
HM450K CpG probes within target regions for all patients and normal individuals. I 
then computed the mean methylation index (MI) at each target regions for all 
individuals (i.e. patients and controls) and calculated MI standard errors (SE) for all 
patients. I also calculated the grand mean MI and associated standard deviation 
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(SD) for normal individuals. At each target region, samples were considered 
demonstrating GOM (above) or LOM (below) if both conditions were filled: 
i. their MI and SE were above or below 3 SDs calculated from the grand mean of 
the normal individuals group. 99.73% of values lie within 3 SDs of the mean. 
Consequently, using such stringent threshold should significantly limit the 
discovery of false positives. 
ii. at least 60% of the patient interrogated probes were above or below the 3 SDs 
threshold (Figure 4.3). 
 
 
Figure 4.3: Illustration of epimutation methodology. 
 
Additionally, polymorphic methylation change at each target regions were assessed 
by Fisher’s exact test followed by false discovery rate (FDR) correction. Statistical 
tests were performed in R. Aberrant methylation, either GOM or LOM, with FDR ≥ 
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0.05 were considered polymorphic (Table 4.6). 
 




Establishing methylation profiles for all BWS and SRS patients across the targeted 
regions (e.g. imprinted DMRs) was performed in R. Providing the manual input of 
the required variables, the R script will automatically load methylation data, subset 
and save methylation data associated with CpG probes overlapping the region of 
interest, compute GOM and LOM in patient and in control individuals and save a 
corrected (i.e. all reported loci that are not polymorphic) and uncorrected (i.e. some 
reported loci may be polymorphic) epimutation table for all patients. The R script 
used to process the data is available in Appendix 3. 
 
4.2.4.1.4 DMR hunting 
Bumphunter (Jaffe et al. 2012; Aryee et al. 2014) function was used to identify 
genomic regions that were differentially methylated between two conditions (e.g. 
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BWS_IC1 patients versus control individuals). The function was run in R and the 
script used to process the data is available in Appendix 4. It first computed a t-
statistic with smoothing at each genomic location. Then, it defined a candidate region 
to be a cluster of probes for which all the t-statistics exceeded a predefined threshold 
(delta β ≥ 0.15 between the two groups) and significance of the candidate regions 
was calculated using permutations test (n=1000). Candidate regions with FDR > 
0.05, FWER (family-wise error rate) > 0.3 and encompassing less than three probes 
were filtered out. 
 
4.3 Results 
4.3.1 Data pre-processing 
4.3.1.1 Normalisation 
In normal conditions, the majority of CpG sites can be either methylated or 
unmethylated. On the HM450K, this assumption can be defined with a density 
methylation peak at β~0 (i.e. 0% methylated) and β~1 (i.e. 100% methylated). In the 
uncorrected HM450K dataset (i.e. 21 BWS, 91 SRS and 1471 normal control 
individuals), I observed a peak of methylation distribution at β~0.2 (i.e. 20% 
methylated) and another peak at β~0.7 (i.e. 70% methylated) (Figure 4.4, red line). 
This could be explained by the chemistry differences between the two types of 
probes within HM450K array (i.e. Infinium I and Infinium II). Indeed, Infinium II probes 
are known to be less accurate than Infinium I probes and therefore, data needed to 
be corrected prior to analysis (Dedeurwaerder et al. 2011). Hence, methylation 
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values were normalised with Beta Mixture Quantile (BMIQ) normalisation algorithm 
(Teschendorff et al. 2013) included in RnBeads R package (Assenov et al. 2014). 
After correction, peaks of density methylation shifted from β~0.2 to β~0.05 and from 
β~0.7 to β~0.9 (Figure 4.4, blue line), illustrating the effectiveness of the data 
normalisation. 
 
Figure 4.4: Effect of the correction on methylation value. 
Infinium I and Infinium II β value (i.e. methylation value) were corrected with BMIQ 




After normalisation, problematic samples and probes were filtered out. Out of the 
1583 samples, 33 control individuals were removed due to bad sample P-value 
(higher than 0.01). Out of the 485577 probes present on the HM450K array, 413997 
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were retained for analysis. The remaining 71580 probes were removed because 
12416 probes overlapped with SNPs in their last 5 bases of their targets, 29675 
probes contained non-specific sequences and had a high likelihood of cross-
hybridisation, 19071 probes had low quality (P-value > 0.01), 1074 probes were not 
in CpG contexts and 9344 probes were on sex chromosomes Figure 4.5). 
 
Figure 4.5: Proportion of retained and removed probes. 
Probes overlapping SNPs, non-specific, with P-value above 0.01, on sex 
chromosomes or in a non-CpG context were removed from analysis. 
 
 
4.3.1.3 Batch effect and biological artefacts correction 
Batch effects (Leek et al. 2010) are systematic biases in the data that are unrelated 
to the research question but that arise from undesirable differences in sample 
handling (i.e. chip or instrument used, date of experiment, technician running 
samples, etc.). The control individuals methylation dataset has been processed on 
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the same platform (Cambridge Genomic Services) but on different date, different 
HM450K array slides, and by different technicians, resulting in potential batch 
effects. Although not all technical variabilities were known, the array slides and array 
positions were accounted for batch effects correction. 
Biological artefacts are unwanted variations (i.e. gender, sex, tissue, etc.) that could 
also lead to biases in the data. As an example, loss of DNA methylation is observed 
in ageing (Wilson et al. 1987; Fraga et al. 2007). BWS and SRS are both paediatric 
disorders. Hence, it was important to use an age-match control individual population 
for comparison. Age of patient and control individuals were first estimated ((Horvath 
2013), https://labs.genetics.ucla.edu/horvath/dnamage/). An age difference was 
observed between the disease patients group (mean: 6.9 years old) and normal 
individual controls group (mean: 56 years old) (Table 4.7). Age of all individuals were 
then categorised into 9 groups (A, 0 to <10 years old; B, 10 to <20 years old; C, 20 
to <30 years old; D, 30 to <40 years old; E, 40 to <50 years old; F, 50 to <60 years 
old; G, 60 to <70 years old; H, 70 to <80 years old; I, 80 to <90 years old) and the 
age variable was accounted for biological artefacts correction. 
 
Table 4.7: Age distribution in disease and normal individual groups.  
 Mean age (in years) 
Standard 
deviation 
Disease patient group (n=111) 6.9 9.6 




To remove both technical (i.e. array slides and array positions) and biological (i.e. 
age) effects, I used the ComBat method (Johnson et al. 2007) included in the sva R 
package (Leek et al. 2012). Principal component analysis before applying ComBat 
showed variable data (multiple clusters) most likely related to technical and biological 
effects as further confirmed by principal component regression analysis (Figure 4.6-
a and b). After applying ComBat on the normalised methylation data, the variability 
observed among the 1550 individuals is now mostly associated with the disease 
status of individuals (i.e. Sample_Group) and most of the bias associated with both 
technical batch effects (i.e. Sentrix_Position and Sentrix_ID) was efficiently removed 
from data. Bias associated with age was also removed but in a lesser extent (Figure 
4.6-c and d). The age of individuals was confounded with their disease status (i.e. 
young BWS and SRS patients, and old normal control individuals), thus resulting in 





Figure 4.6: Effects of technical and biological artefacts. 
On normalised data, the 10000 most variable probes were analysed by principal 
component analysis and by principal component regression analysis (a-b) before 
and (c-d) after ComBat correction. Principal component regression analysis was 
performed in R using ENmix (Xu et al. 2016). 
 
 
4.3.2 Targeted methylation profiling 
I first investigated and compared the methylation index (MI) at 46 targeted imprinted 
DMRs in BWS and SRS patients with the MI in a group of normal individuals. I 
defined a MI in patients above or below 3 standard deviations calculated from the 
grand mean of the normal individuals as hyper- or hypomethylated respectively.  
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4.3.2.1 Methodology validation 
My method based on three standard deviations epimutation threshold was validated 
by investigating MI at H19/IGF2:IG-DMR and KCNQ1OT1:TSS-DMR in five group of 
patients (i.e. BWS_IC1, BWS_IC2, BWS_UPD11, SRS_IC1 and SRS_UPD7). In our 
cohort, MI at both loci have been previously tested in a clinical setting for diagnostic 
purposes and epimutations, if any, were already known. Using HM450K array and 
my methodology, the H19/IGF2:IG-DMR locus was hypermethylated in all (n=4) 
BWS_IC1 patients and in 7 out of 8 patients with BWS_UPD11, hypomethylated in 
all (n=15) SRS_IC1 patients, and a MI within the normal range was observed in all 
BWS_IC2 (n=78) and SRS_UPD7 (n=6) patients and in 1 out of 8 patient with 
BWS_UPD11 (Figure 4.7-a). The KCNQ1OT1:TSS-DMR locus was hypomethylated 
in all BWS_IC2 and BWS_UPD11 patients, and normal methylation was observed in 
all BWS_IC1, SRS_IC1 and SRS_UPD7 patients (Figure 4.7-b). Although this 
methodology was very stringent and conservative, the results were mostly consistent 
with the results from clinical molecular testing using methylation-specific multiplex 
ligation-dependent probe amplification. I found complete correlation between the 
results from clinical testing and HM450K analysis of the methylation patterns at 
H19/IGF2:IG-DMR and KCNQ1OT1:TSS-DMR in 110 of 111 patients. The exception 
was one individual with BWS diagnosed with pUPD11 in whom the expected 





Figure 4.7: Methodology validation. 
Methylation index (β-value) of all patients was measured at (a) H19/IGF2:IG-DMR 
and (b) KCNQ1OT1:TSS-DMR. The black box represents normal individuals range: 
top of the box is 3 standard deviations above control individuals grand mean, the 
bottom of the box is 3 standard deviations below control individuals grand mean and 
the middle line is grand mean of control individuals. BWS_IC1, BWS patient with IC1 
GOM; BWS_IC2, BWS patients with IC2 LOM; BWS_UPD11, BWS patients with 




4.3.2.2 Polymorphic imprinted DMRs 
Following method validation, methylation profiling was performed at 46 imprinted 
DMRs (Table 3.1) across all individuals. Whilst multiple epimutations were observed 
in our disease patient group it was necessary to discriminate between methylation 
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abnormalities that were (i) probably linked to the disorder (i.e. outcome of interest), 
(ii) random epigenetic events or (iii) common within general population (Tee et al. 
2013). Although discriminating between the random occurrence of epigenetic events 
and linkage to the disorder was complicated, it was possible to assess whether or 
not the observation was common in the general population (i.e. polymorphic). In this 
regard, the number of GOM and LOM findings were calculated for all loci in both 
populations and compared using Fisher’s exact test followed by false discovery rate 
(FDR) adjustment using the Benjamini-Hochberg procedure (Benjamini and 
Hochberg 1995). For GOM, out of the 46 investigated imprinted DMRs 12 had MI 
within normal individual range and 34 loci were hypermethylated, of which 8 were 
significant (FDR <0.05) and 26 were polymorphic. For LOM, 6 imprinted DMRs had 
MI within normal individual range and 40 loci were found hypomethylated, of which 
22 were significant (FDR <0.05) and 18 were polymorphic (Table 4.8). 
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4.3.2.3 Targeted methylation profiling of SRS patients at imprinted DMRs 
4.3.2.3.1 SRS with mUPD7 cohort 
Methylation profiling of 6 individuals in the SRS_UPD7 group showed 
hypermethylation at GRB10:alt-TSS-DMR, PEG10:TSS-DMR, MEST:alt-TSS-DMR 
and HTR5A:TSS-DMR in all patients. This was expected as these DMRs are located 
on chromosome 7 and are methylated on the maternal allele. In addition, 1 patient 
had GOM at ZDBF2/GPR1:IG-DMR and LOM at IGF1R:Int2-DMR. MLID was 
detected in only 1 patient out of 6 (17%) (Figure 4.8). 
 
4.3.2.3.2 SRS with IC1 LOM cohort 
Methylation profiling of 15 individuals in the SRS_IC1 group showed, as expected, 
hypomethylation at H19/IGF2:IG-DMR in all patients. In addition, hypomethylation at 
IGF2:alt-TSS-DMR was also detected in 11 patients out of 15, but this was not 
considered as MLID as both H19/IGF2:IG-DMR and IGF2:alt-TSS-DMR belong to 
the same imprinted cluster. Finally, one SRS_IC1 patient had an additional LOM at 
L3MBTL1:alt-TSS-DMR and, interestingly, one other patient had GOM at imprinted 
DMRs (GRB10:alt-TSS-DMR, PEG10:TSS-DMR, MEST:alt-TSS-DMR and 
HTR5A:TSS-DMR) located on chromosome 7 and normally associated with 
SRS_UPD7 aetiology (Figure 4.8). Taken together, these results suggested that 





Figure 4.8: Multilocus imprinting disturbances and SRS. 
Epimutations at imprinted DMRs in SRS_UPD7 (n=6) and SRS_IC1 (n=15). 
Epimutations distribution in the different SRS group of patients (x-axis) across the 
46 interrogated imprinted DMRs (y-axis). Red, loss-of-methylation; green, gain-of-
methylation; black: no epimutations. 
 
 
4.3.2.4 Targeted methylation profiling of BWS patients at imprinted DMRs 
4.3.2.4.1 BWS with pUPD11 cohort 
As previously mentioned (see section 4.3.2.1 - Methodology validation) methylation 
profiling of 8 individuals in the BWS_UPD11 group showed GOM at H19/IGF2:IG-
DMR and IGF2:alt-TSS-DMR in 7 out of 8 patients, GOM at IGF2:Ex9-DMR in 1 out 
of 8 patients and LOM at KCNQ1OT1:TSS-DMR in all patients. For 7 out of 8 
patients, these results are consistent with clinical diagnosis. As expected, 
H19/IGF2:IG-DMR is hypermethylated and KCNQ1OT1:TSS-DMR is 
hypomethylated. For one patient, we failed to detect hypermethylation at 
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H19/IGF2:IG-DMR, but this could be explained by our very stringent methodology. 
Finally, 1 out of 8 (12.5%) patient has MLID. The patient has hypermethylation at 
PEG10:TSS-DMR (Figure 4.9). 
 
4.3.2.4.2 BWS with IC1 GOM cohort 
Methylation profiling of 4 individuals in the BWS_IC1 group showed, as expected, 
hypermethylation at H19/IGF2:IG-DMR and IGF2:alt-TSS-DMR in all patients and 
two patients had hypermethylation at IGF2:Ex9-DMR. MLID was not detected in this 
group of patient (Figure 4.9). 
 
4.3.2.4.3 BWS with IC2 LOM cohort 
Methylation profiling of 78 individuals in the BWS_IC2 group showed, as expected, 
LOM at KCNQ1OT1:TSS-DMR in all patients. Additionally, MLID was detected in 31 
out of 78 (40%) of patients of this cohort. Of the 31 BWS_IC2 with MLID, 5 (16%) 
patients had GOM at ZDBF2/GPR1:IG-DMR and LOM was observed in 8 (26%) at 
DIRAS3:TSS-DMR, 5 (16%) at DIRAS3:Ex2-DMR, 8 (26%) at FAM50B:TSS-DMR, 
5 (16%) at PLAGL1:alt-TSS-DMR, 5 (16%) at IGF2R:Int2-DMR, 4 (13%) at 
MEST:alt-TSS-DMR, 14 (45%) at FANCC:Int1-DMR, 2 (6%) at INPP5F:Int2-DMR, 2 
(6%) at SNURF:TSS-DMR, 5 (16%) at IGF1R:Int2-DMR, 3 (10%) at ZNF331:alt-
TSS-DMR1, 3 (10%) at ZNF331:alt-TSS-DMR2, 3 (10%) at NNAT:TSS-DMR, 10 
(32%) at L3MBTL1:alt-TSS-DMR, 3 (10%) at GNAS-AS1:TSS-DMR, 2 (6%) at 
GNAS-XL:Ex1-DMR, 3 (10%) at GNAS-AB:TSS-DMR, 3 (10%) at WRB:alt-TSS-




Figure 4.9: Multilocus imprinting disturbances and BWS. 
Epimutations at imprinted DMRs in BWS_UPD11 (n=8), BWS_IC1 (n=4) and 
BWS_IC2 (n=78). Epimutations distribution in the different BWS group of patients 
(x-axis) across the 46 interrogated imprinted DMRs (y-axis). Red, loss-of-




Figure 4.10: Comparison of the frequency of epimutated DMRs in BWS_IC2 
with MLID patients. 
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MLID frequency calculated in the current study was significantly higher (p=0.0051) 
than the frequency obtained from seven combined previous reports. However, when 
compared to two previous studies that also used HM450K for methylation profiling 
(Court et al. 2013; Maeda et al. 2014), the MLID detection rates were similar 
(p=0.421) (Table 4.9). 
 
Compared to the imprinted DMRs that were investigated in at least 3 other studies, 
the frequency of disturbances calculated in my cohort was concordant with previous 
reports at PEG10:TSS-DMR, H19/IGF2:IG-DMR, MEG3:TSS-DMR, SNRPN:alt-
TSS-DMR, PEG3:TSS-DMR. Those loci were found mostly unaffected in the 
majority of studies, including mine. However, the frequency of disturbances observed 
at PLAGL1:alt-TSS-DMR, IGF2R:Int2-DMR, GRB10:alt-TSS-DMR, MEST:alt-TSS-
DMR, GNAS-NESP:TSS-DMR, GNAS-AS1:TSS-DMR, GNAS-XL:Ex1-DMR was 
below the 25th percentile calculated from the 7 previous studies at those DMRs. 
Nonetheless, it was noted that the observed frequency of epimutations reported 
previously was very variable between studies. As an example, PLAGL1:alt-TSS-
DMR was epimutated in 16% in our cohort and in 39% (median) with a minimum of 
7%, a maximum of 63% and a standard deviation of 18.6 in previous studies. 
Similarly, MEST:alt-TSS-DMR was epimutated in 13% in our cohort and in 35% 
(median) with a of minimum 7%, a maximum of 61% and a standard deviation of 









Figure 4.11: Meta-analysis of reported MLID frequency in BWS_IC2 cohort. 
Comparison of the frequency of disturbances across imprinted DMRs in BWS_IC2 
MLID observed in the current study (red triangle) and in 7 previous studies (colour 
dots). Box-and-whisker plots were calculated from the 7 previous reports indicated 
in plot key. 
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The number of additional epimutated DMRs per patient ranged from 1 to 12. The 
majority of patient had only 1 (10/31) or 2 (8/31) additional epimutated DMRs and 
the remaining 13 patients had between 3 and 12 additional epimutated DMRs, 
indicating that the more additional epimutated DMRs was observed the fewer 
patients were affected (Figure 4.12-a). Within these 31 patients, I counted a total of 
139 epimutations affecting 21 imprinted DMRs. Out of the 139 observed 
epimutations, 134 were LOM affecting 20 maternal imprinted DMRs (DIRAS3:TSS-
DMR, DIRAS3:Ex2-DMR, FAM50B:TSS-DMR, PLAGL1:alt-TSS-DMR, IGF2R:Int2-
DMR, MEST:alt-TSS-DMR, FANCC:Int1-DMR, INPP5F:Int2-DMR, 
KCNQ1OT1:TSS-DMR, SNURF:TSS-DMR, IGF1R:Int2-DMR, ZNF331:alt-TSS-
DMR1, ZNF331:alt-TSS-DMR2, NNAT:TSS-DMR, L3MBTL1:alt-TSS-DMR, GNAS-
AS1:TSS-DMR, GNAS-XL:Ex1-DMR, GNAS-AB:TSS-DMR, WRB:alt-TSS-DMR, 
SNU13:alt-TSS-DMR). The remaining 5 disturbances were GOM affecting the 
paternal DMRs ZDBF2/GPR1:IG-DMR (Figure 4.12-b). This suggested that LOM 
was more common than GOM in BWS_IC2, and that LOM occurred at maternal 
DMRs only whilst GOM was more associated with paternal DMRs. No epimutation 
preference toward maternal DMRs was found as statistical test failed to reach 





Figure 4.12: Imprinting disturbances in BWS_IC2 patients. 
(a) Comparison of the number of additional epimutated loci in BWS_IC2 with MLID 
patients. (b) Comparison of the total GOM and LOM in BWS_IC2 with MLID patients. 
(c) Comparison of the number of aberrantly methylated DMRs between matDMRs 
and patDMRs. Fisher’s exact test was used for statistical analysis. GOM, gain-of-




Epimutation correlation and associated significance level were calculated for all 
imprinted DMRs detected to be epimutated in BWS_IC2 MLID patients. Using an 
absolute correlation threshold of at least 0.6 and significance level threshold of 0.01, 
IGF1R:Int2-DMR, GNAS-AS1:TSS-DMR, GNAS-XL:Ex1-DMR and GNAS A/B:TSS-
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DMR had significant positive correlation. The two imprinted DMRs located at 
DIRAS3 locus (DIRAS3:TSS-DMR and DIRAS3:Ex2-DMR) had significant positive 
correlation. The two imprinted DMRSs located at ZNF331 locus (ZNF331:alt-TSS-
DMR1 and ZNF331:alt-TSS-DMR2) had significant positive correlation. Finally, 
NNAT:TSS-DMR on chromosome 20 had significant positive correlation with 
ZNF331:alt-TSS-DMR1, ZNF331:alt-TSS-DMR2 on chromosome 19 and 






Figure 4.13: Epimutations correlation calculated at epimutated imprinted 
DMRs in BWS_IC2 MLID patients. 
Pearson's product-moment correlation was used to compute correlation and 
associated p-value. Numeric values, r correlation; red, toward negative correlation; 







4.3.3 DMR hunting 
Bumphunter (Jaffe et al. 2012; Aryee et al. 2014) R package was used to identify 
genomic regions that were differentially methylated between two conditions (e.g. 
BWS_IC1 patients versus control individuals). Resulting candidate regions were 
then processed with our epimutation methodology (see section 4.2.4.1.3 - 
Epimutation methodology) to retain the most interesting ones. Following this 
procedure, I detected DMRs at most of the well-described loci involved in the 
aetiology of each group of patients (H19/IGF2:IG-DMR, KCNQ1OT1:TSS-DMR, 
PEG10:TSS-DMR, MEST:alt-TSS-DMR and GRB10:alt-TSS-DMR). In addition, I 
found two new significant DMRs overlapping the promoter of the lymphotoxin alpha 
(LTA) gene (Figure 4.14-a) and in the exon 4 of the solute carrier family 12 member 
9 (SLC12A9) gene (Figure 4.14-b) in BWS_IC2. LTA promoter was found 
hypomethylated in 7 out of the 78 (9%) BWS_IC2 patient and SLC12A9 exon 4 was 
found hypermethylated in 34 out of 78 (44%) patients (Figure 4.14-c). I also found 
two new significant DMRs overlapping SLC12A9 exon 4 (Figure 4.14-d) and in the 
promoter of the potassium voltage-gated channel subfamily A regulatory beta 
subunit 3 (KCNAB3) gene (Figure 4.14-e) in BWS_UPD11. To be noted that two 
probes within SLC12A9 DMR detected in BWS_UPD11 were not found significant in 
BWS_IC2, resulting in a smaller cluster in the latter group. SLC12A9 exon 4 was 
found hypermethylated in 6 out of 8 (75%) BWS_UPD11 patients and KCNAB3 
promoter was found hypomethylated in 4 out of 8 (50%) patients (Figure 4.14-f). No 
additional significant DMRs were found in BWS_IC1, SRS_IC1 and SRS_UPD7 
 
132 
(Table 4.10). Finally, although it was not detected by bumphunter, I also found that 
KCNAB3 promoter was hypomethylated in 14 out of 78 (18%) BWS_IC2 patients 
(Figure 4.15-a, b). 
 
 
Figure 4.14: DMR hunting in BWS. 
(a,b,d,e) Methylation index (y-axis) of HM450K CpG probes (x-axis) of patients 
(orange) and normal individuals (blue) at (a) LTA (b) SLC12A9 in BWS_IC2 and at 
(d) SLC12A9 and (e) KCNAB3 in BWS_UPD11. Vertical black lines represent DMR 
boundaries defined by bumphunter. (c,f) Frequency of (c) BWS_IC2 and (f) 









Figure 4.15: KCNAB3 is also aberrantly methylated in BWS_IC2. 
(a) Methylation index (y-axis) of HM450K CpG probes (x-axis) of BWS_IC2 patients 
(orange) and normal individuals (blue) at KCNAB3 promoter. Vertical black lines 
represent DMR boundaries detected in BWS_UPD11. (b) Frequency of BWS_IC2 





Data preprocessing was performed with the R package RnBeads, a specialist 
bioinformatic pipeline designed to handle HM450K data. Technical and biological 
biases were efficiently removed from data using the R package ComBat although 
the algorithm started to show its limitations whilst dealing with confounding 
covariates such as the age in our dataset. The use of younger normal control 
individuals and a better random allocation of the samples to HM450K slides and 
HM450K positions (i.e. Sentrix_ID and Sentrix_Position respectively) to minimise 
confounding covariates would have greatly helped to reduce the bias associated with 
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those variables. Additionally, the ComBat algorithm would have performed better for 
bias correction. However, the methylation data used in this study was generated by 
multiple groups (i.e. our group and collaborators) and therefore it was hardly possible 
to elaborate a better experimental design that took into account all of those variables. 
 
4.4.2 Methodology 
My epimutation methodology was validated by assessing the methylation level at 
H19/IGF2:IG-DMR and at KCNQ1OT1:TSS-DMR in all patients. By comparison with 
clinical diagnostic testing results, my method detected the correct epimutation 
pattern in all individuals except for one BWS_UPD11 patient for which it failed to 
detect H19/IGF2:IG-DMR GOM. We hypothesised that mosaicism could explained 
the epimutation detection failure observed in that patient. Indeed, mosaicism is 
commonly associated with BWS_UPD11 patients (Slatter et al. 1994; Weksberg et 
al. 2010) and, hence, our method may not be sensitive enough to detect lower-level 
disomy in that group of patient. Selecting a two standard deviations threshold may 
have improved epimutation sensitivity detection for low-level disomy but this may 
have been at the cost of increasing false positive epimutation rate. In conclusion, our 
method performed well for the methylation profiling of BWS and SRS individuals at 
H19/IGF2:IG-DMR and at KCNQ1OT1:TSS-DMR and, therefore, it can be applied 
to other target regions such as other imprinted DMRs. However, additional care need 




4.4.3 Polymorphic epimutation 
The epimutation rate at each targeted imprinted DMR was evaluated in both patients 
and normal individuals. Comparison of both groups using Fisher’s exact test followed 
by FDR adjustment showed that more than half of imprinted DMRs with abnormal 
methylation findings were in fact polymorphic for GOM or LOM only or for both. This 
confirmed previous published data where the imprinted DMRs IGF2R:Int2-DMR was 
found polymorphic for GOM but not LOM (Tee et al. 2013). 
 
4.4.4 Genomic imprinting methylation in SRS_UPD7 
In SRS_UPD7, MLID was detected in 1 out of 6 (17%) patient. The individual had 
GOM at ZDBF2/GPR1:IG-DMR and LOM at IGF1R:Int2-DMR. Previous published 
data has shown hypermethylation at RB1, ANKRD11 and MCTS2 (Prickett et al. 
2015) in SRS_UPD7 patients, but none of these loci were found to be epimutated in 
our cohort. In our study, RB1 and MCTS2 were found polymorphic for both GOM and 
LOM (i.e. high frequency of GOM and LOM is observed in the normal control 
population) and ANKRD11 has not been evaluated. 
 
4.4.5 Genomic imprinting methylation in SRS_IC1 
In SRS_IC1, MLID was detected in 13% (2 out of 15). This is slightly above the 
published common consensus of 7-10% (9 out of 97 in combined previous reports; 
p=0.64) (Azzi et al. 2009; Turner et al. 2010). Of the two individuals with MLID, one 
had additional LOM at L3MBTL1:alt-TSS-DMR and, interestingly, the other one had 
 
137 
additional GOM at GRB10:alt-TSS-DMR, PEG10:TSS-DMR, MEST:alt-TSS-DMR 
and HTR5A:TSS-DMR. This observation was very intriguing as GOM at 
chromosome 7 is normally associated with SRS_UPD7 and not SRS_IC1. 
Additionally, methylation disturbances at these loci, if any, are generally LOM 
according to previous published data (Azzi et al. 2009; Turner et al. 2010; Court et 
al. 2013). Accordingly, this patient sample was suspected to have been mislabelled 
as SRS_IC1 instead of SRS_UPD7. Taking the latter patient out of that group, MLID 
was detected in approximatively 7% (1 of 14) of SRS_IC1. 
 
4.4.6 Genomic imprinting methylation in BWS_UPD11 
Of the 8 BWS_UPD11 patient, 1 (12.5%) had MLID. The patient has GOM at 
PEG10:TSS-DMR. To the best of my knowledge, this is the first time that an 
additional epimutation affecting another chromosome than chromosome 11 has 
been identified in BWS_UPD11 cohort. However, the clinical relevance of the 
findings is yet to be described. 
 
4.4.7 Genomic imprinting methylation in BWS_IC1 
MLID was not detected in any individuals although a recent report suggested that 
MLID can occurred in up to 30% (3 in 10) of BWS_IC1 patient (Maeda et al. 2014). 
In the latter, the germline DMR INPP5Fv2 was found hypomethylated in two patients 
and the somatic DMR NESP was found hypermethylated in a third patient. In our 
cohort, only a few patients (n=4) were methylation profiled and, hence, could 
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explained why no MLID was detected. 
 
4.4.8 Genomic imprinting methylation in BWS_IC2 
MLID was detected in 31 out of 78 (40%) of patients, which was significantly higher 
(p=0.0051) than the common consensus of approximatively 24% (all previous 
studies combined: 113 of 473) (Rossignol et al. 2006; Bliek et al. 2008; Azzi et al. 
2009; Court et al. 2013; Poole et al. 2013; Tee et al. 2013; Maeda et al. 2014). 
However, with the increasing use of modern technics such as Illumina methylation 
array, imprinted DMRs that were not assessed previously are also shown to be 
epimutated in BWS. Consequently, the previously reported consensus is likely to 
underestimate the frequency of MLID in BWS with IC2 LOM as some patients may 
have additional epimutations at previously unscreened imprinted DMRs but no 
abnormalities at previously screened imprinted DMRs. To support this hypothesis, 
the authors of two recent studies used high-throughput methods for the methylation 
profiling of more than 20 imprinted DMRs and both authors reported MLID in 14 out 
of 43 (33%) and in 15 out of 44 (34.1%) (Court et al. 2013; Maeda et al. 2014). Taken 
together with my study, it seems that the methylation profiling of more imprinted 
DMRs is associated with and increased frequency of MLID discovery through the 
identification of epimutated DMRs that were not screened in the past. Additionally, it 
confirmed that MLID is likely to be more frequent than originally thought. 
 
There was considerable variance in the number of loci affected, ranging from one to 
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12 additional imprinted DMRs and the majority of individuals had less than two 
disturbed loci. This showed that BWS_IC2 cases with extreme abnormal 
epigenotype are rare but still exist. It remained to evaluate the consequences of such 
extreme epigenotype and see if those rare patients have a more severe form of BWS 
or an unusual phenotype. 
 
Both paternal and maternal DMRs were affected with GOM associated with paternal 
DMRs and LOM associated with maternal DMRs. No epimutation preference toward 
maternal or paternal DMRs was found (p=0.106, Fisher’s exact test) which contrasts 
with a previous report where maternal DMRs have been found significantly more 
epimutated than paternal DMRs (p=0.042, Fisher’s exact test) (Maeda et al. 2014). 
 
The somatic locus ZDBF2/GPR1:IG-DMR was shown to gain methylation in 5 (16%) 
of our patient and it was the only interrogated imprinted DMRs that was 
hypermethylated. This acquisition was believed to being due to a concomitant LOM 
in the nearby maternally methylated GPR1-AS:TSS-DM, which is known to regulate 
the methylation of the somatic DMR ZDBF2/GPR1:IG-DMR in a hierarchical fashion 
(H. Kobayashi et al. 2013). In my study, methylation profiling at GPR1-AS:TSS-DMR 
did not show LOM but this was expected as GPR1-AS:TSS-DMR acquires 
immediate biparental methylation following implantation (H. Kobayashi et al. 2013). 
 
Finally, no distinct epimutation correlations were found between 'unrelated DMRs'. 
Imprinted DMRs belonging to the same imprinting cluster tend to be epimutated 
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simultaneously but this was expected. 
 
4.4.9 DMR hunting 
DMR hunting revealed 3 new potential candidate regions (SLC12A9, LTA and 
KCNAB3) that may be involved in BWS_IC2 and BWS_UPD11 aetiology. 
 
SLC12A9 belongs to the solute carrier 12 (SLC12) gene family. This gene family 
encodes electroneutral inorganic cation-chloride cotransporters (CCCs) that are 
plasma membrane proteins mediating the movement of inorganic sodium (Na+) 
and/or potassium (K+) cations, tightly coupled to the movement of chloride (Cl−) 
anions. Mutations and or dysfunctions in members of this gene family have been 
associated with pathophysiological disorders such as Bartter syndrome, Gitleman 
syndrome and Andermann syndromes (Gagnon and Delpire 2013). However, little is 
known about SLC12A9 for which no protein function has yet been described and 
relevance to human disease is not known. 
 
LTA gene encodes a cytokine produced by lymphocytes. The protein, belonging to 
the tumour necrosis factor family, is highly inducible, secreted, and forms 
heterotrimers with lymphotoxin-beta which anchor lymphotoxin-alpha to the cell 
surface. This protein also mediates a large variety of inflammatory, 
immunostimulatory, and antiviral responses, is involved in the formation of 
secondary lymphoid organs during development and plays a role in apoptosis. 
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Genetic variations in this gene are associated with susceptibility to leprosy type 4, 
myocardial infarction, non-Hodgkin's lymphoma, and psoriatic arthritis. However, 
LTA clinical relevance in BWS is currently not known. 
 
KCNAB3 gene encodes a member of the potassium channel, voltage-gated, shaker-
related subfamily. The encoded protein is one of the beta subunits, which are 
auxiliary proteins associating with functional Kv-alpha subunits. The encoded protein 
forms a heterodimer with the potassium voltage-gated channel, shaker-related 
subfamily, member 5 (KCNA5) gene product and regulates the activity of the alpha 
subunit (Leicher et al. 1998). Interestingly, recent published papers reported 
complete or partial LOM at KCNAB3 in MLID patients with, in some cases, mutation 
in NLR family pyrin domain containing 7 (NLRP7) gene and in ZFP57 zinc finger 











5.1.1 Assisted reproductive technologies and MLID 
Assisted reproductive technology (ART) is a generic term given to describe a number 
of different treatments, including ovarian stimulation, in vitro fertilisation (IVF) and 
intra-cytoplasmic sperm injection (ICSI), that can be performed to help achieve 
pregnancy. ART is used primarily for infertility treatment but can also be used for 
fertile couples to reduce the risk of potential diseases (e.g. when combined with 
preimplantation diagnosis). The potentially increased frequency of deregulated 
genomic imprinting in children conceived with the help of ART has raised concerns 
about how the procedures may predispose the embryos to acquire imprinting 
disturbances and in fine to diseases. 
 
5.1.1.1 Ovarian stimulation 
Ovarian stimulation (OS) is the induction of ovulation by the injection of a fertility 
hormone (e.g. clomiphene, gonadotropin). It is usually used to stimulate the 
development of ovarian follicles to reverse anovulation (where the ovaries do not 
release an oocyte) or oligoovulation (where ovulation is infrequent or irregular). To 
achieve ovulation and pregnancy, anovulatory and oligoovulatory patients are given 
enough hormones to reach a threshold sufficient to initiate growth and development 
of a number of follicles but ideally only maintain the growth of one follicle or certainly 




OS can also be used for controlled ovarian hyperstimulation (COH). In contrast to 
OS in anovulatory and oligoovulatory patients in which the aim is to produce a 
monofollicular ovulation, COH aims to produce multiple follicular development in 
order to harvest a suitable number of oocytes. Patients that undergo COH are given 
a larger dose of hormones than anovulatory and oligoovulatory patients to treat their 
conditions. COH is used in conjunction with ART procedures such as IVF or ICSI. 
 
In both OS and COH procedures, a trigger shot of hormones (e.g. human chorionic 
gonadotropin) can also be administered to patients to induce final maturation of 
oocytes and/or trigger oocytes release. This would allow scheduling sexual 
intercourse or intrauterine insemination and thus increasing chances of pregnancy 
in anovulatory and oligoovulatory patients. In the case of IVF or ICSI, this would avail 
the retrieval of fully mature eggs. 
 
Ovarian stimulation is considered a safe procedure but complication may arise in 
some cases. One of the main risk associated with OS and COH is that patients may 
develop an ovarian hyperstimulation syndrome (OHSS), which can occur when too 
much hormone medication is administered. Symptoms of OHSS range from mild 
abdominal distention due to swollen and painful ovaries alone or with an 
accompanying fluid shift into the abdomen, to renal failure and death as a result of 
haemoconcentration and reduced perfusion of organs such as the kidneys, heart 
and brain (Fiedler and Ezcurra 2012). There is also a risk of multiple pregnancy when 
an excess of follicles are produced. 
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5.1.1.2 In vitro fertilisation 
IVF treatment involves the fertilisation of an egg (or eggs) outside the body. The 
treatment can be performed using an individual’s own eggs and sperm, or using 
either donated sperm or donated eggs, or both. IVF is an ART procedure that is 
recommended in cases where there is underlying unexplained infertility problems, 
the fallopian tubes are blocked, the male partner has non severe fertility problems, 
or the embryos need to be tested to avoid passing on a genetic condition. The 
protocol used for IVF is not fully consistent between places, they can differ between 
birth centres and countries for example, but the concept remains the same. The IVF 
procedure starts with COH (see section 5.1.1.1 - Ovarian stimulation). The 
stimulated and matured eggs are then collected from ovaries and prepared for 
fertilisation. In parallel, sperm is washed to remove inactive cells and seminal fluid. 
Prepared eggs and sperm are incubated together in a culture media to achieve 
fertilisation. The embryos (fertilised eggs) are passed into growth media and cultured 
until cleavage stage or blastocyst stage. In some cases, preimplantation genetic 
diagnosis can be performed and one or two cells are removed from the developing 
embryo and tested for a specific genetic disease. Finally, selected embryos are 
transferred into the uterus. Non transferred embryos are stored by cryopreservation 
and may be used in subsequent cycles if pregnancy is not achieved after the first 
attempt. 
 
5.1.1.3 Intra-cytoplasmic sperm injection 
ICSI is most commonly used to overcome male fertility problems. The procedure is 
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very similar to IVF and only differs in the techniques used to fertilise the eggs. With 
ICSI, a matured and healthy single sperm is first selected and then directly injected 
into an egg. The embryos are cultured and transferred into the uterus in a similar 
manner to IVF. 
 
5.1.1.4 Evidence of ART disrupting genomic imprints 
Evidence to suggest that ART may disrupt normal growth and development through 
epigenetic alterations of genomic imprinting was first seen in animal studies. In large 
domestic animals, such as cattle and sheep, a considerable number of abnormally 
large animals were born subsequent to various embryo manipulations before the 
blastocyst stage. The resulting aberrant overgrowth phenotype seen in the animals 
was very similar to the human disorder BWS and it was referred to as the large 
offspring syndrome (LOS) (Young et al. 1998). At the time, it was hypothesised that 
LOS may be caused by an epigenetic deregulation that would impair gene 
expression, especially imprinted gene expression, and this could be a consequence 
of the embryo manipulations. The investigation of sheep foetuses recovered at day 
125 of gestation (term=147 days) and conceived by ART revealed that 12 out of 48 
foetuses had LOS (compared to none in naturally conceived foetuses, n=22). 
Interestingly, the aberrant phenotype observed in the 12 foetuses was associated 
with a significant reduction in the expression of the imprinted gene IGF2R. In 9 of 
the 12 foetuses, the reduced IGF2R gene expression was further explained by a 
loss-of-methylation of IGF2R-DMR2, the imprinting control region regulating IGF2R 
expression (Young et al. 2001). In mice, IGF2R was shown to degrade the excess 
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IGF2 (Ludwig et al. 1995) and mouse embryos lacking Igf2r were shown to be larger 
than normal at day 18.5 of gestation and at birth (Ludwig et al. 1996). More recently, 
the investigators of another study showed that in addition to the increased of 
bodyweight, LOS hybrid bovine foetuses conceived with ART have also 
macrosomia, macroglossia, and umbilical hernia, which are primary characteristics 
of BWS. More importantly, besides the phenotypic similarities the foetuses with LOS 
and conceived with ART also had epigenetic similarities with BWS. Indeed the 
investigators found that in these foetuses KCNQ1OT1, which is the main locus 
involved in BWS molecular aetiology (~ 50%), was biallelicaly expressed and this 
was due to a loss-of-methylation on the maternal allele of KCNQ1OT1:TSS-DMR (Z. 
Chen et al. 2013). 
 
5.1.1.5 Evidence of association between ART and imprinting disorders 
In humans, an association between ICSI and Angelman syndrome (AS) due to an 
imprinting defect was suggested following the report of three children who were 
conceived in such manner and subsequently developed the syndrome. Methylation 
profiling revealed complete or partial LOM at the imprinted DMR SNRPN:alt-TSS-
DMR (Cox et al. 2002; Ørstavik et al. 2003). 
 
A similar association between ART and BWS has also been reported. In the general 
population, the prevalence of ART is estimated between 0.8 and 1.3% whilst the 
prevalence of ART in BWS population is estimated between 4 and 4.6% (DeBaun et 
al. 2003; Gicquel et al. 2003; Maher et al. 2003). The investigators of a case-control 
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study performed in Australia reported a prevalence of ART in BWS group as high as 
10.81% whilst in the general population the ART prevalence was of 0.67% (Halliday 
et al. 2004). Interestingly, across these studies 95% of BWS patients conceived with 
ART were due to the LOM at KCNQ1OT1:TSS-DMR whilst in BWS patients 
conceived naturally the imprinting disturbance accounts for approximatively 50% of 
cases (DeBaun et al. 2003; Gicquel et al. 2003; Maher et al. 2003; Halliday et al. 
2004; Weksberg et al. 2010). Taken together, these reports showed clear evidence 
that ART is associated with BWS due to imprinting defects at KCNQ1OT1:TSS-
DMR. 
 
5.1.1.6 Investigation of potential ART association with MLID in BWS 
The study of several BWS with LOM at KCNQ1OT1:TSS-DMR (BWS_IC2) cohorts 
have identified a significant associations between MLID in BWS_IC2 and the use of 
ART. A first study reported that 3 out of 8 BWS_IC2 patients conceived with ART had 
MLID compared to 3 out of 47 for naturally conceived patients (p=0.034) (Lim et al. 
2009). In another report, MLID was detected in one BWS_IC2 patient conceived with 
the help of ART (ICSI) and in one out of five BWS_IC2 patients conceived naturally. 
Although only one ART patient was available, the authors suggested a possible 
association between BWS_IC2 and the widespread methylation disturbances (Hiura 
et al. 2012). Finally, the association was further demonstrated in a third report in 
which MLID was reported in 7 out of 14 BWS_IC2 ART patients compared to 26 out 
of 173 of patients conceived naturally (p=0.0033) (Tee et al. 2013). However, such 
associations are not consistent between publications and other research studies 
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have reported there was no significant association between the two. A first study 
suggesting there was no association reported MLID in 3 out of 11 BWS_IC2 patients 
conceived with ART and in 7 out of 29 patients conceived normally (p=1) (Rossignol 
et al. 2006). Furthermore, the investigators of another study reported MLID in 
BWS_IC2 in 4 out of 12 patients conceived with ART and in 12 out of 55 patients 
conceived naturally and they concluded that ART was not responsible for MLID 
(p=0.46) (Azzi et al. 2009). It remains unclear what is the impact of ART on genomic 
imprinting methylation but the study of more extensive patient cohort will help to 
determine whether or not ART predispose embryos to acquire imprinting errors and 
diseases. 
 
5.1.2 Trans-imprinting defect and MLID 
The genetic alterations of genes required for establishing and maintaining 
methylation, or shown to be essential for embryonic development may lead to the 
disruption of genomic imprinting methylation through trans-mechanism defects. 
Furthermore, several pieces of evidence have demonstrated that a subset of 
imprinted genes belongs to a co-ordinately regulated network. Within the same 
imprinted gene network, imprinted genes can modify in trans the expression of other 
imprinted genes (Varrault et al. 2006; Patten et al. 2016; Soellner et al. 2016). As an 
example, experiments in mouse brain neuroblastoma cell lines and meta-analysis of 
mouse microarray data sets have shown that the imprinted transcription factor Plagl1 
promotes the expression of several genes, including the imprinted genes Igf2, H19, 
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Kcnq1ot1, Cdkn1c and Dlk1 (Varrault et al. 2006). Therefore, the existence of such 
network may suggest that the genetic insult of a member of the network may first 
result in a cis-defect, and subsequently to further downstream trans-imprinting 
failures. However, no evidences reporting that this mechanism may acts at the 
imprinting methylation level were found yet.  
 
To date, a few pathological mutations affecting maternal-effect genes (NLRP7, 
KHDC3L (previously known as C6ORF221), NLRP2 and NLRP5) and maternal-
zygotic effect gene (ZFP57) were identified in syndromes with MLID. 
 
5.1.2.1 Maternal-effect and maternal-zygotic effect genes 
Maternal-effect genes are a special class of genes that are required for normal 
embryonic development. The RNA or protein products of those genes are supplied 
by the mother and are produced or deposited in the oocyte or are present in the 
fertilised egg or embryo before the expression of zygotic genes is initiated. In 
contrast, genes whose RNA and protein products are only produced after zygotic 
genome activation, at or after the maternal to zygotic transition stage, are zygotic 
genes (Marlow 2010). The maternal to zygotic transition starts during the early two-
cell stages in the mouse (L. Li et al. 2010) (Figure 5.1) and by the 4- to 8-cell stages 
in the human (Schultz 2002). 
 
To date, the gene knockout and gene knockdown in mammalian animal models 
(mice) and the study of rare human disorders have helped to identify approximatively 
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60 maternal-effect genes for which the zygotic transcription has not rescued the 




Figure 5.1: Maternal to zygotic gene transition in the mouse. 
Maternal RNA and proteins accumulate during oocytes maturation and will slowly 
degrade starting from the ovulation stage. In contrast, the activation of the embryonic 
genome will start from the 1/2-cell stage (E1.5) and will remain active thereafter. 
(Adapted from L. Li et al. 2010). 
 
 
5.1.2.1.1 Zygotic effect 
Recessive mutations disrupting the zygotic gene function will be visible in embryos 
homozygous for the mutant genotype. The abnormal embryo will inherit one copy of 
the mutated gene from its father and one copy of the mutated gene from its mother. 
Both parents will be heterozygous for the pathogenic mutation. Embryos with a 





Recessive mutations disrupting the maternal gene function will be visible in embryos 
for which the mother is homozygous for the mutant genotype (X. Li 2010; Marlow 
2010). The embryo genotype, either homozygous or heterozygous for the mutant 
allele, has no effect on the phenotype.  
 
5.1.2.1.3 Maternal-zygotic effect 
Recessive mutations disrupting maternal-zygotic gene function will be visible in 
embryos for which its genotype and its mother genotype are both homozygous for 
the mutant allele (X. Li 2010; Marlow 2010). If one of the embryo or the mother is 
heterozygous for the mutant genotype, the embryo may display a reduced or no 
signs of the abnormal phenotype.
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Table 5.11: List of mammalian maternal-effect genes. 
(Maternal-effect was mainly described in mice (Condic 2016)). 
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Table 5.11: List of mammalian maternal-effect genes (continued). 
(Maternal-effect was mainly described in mice (Condic 2016)). 
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Table 5.11: List of mammalian maternal-effect genes (continued). 





Familial biparental hydatidiform moles (FBHM) (OMIM 231090) are aberrant human 
pregnancies in which there is nonexistent or abnormal embryonic development, 
excessive trophoblastic proliferation, and cystic degeneration of chorionic villi into 
grape-like structures (Rezaei et al. 2016). Unlike complete hydatidiform moles which 
are mostly sporadic and wholly androgenic, women with FBHM suffer from recurrent 
molar pregnancies and the molar tissues are not androgenetic but show a normal 
pattern of bi-parental diploid inheritance (Van den Veyver and Al-Hussaini 2006). 
FBHM is associated with global failure in the establishment and or the maintenance 
of methylation marks at maternal imprinting centres during oocyte growth or post-
zygotic development, respectively. The genome-wide methylation analysis of molar 
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tissues showed widespread hypomethylation at maternal DMRs, including placental-
specific DMRs (Court et al. 2014), whilst the paternal DMRs (e.g. H19/IGF2:IG-DMR 
and MEG3/DLK1:IG-DMR) and non-imprinted regions are unaffected (Judson et al. 
2002; El-Maarri 2003; Djuric et al. 2006; Kou et al. 2008; Hayward et al. 2009; 
Sanchez-Delgado et al. 2015). The genetic investigations of FBHM identified 
recessive mutations in the maternal-effect gene NLRP7 in approximatively 70% of 
cases. Consequently, it was suggested that the NLRP7 maternal loss of function was 
responsible for FBHM phenotype (Murdoch et al. 2006; Kou et al. 2008; Hayward et 
al. 2009). To date, 59 pathogenic recessive mutations in NLRP7 have been 
described in the aetiology of FBHM (Reddy et al. 2016). 
 
NLRP7 (NLR family pyrin domain containing 7) is a maternal-effect gene for which 
the transcript product has been documented in a large number of human tissues 
including liver, lung, placenta, spleen, thymus, peripheral blood leukocytes, testis 
and ovaries (Slim and Wallace 2013). NLRP7 transcripts are found in all oocyte and 
preimplantation embryo stages (Murdoch et al. 2006). Its transcript concentration 
decreases during oocyte maturation until the morula stage where it reaches its 
lowest level. The transcript level then increases rapidly from day 3 to day 5, which 
corresponds to the blastocyst stage and the activation of the embryonic genome 
(Murdoch et al. 2006; P. Zhang et al. 2008; Slim and Wallace 2013). NLRP7 gene 
product was also found to be involved in cell proliferation, although its precise role 
has not been fully described yet (Okada et al. 2004; Khare et al. 2012). Some studies 
have suggested that NLRP7 silencing induces growth inhibition (Okada et al. 2004) 
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whilst others have suggested the opposite (Khare et al. 2012). NLRP7 is also known 
to be a negative feedback regulator of the interleukin 1 beta (IL-1B) cytokine and 
consequently plays a role in the inflammatory pathway (Kinoshita et al. 2005; 
Messaed et al. 2011). The inflammasome is an important mechanism during pre-
implantation of the embryo. It facilitates the implantation of the blastocyst, regulates 
the protease network and controls the extent to which the trophoblast may invade 
the maternal endometrium (Karmakar and Das 2002; Strakova et al. 2002; Murdoch 
et al. 2006). Finally, pathogenic mutations in NLRP7 may also be associated with 
the global maternal genomic imprinting alteration in FBHM, hence suggesting that 




Transient neonatal diabetes mellitus type 1 (TNDM1) is a form of diabetes mellitus. 
TNDM1 is caused by the over-expression of the PLAGL1 imprinted gene (paternally 
expressed) located at chromosome 6q24 (Gardner et al. 2000; Kamiya et al. 2000). 
The loss-of-methylation of the imprinting centre PLAGL1:alt-TSS-DMR, which is 
normally maternally methylated and regulates PLAGL1 gene expression, accounts 
for approximatively 20% of TNDM1 cases. Among these patients, approximatively 
half of them also have mosaic pattern of hypomethylation affecting other maternally 
methylated imprinted DMRs (Mackay et al. 2006). Recessive homozygous and 
compound heterozygous mutations in the maternal-zygotic gene ZFP57 have been 
identified in approximatively 50% of TNDM1 with MLID patients, consequently 
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suggesting that MLID may be the result of a trans-mechanism defects involving 
ZFP57 (Mackay et al. 2008). 
 
ZFP57 (ZFP57 zinc finger protein) is a maternal-zygotic gene that encodes for a 
protein containing a Krüppel-associated box (KRAB) domain and 7 zinc fingers. The 
maternal and zygotic products are both required for normal embryonic development. 
In mice, the single loss of zygotic Zfp57 results in partial neonatal lethality whilst the 
lost of both the maternal and the zygotic function results in a highly penetrant 
embryonic lethality (X. Li et al. 2008). Zfp57 was shown to be required for the 
establishment of DNA methylation at some maternally methylated DMRs but overall 
that it was not an essential factor for general maternal germline imprinting. Indeed, 
the loss of Zfp57 maternal function in oocytes results in the failure to establish 
methylation at the maternally methylated Snrpn DMR but not at Peg1, Peg3, and 
Peg5/Nnat DMRs (X. Li et al. 2008). ZFP57 is also essential for faithful maintenance 
of DNA methylation at paternal and maternal imprinted DMRs. The maintenance of 
DNA methylation at the paternally methylated IG-DMR and at the maternally 
methylated Snrpn, Peg1, Peg3, and Peg5/Nnat DMRs failed in embryos lacking both 
maternal and zygotic Zfp57 functions. In embryos lacking Zfp57 maternal function 
only, the loss of DNA methylation is rescued by the zygotic Zfp57, whilst the 
maintenance of DNA methylation is sometimes compromised in embryos lacking the 
zygotic Zfp57 only (X. Li et al. 2008). In humans, the study of TNDM1 patients 
showed that pathogenic mutations in ZFP57 was associated with mosaic pattern of 
MLID, hence demonstrating the critical role of ZFP57 in the maintenance of genomic 
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imprinting methylation (Mackay et al. 2008). Finally, the investigation of mouse 
embryonic stem cells revealed that ZFP57 recognises and binds specifically to the 
methylated TGCC[met]GC hexanucleotide motif and subsequently associates with 
TRIM28 (also known as KAP1), the H3K9 methyltransferase SETDB1 and the 
heterochromatin HP1 (Quenneville et al. 2011; Zuo et al. 2012). The protein complex 
is particularly enriched at all known imprinting centres, protect the DNA methylation 
from the genome-wide epigenetic reprogramming occurring after fertilisation and 
maintain the DNA methylation status during development, consequently preserving 
the parent of origin-specific gene expression (Quenneville et al. 2011). The knockout 
of Zfp57 in mouse embryonic stem cells demonstrated that the loss of Zfp57 results 
in hypomethylation at multiple imprinted loci (Quenneville et al. 2011; Zuo et al. 2012) 
and that the loss of the epigenetic memory at these DMRs was irreversible (i.e. not 
re-established) even upon re-introduction of exogenous Zfp57 (Zuo et al. 2012). 
 
5.1.2.4 NLRP2 
A trans-mechanism involving the maternal-effect gene NLRP2 (NLR family pyrin 
domain containing 2) has been described in BWS with MLID. NLRP2 is a member 
of the NACHT, LRR and PYD domains-containing protein family and is highly 
homologous to NLRP7. A recessive homozygous frameshift mutation affecting 
NLRP2 and resulting in a truncated protein has been found in the unaffected mother 
of three children, of which two were diagnosed with BWS. Complex consanguinity 
was described in the family and the mother was also suspected to have a 
hydatidiform mole pregnancy. One child had LOM at KCNQ1OT1:TSS-DMR and 
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was homozygous for the mutation. The second child with BWS had LOM at both 
KCNQ1OT1:TSS-DMR and at MEST:alt-TSS-DMR and was heterozygous for the 
mutation. Consequently, it was suggested that the BWS phenotype was likely due to 
NLRP2 maternal-effect mutation rather than the loss of NLRP2 zygotic function. To 
date, it is the only report linking imprinting disorders to mutations in NLRP2, which 
suggests that NLRP2-induced imprinting disorders is very rare and appears to affect 
a small minority of cases. 
 
NLRP2 has been shown to negatively regulate the activation of the transcription 
factor NFkB induced by various pro-inflammatory stimuli, including tumour necrosis 
factor alpha (TNFa) and interleukin 1 beta (IL1B) (Bruey et al. 2004). The interaction 
of NLRP2 with PYCARD, a member of the caspase-associated recruitment domains-
containing adaptor protein family, was shown to enhance caspase 1 activation and 
IL1B secretion (Bruey et al. 2004). Multiple evidences have suggested that NLRP2 
is a maternal-effect gene required for early embryonic development. Similarly to 
NLRP7, NLRP2 transcripts are found in all oocyte and pre-implantation embryo 
stages (Murdoch et al. 2006) and NLRP2 transcript level is at the highest in the 
oocyte, then slowly decrease from the germinal vesicle stage to day 3 embryos and 
finally increase again on day 5 (P. Zhang et al. 2008). The knockdown of Nlrp2 in 
mouse oocytes results in normal maturation of the oocytes but the development of 
parthenogenetic embryos derived from Nlrp2 knockdown oocytes mainly arrest at 
the 2-cell stage. In contrast, 60% of the control parthenogenetic embryos reached 
the blastocyst stage (Peng et al. 2012). Similarly, the depletion of maternal Nlrp2 in 
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zygotic embryos also showed an early embryonic development arrest between the 
2- to 8- cells stage (Peng et al. 2012). Finally, as mentioned above, a maternal-effect 
mutation in NLRP2 was linked to MLID and BWS phenotype. Therefore, it was 
suggested that NLRP2 might play a role in the establishment and or maintenance of 
the DNA methylation at imprinted regions, but the exact mechanism remains 
unknown (Meyer et al. 2009). 
 
5.1.2.5 KHDC3L 
KHDC3L (KH domain containing 3 like, subcortical maternal complex member), is a 
maternal-effect gene that has been found responsible for approximatively 5% of 
NLRP7-negative familial biparental hydatidiform moles cases (Parry et al. 2011). To 
date, 6 maternal-effect recessive mutations in KHDC3L gene have been described 
in the aetiology of FBHM (Parry et al. 2011; Reddy et al. 2013; Rezaei et al. 2016). 
 
KHDC3L precise protein function remains unknown but the protein belongs to the 
KHDC1 (KH homology domain containing 1) protein family which are known to bind 
RNA. Several pieces of evidence suggest that KHDC3L is a maternal-effect gene 
and may have similar or overlapping functions to NLRP7 in the oocyte and in early 
embryonic development. As mentioned above, pathogenic maternal recessive 
mutations in KHDC3L are associated with abnormal embryonic development in 
FBHM (Parry et al. 2011). KHBC3L has a very similar expression pattern than 
NLRP7; KHDC3L transcript levels appear to be at their highest in germinal vesicle 
oocytes and then decrease during preimplantation development and become 
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undetectable at the blastocyst stage (Parry et al. 2011). KHDC3L colocalises with 
NLRP7 to the microtubule organising centre and the Golgi apparatus in human 
hematopoietic cells (Messaed et al. 2011; Reddy et al. 2013), and at the cytoskeleton 
of the oocytes where they are both particularly abundant at the cortical region 
(Akoury et al. 2014). Finally, KHDC3L forms with NLRP5 (NLR family pyrin domain 
containing 5), OOEP (oocyte expressed protein) and TLE6 (transducin like enhancer 
of split 6) the human subcortical maternal complex (SMC) protein (Zhu et al. 2015). 
The human SMC may have a very similar role to the SMC counterpart in mice, which 
was found to be essential for developmental progression beyond the first zygotic cell 
divisions (L. Li et al. 2008; Yu et al. 2014). The MLID at maternal imprinted DMRs 
associated with KHDC3L-positive FBHM cases also suggests that KHDC3L may 
play a role in the establishment or maintenance of methylation at maternal imprinted 
DMRs during oogenesis and early embryogenesis respectively. However, and similar 
toNLRP7, this mechanism currently remains unknown. 
 
5.1.2.6 NLRP5 
Seven individuals with MLID were recently reported in five families. The clinical 
features of the affected individuals were heterogeneous, with three children 
diagnosed with BWS and MLID, two with SRS and MLID and two with non-specific 
phenotype and MLID. Pregnancy losses and infertility issues were also reported in 
some families. Genetic investigations of proband’s family pedigree have identified 
pathogenic homozygous and compound heterozygous mutations in the maternal-
effect gene NLRP5 in the proband’s mother. It was consequently suggested that the 
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maternal NLRP5 depletion was responsible for the diseases phenotype and the 
pregnancy losses and was likely involved in the genomic imprinting disturbances 
(Docherty et al. 2015). 
 
Nlrp5, also known as Mater, is exclusively expressed in the oocyte and was first 
described as an antigen associated with ovarian autoimmunity in mice (Tong and 
Nelson 1999). Nlrp5 was later found to be a maternal-effect gene required for normal 
embryonic development (Tong et al. 2000). The Nlrp5 null female mice have normal 
oocyte maturation and ovulation, but they are sterile. The Nlrp5 maternal loss of 
function results in embryonic developmental arrest at the 2-cell stage. Similar 
phenotypes were also observed in rhesus macaque monkeys, in which the maternal 
depletion of NLRP5 resulted in embryonic developmental arrest between the 8-cell 
and the 16-cell stage (Wu 2009). Some data also showed that the depletion of 
NLRP5 in mice disrupts the assembly of the subcortical maternal complex, which 
was found to be essential for developmental progression beyond the first zygotic cell 
divisions (L. Li et al. 2008; Yu et al. 2014). Finally, both paternal and maternal 
imprinted DMRs are disturbed in MLID patients with a maternal depletion of NLRP5 
(Docherty et al. 2015), hence suggesting an unrecognised role in the maintenance 
of genomic imprinting methylation. 
 
5.1.2.7 Other candidate genes 
In addition to the few known causative genes described in the aetiology of MLID, 
other candidates have been proposed to be involved in the disruption of genomic 
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imprinting via trans-mechanism defects. This includes the maintenance DNA 
methyltransferase DNMT1, the active de novo DNA methyltransferases DNMT3A, 
DNMT3B and the enzymatically inactive DNMT3L, the ZFP57 co-factor TRIM28, the 
DNA-binding protein CTCF, the methyl-CpG-binding proteins MBD3 and the 
developmental pluripotency-associated protein DPPA3 (Begemann et al. 2011; Azzi 
et al. 2014; Caliebe et al. 2014). However, to date no additional causative gene 
mutations have been described in MLID pathway. 
 
5.1.3 Aim 
The underlying causes resulting in MLID are still not clearly understood but a few 
hypotheses have been formulated to explain the widespread methylation defects 
observed in imprinting disorders. As seen previously, environmental insults such as 
ART could directly disrupt the genomic imprinting. Additionally, mutations occurring 
in maternal-effect genes have been found in patients with MLID, hence suggesting 
those genes might play a critical role in MLID aetiology. Although it has not been 
reported yet, I also hypothesised that mutations in genes associated to the 
methylation pathway could cause methylation disturbances at imprinted loci via a 
trans-mechanism. Finally, many imprinted genes belong to a complex imprinted 
gene network. I hypothesised that pathogenic mutations occurring in one of the 
member of the network may result to cis-defects and then to possible subsequent 
trans-methylation disturbances at other members of the network. In that regards, in 
order to gain additional insights into the underlying causes responsible for MLID in 
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BWS I performed methylation profiling using the HM450K platform and my 
bioinformatic pipeline (see section 4.2.4 - DNA methylation profiling using HM450K) 
of BWS_IC2 patients conceived with the help of ART and studied the effects of the 
ART procedures on genomic imprinting methylation. Additionally, using whole-
exome sequencing (WES) I compared the genetics of BWS_IC2 individuals with and 
without MLID to identify potential genetic components responsible for the 
widespread genomic imprinting disturbances. 
 
5.2 Materials and methods 
5.2.1 Patient DNA 
According to the criteria described in the literature (http://www.geneclinics.org), BWS 
was diagnosed in 78 screened patients. The molecular diagnostic investigations 
undertaken in NHS laboratories identified LOM at KCNQ1OT1:TSS-DMR 
(BWS_IC2) as the cause of the BWS phenotype. 13 of these patients were reported 
as conceived with the help of ART (2 following OS, 3 following IVF and 8 following 
ICSI). The use of ART was not reported in the remaining 65 BWS_IC2 individuals. 
 
5.2.2 DNA quantification 
See section 2.3 - DNA quantification. 
 
5.2.3 DNA purification 
See section 2.2 - DNA purification. 
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5.2.4 Sodium bisulfite treatment 
See section 2.4 – Sodium bisulfite treatment. 
 
5.2.5 DNA methylation profiling using HM450K 
See section 4.2.4 - DNA methylation profiling using HM450K. 
 
5.2.6 Whole-exome sequencing 
In order to investigate the potential genetic causes that could lead to MLID, 25 
BWS_IC2 patients with MLID and 17 BWS_IC2 patients with no MLID were 
processed for whole-exome sequencing and analysed as described below (Figure 
5.2). 
 
5.2.6.1 Library preparation and sequencing 
gDNA was quantified with Qubit® dsDNA HS Assay Kits (see section 2.3 - DNA 
quantification) and 50 ng was used to perform whole-exome sequencing. Library 
preparation (Nextera Rapid Capture Exomes (Dual Indexed), Illumina) and 
sequencing (NextSeq500, High Output 300 cycle (2x150bp Paired End), Illumina) 
was performed at the Stratified Medicine Core Laboratory (SMCL) Next Generation 






5.2.6.2 Alignment and variant calling 
Read alignments and variant calling were kindly done by Dr. Ezequiel Martín 
Rodríguez. The bioinformatic pipeline relies on freely available bioinformatic tools 
such as Burrows-Wheeler transformation (BWA) v0.7.5a-r405 for 
sequences alignment to the Genome Reference Consortium Human Build 38 patch 
release 6 (GRCh38.p6), samtools (H. Li et al. 2009) v0.1.19 for manipulating files 
and removing reads duplicates and Genome Analysis Toolkit (GATK) 
(McKenna et al. 2010; DePristo et al. 2011) v3.3-0-g37228af for realigning 
complicated regions such as insertion-deletion (indel), recalibration of base quality 
scores (i.e. Q scores) and variant calling. 
 
5.2.6.3 Filtering and annotation 
vcftools (Danecek et al. 2011) v0.1.12b was used to filter out low quality score (Q 
<30), low read depth coverage (DP <20x) and homozygous variants for the reference 
allele. Filtered files were then annotated with Annovar (Kai Wang et al. 2010) using 
available database. This includes, but not limited to, gene, transcript and protein 
names (e.g. NCBI Reference Sequence (RefSeq)), single nucleotide polymorphism 
(e.g. avSNP147), allele frequency (e.g. 1000 Genome Project, Exome Aggregation 
Consortium (ExAC), NHLBI GO Exome Sequencing Project (ESP)), genomic 
variation and its relationship to human health (e.g. ClinVar, Catalogue of Somatic 
Mutations in Cancer (COSMIC)), effects of amino acid substitution or indels on the 
structure and function of a human protein (e.g. SIFT (Henikoff and M.M. Smith 2015), 
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PROVEAN (Choi et al. 2012), PolyPhen-2 (Adzhubei et al. 2010)) and effects of 
genetic variants on human splicing (e.g. ada-boost and random forest dbscSNV 
scores (Jian et al. 2014), SPIDEX™ (Xiong et al. 2015)). 
 
5.2.6.4 Variant call analysis 
Filtered variant call files were analysed in R. Variants occurring in exonic or splicing 
regions with minor allele frequency below 1% in the frequency databases 1000 
Genome Project, ExAC and ESP and affecting protein function or splicing were 
retained for analysis. Based on literature research, I elaborated a list of candidate 
genes for which I believed genetic mutation altering their functions may have 
dramatic consequences in the establishment, maintenance or erasure of genomic 
imprinting. Consequently, rare variants occurring in gene shown to have a maternal-
effect in mammalian species (Table 5.11) or associated with methylation pathways 
(Table 5.12) were flagged as potential disease causing candidates. Furthermore, due 
to the existence of complex interactions between imprinted genes (i.e. imprinted 
gene network (Varrault et al. 2006; Patten et al. 2016; Soellner et al. 2016)), rare 
variants occurring in imprinted genes (Table 5.13) were also flagged as potential 
disease causing candidates. Finally, web-tools such as ToppGene (J. Chen et al. 





Figure 5.2: Overview of the whole-exome sequencing workflow. 
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Table 5.12: List of methylation associated genes. 
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Table 5.12: List of methylation associated genes (continued). 
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Table 5.12: List of methylation associated genes (continued). 
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Table 5.13: List of imprinted genes. 
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5.2.7 Sanger sequencing 
5.2.7.1 Polymerase chain reaction 
For polymerase chain reaction (PCR) amplification, patient gDNA was quantified with 
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NanoDrop® ND-1000 (see section 2.3 - DNA quantification) and 30 ng of gDNA was 
mixed with 0.125 µl of 5 U/µl AmpliTaq Gold DNA Polymerase (Thermo Fisher 
Scientific), 2.5 µl of 10X PCR Buffer I, 0.5 µl of 10 mM dNTP mix, 0.5 µl of each 10 
µM forward and reverse primers (see Table 5.14) and distilled water for a final 
reaction volume of 25 µl. The mixture was mixed by pipetting up and down several 
times and then placed in a thermocycler. The reaction was then incubated at 95 °C 
for 10 minutes, 30 cycles of 95 °C for 1 minute; 65 °C for 45 seconds and 72 °C for 
45 minutes, 72 °C for 10 minutes and then hold at 4 °C. PCR products and 1 kb DNA 
ladder (Bioline) were loaded on a 1.5% agarose gel electrophoresis (1.5 g agarose 
dissolved in 100 ml 1X TAE (see section 2.1.7 - 1X TAE), 2 µl of SYBR Safe) and 
the gel was run for 40 minutes at 100 V. Once finished, the gel was placed into Gel 
Doc XR+ System (Bio-Rad) for UV exposition. The size of amplicons was compared 
to the 1 kb DNA ladder and successful amplified PCR products (i.e. the one with 








5.2.7.2 PCR product purification 
Excess of primers and other types of singled stranded DNA contaminants were 
removed from the successfully amplified PCR products using MultiScreen-PCR96 
Filter Plate (Millipore). All the PCR product were pipetted into the filter plate. The 
plate was placed on a vacuum manifold and pressed down until a vacuum is created. 
The plate was let on the vacuum manifold until the filter was dry (approximatively 3 
minutes). The plate was then removed from the vacuum manifold, 20-25 µl of distilled 
water was added to the purified product and the plate was left at room temperature 
for 20 minutes. To dissolve completely the DNA, the water was mixed by pipetting 
up and down several times and the resulting purified DNA was transferred into a new 
plate. The purified DNA was used immediately after or stored at -20 °C for later use. 
 
5.2.7.3 Sequencing reaction 
The sequencing reaction was set up in PCR plates (Starlab) and sealed with Thermo 
Seal Film (Starlab). In a PCR plate, 2 µl of purified PCR product was mixed with 1 µl 
of BigDye Terminator 3.1 (Applied Biosystems), 4 µl of BigDye Terminator 
sequencing buffer, 1 µl of 10 µM forward (or reverse) primer (see Table 5.14) and 11 
µl of distilled water. The plate was placed in a thermocycler and incubated at 96 °C 
for 5 minutes and 25 cycles of 96 °C for 10 seconds; 50 °C for 5 seconds and 60 °C 
for 4 minutes, and hold at 4 °C. Products of BigDye termination sequencing reactions 





5.2.7.4 Sequencing clean-up 
Prior sequence data collection, the sequencing reaction was cleaned-up using 
ethanol precipitation (see section 2.2 - DNA purification). However, the purified pellet 
was kept dry and stored at -20 °C until ready to put the reaction on the sequencer. 
 
5.2.7.5 Sequence electrophoresis 
The dry pellet was resuspended in 10 µl of distilled water and 10 of µl HiDiTM 
formamide (Applied Biosystems). The mixture was denatured at 96 °C for 2 minutes, 
and then cooled down on ice protected from lights. The mixture was then ready to 
be place in an ABI 3730 capillary sequencer (Applied Biosystems) for sequencing 
electrophoresis. 
 
5.2.7.6 Sequence data analysis 
Sequencing data were analysed using Sequencher v5.4.5 (Gene Codes). In 
Sequencher, the sequencing reads were first aligned against an appropriate gene 
specific reference file (GenBank file) downloaded from NCBI and the discrepancies 
were detected and highlighted by the software. 
 
5.3 Results 
5.3.1 Methylation profiling of BWS_IC2 patients conceived with 
ART 
Among the 78 BWS_IC2 patients, 13 were conceived with the help of ART: 2 were 
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following ovarian stimulation (OS) only, 3 were following in vitro fertilisation (IVF) and 
8 were following intra-cytoplasmic sperm injection (ICSI). ART was not reported in 
the 65 other patients. Additionally to LOM at KCNQ1OT1:TSS-DMR, methylation 
profiling of ART patients revealed MLID in 1 out of 2 (50%) patient conceived with 
the help of OS, 2 out of 3 (67%) patient conceived with the help of IVF and 6 out of 
8 (75%) patients conceived with the help of ICSI. Although 1 patient conceived with 
OS had MLID, I didn’t draw a conclusion regarding the prevalence of MLID in this 
group as a limited number of cases were studied. IVF and ICSI follow similar clinical 
procedures and therefore were grouped. Taken together, MLID was detected in 8 out 
of 11 (73%) patients conceived with the help of IVF/ICSI. Out of the 65 naturally 
conceived patients 22 had MLID (34%) (Figure 5.3). MLID frequency in the IVF/ICSI 
group was compared to the MLID frequency in the no ART reported group. Statistical 
analysis using Fisher’s exact test showed that ART procedures (i.e. IVF and ICSI) 
were significantly associated with MLID in BWS_IC2 (p=0.021) (Figure 5.4). Finally, 
the frequency of epimutation at imprinted DMRs in IVF/ICSI MLID group was 
compared to the frequency of epimutation at imprinted DMRs in the no ART reported 
MLID group. Whilst some DMRs appeared to be more frequently epimutated in one 
group than in the other (e.g. MEST:alt-TSS-DMR: 25% in ART, 9% in non-ART; 
FAM50B:TSS-DMR: 12.5% in ART, 32% in non-ART) no significant association 
between the IVF/ICSI procedures and epimutations at imprinted DMRs was found 




Figure 5.3: ART and genomic imprinting methylation in BWS_IC2. 
Multilocus imprinting disturbances and ART. Epimutations distribution at 46 imprinted 
DMRs (y-axis) in BWS_IC2 patients conceived with or without the help of assisted 
reproductive technology (x-axis). Red, loss-of-methylation; green, gain-of-






Figure 5.4: Significance of ART of MLID epigenotype in BWS_IC2 patients. 
Comparison of the number of BWS_IC2 patients conceived with or without the help 
of ART (IVF/ICSI) and with or without MLID. ART, assisted reproductive technology; 
MLID, multilocus imprinting disturbances; statistical analysis was done using 




Figure 5.5: ART is not associated with a specific epimutation at imprinted 
DMRs in BWS_IC2 cohort 
Comparison of imprinted DMRs epimutation frequency in 8 BWS_IC2 patients with 
MLID conceived with ART (IVF/ICSI) and in 22 BWS_IC2 patients with MLID 
conceived naturally. ART, assisted reproductive technology. 
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5.3.2 Genetic investigation of BWS_IC2 patients 
WES was performed on 42 BWS_IC2 patients (25 with MLID and 17 with no MLID). 
The sequencing read depth was assessed in all samples and at least 87% of bases 
in 41 samples and at least 80% of bases in 1 sample were sequenced at least 20 
times (i.e. 20x) (Figure 5.6). This meant a reliable bases calling, hence a good 
certainty for further variants analysis. In total, WES analysis revealed 18 rare genetic 
alterations that were predicted to be damaging for the protein function or splicing and 













5.3.2.1 Analysis of methylation associated genes 
I analysed WES data for the 138 genes identified as important in or associated with 
methylation pathways (see Table 5.12 in section 5.2.6.4 - Variant call analysis) and 
interesting variants were validated by Sanger sequencing wherever possible. An 
average of the proportion of exons successfully sequenced for each gene for all 
patients was calculated. Out of 138, 6 genes had a very poor to average (<60%) 
proportion of exons sequenced and 132 had a high to complete coverage (>60%) 
(Figure 5.7). 
 
No stop-gain affecting a gene associated with methylation pathways were found. A 
single frameshift insertion in the thymine DNA glycosylase (TDG) gene (variant 1: 
NM_003211, c.965dupA, p.E322fs, rs764159587) was found in 33 patients; all were 
heterozygotes for the variant. Additionally, 6 heterozygotes splicing variants in TDG 
(variant 2: NM_003211, c.964+1G>A; variant 3: NM_003211, c.964+2T>G, 
rs760400700; variant 4: NM_003211, c.408+1G>A, rs780554309; variant 5: 
NM_003211, c.793-2A>C; variant 6: NM_003211, c.793-1G>T; variant 7: 
NM_003211, c.1090+1G>T, rs762057949) affecting in total 28, 32, 4, 13, 14 and 11 
individuals respectively were found. Finally, three non-synonymous variants 
occurring in the PHD finger protein 10 (PHF10) gene were found; variant 8 
(NM_018288 c.T595G, p.Y199D, rs562092150) was present in two individuals. 
These two individuals, as well as one additional patient, also carried variant 9 
(NM_018288, c.C646T, p.R216W, rs77919800) and variant 10 (NM_018288, 
c.T640G, p.L214V, rs144595699). All variants in each patient were in a heterozygous 
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state. Sanger sequencing of an independent PCR product for variant 1 in 31 of 33 
individuals, variant 2 in 28 of 28 individuals, variant 3 in 31 of 32 individuals, variant 
4 in 4 of 4 individuals, variant 5 in 13 of 13 individuals and variant 6 in 14 of 14 
individuals in the TDG gene and for variant 8 in 2 of 2 individuals, variant 9 in 3 of 3 
individuals and variant 10 in 3 of 3 individuals in the PHF10 gene did not successfully 
confirmed the results obtained from WES for those patients (Figure 5.8 and Table 
5.15). Further investigation with the sequencing facility revealed that those variants 
were also commonly detected in other sequencing project, hence suggesting that 
they were sequencer specific sequencing artefacts. Sanger sequencing of variant 7 




Figure 5.7: Proportion of the coverage of the exons of gene associated with 
the methylation pathway. 
Proportion of exons of 138 gene associated with methylation pathway successfully 




Figure 5.8: Validation of the variants found in gene associated with the 
methylation pathway. 
Sanger sequencing of an independent PCR product of variant 1, 2, 3 ,4 ,5 and 6 
(TDG) and variant 8, 9 and 10 (PHF10). Top, patient sequencing trace; bottom, 
control individual sequencing trace; blue inverted triangle, variant position. 
 
 
5.3.2.2 Analysis of maternal effect genes 
I analysed WES data for the 63 genes identified as maternal-effect genes in 
mammals (see Table 5.11 in section 5.1.2.1 - Maternal and maternal-zygotic genes). 
An average of the proportion of exons successfully sequenced for each gene for all 
patients was calculated. Out of 63, 7 genes had a very poor to average (<60%) 
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proportion of exons sequenced and 56 had high to complete coverage (>60%) 
(Figure 5.9). 
 
No stop-gain, frameshifting indel or splicing mutations were found in maternal-effect 
gene. A non-synonymous variant in the basonuclin 1 (BNC1) gene (variant 11: 
NM_001301206, c.C1204A, p.P402T) was found in a heterozygous state in one 
patient with GOM at ZDBF2/GPR1:IG-DMR and LOM at IGF2R:Int2-DMR, 
MEST:alt-TSS-DMR, FANCC:Int1-DMR, KCNQ1OT1:TSS-DMR, SNU13:alt-TSS-
DMR. A non-synonymous variant in the CCCTC-binding factor (CTCF) gene (variant 
12: NM_001191022, c.C943T, p.P315S, rs145727304) was found in a heterozygous 
state in one patient with LOM at DIRAS3:TSS-DMR, DIRAS3:Ex2-DMR, 
FAM50B:TSS-DMR, FANCC:Int1-DMR, KCNQ1OT1:TSS-DMR, IGF1R:Int2-DMR, 
L3MBTL1:alt-TSS-DMR, GNAS-AS1:TSS-DMR and SNU13:alt-TSS-DMR. Finally, 
three non-synonymous variants in the NLRP2 gene (variant 13: NM_001174082, 
c.C1151G, p.T384R, rs139903547; variant 14: NM_001174082, c.C2207T, p.T736M, 
rs200375320; variant 15: NM_001174082, c.G2335A, p.A779T, rs117066658) were 
found. One patient was a homozygous for variant 13 and had LOM at FAM50B:TSS-
DMR and KCNQ1OT1:TSS-DMR. One patient was heterozygous for both variant 14 
and variant 15 and had LOM at KCNQ1OT1:TSS-DMR, L3MBTL1:alt-TSS-DMR and 
SNU13:alt-TSS-DMR. Finally, one patient was heterozygous for variant 15 only and 
had LOM at DIRAS3:TSS-DMR, DIRAS3:Ex2-DMR, FAM50B:TSS-DMR, 
IGF2R:Int2-DMR, PLAGL1:alt-TSS-DMR, MEST:alt-TSS-DMR, FANCC:Int1-DMR, 
KCNQ1OT1:TSS-DMR, ZNF331:alt-TSS-DMR1, ZNF331:alt-TSS-DMR2, 
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NNAT:TSS-DMR, SNU13:alt-TSS-DMR. For which DNA was available, Sanger 
sequencing of an independent PCR product for variant 11 in 1 individual (BNC1), 
variant 12 in 1 individual (CTCF), and variant 15 in 1 of 2 individual (NLRP2) 
successfully confirmed the results obtained from WES (Figure 5.10 and Table 5.15). 
The Sanger sequencing of one individual with variant 13, one individual with variant 
14 and one of two individual with variant 15 was not attended due to the lack of DNA 




Figure 5.9: Proportion of the coverage of the exons of maternal-effect genes. 
Proportion of exons of 63 maternal-effect genes successfully sequenced. Toward 





Figure 5.10: Validation of the variants found in maternal-effect genes. 
Sanger sequencing of an independent PCR product of variant 11 (BNC1), 12 (CTCF) 
and 15 (NLRP2). Top, patient sequencing trace; bottom, control individual 
sequencing trace; blue inverted triangle, variant position. 
 
 
5.3.2.3 Analysis of imprinted genes 
I analysed WES data for the 76 genes identified as imprinted or potentially imprinted 
(see Table 5.13 in section 5.2.6.4 - Variant call analysis). An average of the 
proportion of exons successfully sequenced for each gene for all patients was 
calculated. Out of 76, 8 genes were not sequenced, 29 genes had a very poor to 
average (<60%) proportion of exons sequenced and 39 had high to complete 
coverage (>60%) (Figure 5.11). 
 
A stop-gain variant (variant 16: NM_020923, c.T350G, p.L117X, rs755604527) in a 
individual in heterozygous state with LOM at FAM50B:TSS-DMR and 
KCNQ1OT1:TSS-DMR and a non-synonymous variant (variant 17: NM_020923, 
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c.G6224T, p.R2075M, rs36095066) in another individual in heterozygous state with 
LOM at FANCC:Int1-DMR, INPP5F:Int2-DMR, KCNQ1OT1:TSS-DMR, IGF1R:Int2-
DMR, GNAS-AS1:TSS-DMR, GNAS-XL:Ex1-DMR, GNAS-AB:TSS-DMR were 
found in the zinc finger DBF-type containing 2 (ZDBF2) imprinted gene. Finally, a 
non-synonymous variant (variant 18: NM_000218, c.C1046T, p.S349L) in the 
potassium voltage-gated channel subfamily Q member 1 (KNCQ1) imprinted gene 
was found in a heterozygous state in one patient with LOM at FANCC:Int1-DMR, 
INPP5F:Int2-DMR, KCNQ1OT1:TSS-DMR, IGF1R:Int2-DMR, GNAS-NESP:TSS-
DMR, GNAS-AS1:TSS-DMR and GNAS-XL:Ex1-DMR. The Sanger sequencing of 
an independent PCR product for variant 16 and 17 (ZDBF2) and variant 18 (KCNQ1) 





Figure 5.11: Proportion of the coverage of the exons of imprinted genes. 
Proportion of exons of 76 imprinted or potentially imprinted gene successfully 






Figure 5.12: Validation of the variants found in imprinted genes. 
Sanger sequencing of an independent PCR product of variant 16 and 17 (ZDBF2) 
and variant 18 (KCNQ1). Top, patient sequencing trace; bottom, control individual 




5.4.1 ART and MLID 
Among the 11 patients conceived with the help of ART (IVF/ICSI), 8 had MLID (73%). 
This was significantly higher (p=0.021, Fisher's exact test) than the frequency 
observed in the no ART reported group in which 22 out 65 (34%) patients had MLID. 
This result corroborates with previous studies in which a significant association 
between ART and MLID in BWS_IC2 were found (Lim et al. 2009; Hiura et al. 2012; 
Tee et al. 2013) (it should be noted that the cohort I studied may overlap with those 
in the Lim et al. and Tee et al. reports). However, my observation also contrasts with 
other studies in which ART was not reported to be associated with MLID in BWS_IC2 
(Rossignol et al. 2006; Azzi et al. 2009). 
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The number of disturbances reported at a given imprinted DMRs were variable 
between ART and no ART reported BWS patients. Some DMRs appeared to be more 
frequently epimutated in one group than in the other but statistical analysis did not 
reveal a significant association between the use of ART and the disturbances at 
specific imprinted DMRs. In conclusion, with the exception of KCNQ1OT1:TSS-
DMR, ART seems to disrupt genomic imprinting in a random manner. 
 
Taken together, my data suggests that ART is associated with MLID in BWS_IC2. 
However, it remains to be understood if the imprinting disturbances are the direct 
consequences of ART alone, the products of other factors such as the parental 
infertility or the age of the individuals, or the results of a combination of all. If ART is 
involved, how does it disrupt the genomic imprint and which step of the procedure is 
involved in this mechanism? The ovarian stimulation and the use of an immature 
oocyte may affect the establishment of DNA methylation of genomic imprinting whilst 
the fertilisation, the embryo culture and the uterus implantation steps may disrupt the 
maintenance of this epigenetic mechanism (Hiura et al. 2014). The genome-wide 
methylation analysis using next-generation sequencing and microarrays of animal 
models and extensive patient cohorts will hopefully provide a better picture of the 






5.4.2 Trans-mechanism involving a gene associated with 
methylation pathway 
WES analysis revealed rare variants that have the potential to alter protein function 
or splicing of the TDG and PHF10 genes, both described to be associated with the 
methylation pathway. Though the heterozygous state of the BWS with MLID 
individuals indicated that the TDG and PHF10 potential pathogenic variants raised 
the possibility of being responsible for genomic imprinting disturbances following an 
autosomal dominant mode of inheritance, the identified candidate genetic alterations 
were not validated by Sanger sequencing and were found to be sequencer specific 
sequencing artefacts and so were not considered further. 
 
In summary, I did not identify candidate mutations in a methylation associated gene 
that is likely to be responsible for BWS phenotype and MLID in our cohort. To date, 
no additional candidate mutations in one of these genes have been associated with 
MLID and BWS. Therefore, with the exception of ZFP57 in a subset of TNDM1 
patients, causative pathogenic mutations of such genes are very rare events in the 
aetiology of imprinting disorders with MLID. However, it should be noted that the 
identification of pathogenic mutations is complicated by (i) the increasing burden that 
represents the analysis and interpretation of WES and (ii) some type of mutation, 
such as internal exon deletion, might not be detected by WES. It has been 
established that a sequenced exome of an individual can harbour between 20,000 
to 50,000 variants. Of these, several steps of filtering criteria to remove false-positive 
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calls (e.g. reads quality, out of coding sequence, synonymous coding variants, 
common in dbSNP) and prioritisation strategy (e.g. non-synonymous variants, 
splicing variants) will reduce the list of potential candidates and retain 
approximatively 150 to 500 variants. Of these, further analysis and interpretation in 
the context of the phenotype will be undertaken to hopefully identify the potential true 
pathogenic variants (Gilissen et al. 2012; Robinson et al. 2014). It should be noted 
that this would be true on the assumption that the pathogenic mutations was not 
filtered out during upstream filtering and prioritisation processes, such as a patient 
with heterozygous missense substitution might be undetected compound 
heterozygotes. 
 
5.4.3 Trans-mechanisms involving maternal-effect genes 
I identified five rare variants that may be responsible for BWS phenotype and MLID 
in the maternal-effect genes BNC1, CTCF and NLRP2. These variants were found 
in four distinct individuals with MLID and all variants were predicted to be protein 
damaging. One of the five variants (NLRP2, variant 13) was found in a homozygous 
state whilst the four others (BNC1, variants 11; CTCF, variant 12; NLRP2, variants 
14 and 15) were found in a heterozygous state. Finally, all these variants were 
reported as rare in ESP and ExAC database (variants 11, not reported in ESP and 
ExAC; variant 12, ESP: T=57/C=12939, ExAC: T=258/C=120954; variant 13: ESP: 
G=87/C=12917, ExAC: G=690/C=118704; variant 14: ESP: T=1/C=13005, ExAC: 
T=7/C=121367; and variant 15: ESP: A=138/G=12868, ExAC: A=1126/G=120172). 
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Taking into consideration the rarity of the variants and their potential damaging 
effects on the protein, I hypothesised that they may have been pathogenic and 
associated to BWS and MLID. 
To further investigate the potential significance of these findings it would be 
necessary to sequence the mothers of these cases to see if they were homozygous 
for the variants (or were compound heterozygotes). If this were to be found then it 
could be hypothesised that the genetic variants found in BNC1, CTCF and NLRP2 
might predispose to BWS and MLID in a maternal-effect inheritance manner. 
Additionally, the absence of the variants in the fathers would further support this 
hypothesis. 
 
BNC1 encodes for a zinc-finger protein found in abundance in oocytes and regulates 
the rRNA transcription. BNC1 deficiency in mouse oocytes perturbs both RNA 
polymerase I- and II- mediated transcription and it affects the morphology and 
biochemistry of oocytes. The fertilised Bnc1-deficient eggs failed to develop beyond 
the two-cell stage (Ma et al. 2006; Kim and K.-A. Lee 2014). If the maternal-effect 
inheritance in this patient could be confirmed, this would be the first description of 
BNC1 in BWS aetiology. Moreover, the additional epimutations associated with the 
patient may also indicate that the variant is likely to cause MLID and consequently 
could have an unrecognised role in genomic imprinting. 
 
CTCF encodes for a highly conserved transcription factor with 11 zinc-finger DNA 
binding domains. Using different combinations of zinc fingers domains to bind DNA, 
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CTCF can function as a transcriptional insulator, repressor, or activator, depending 
on the context of the binding site (Ohlsson et al. 2001). Depletion of Ctcf in fertilised 
Ctcf-deficient eggs arrest at the morula stage or at various stages prior to morula 
compaction and only a very small proportion of the embryos are able to develop to 
the blastocyst stage (Fedoriw et al. 2004; Wan et al. 2008). CTCF is critical for 
regulating genomic imprinting at multiple loci including the Igf2/H19 locus. The 
protein binds the unmethylated maternal allele of Igf2/H19 DMR and inhibits the 
maternal Igf2 gene expression via enhancer blocking activity (Bell and Felsenfeld 
2000; Hark et al. 2000). The depletion of Ctcf in mouse oocytes also results in the 
hypermethylation of Igf2/H19 DMR during oocyte growth, indicating that CTCF is 
required to maintain the unmethylated status of the locus (Fedoriw et al. 2004). 
Similarly, the maternal transmission of microdeletion removing CTCF binding sites 
within H19/IGF2:IG-DMR is associated with hypermethylation of the locus, biallelic 
silencing of H19, biallelic expression of IGF2 and, in fine, to BWS phenotype 
(Sparago et al. 2004; Prawitt, Enklaar, Gartner-Rupprecht, et al. 2005; Sparago et 
al. 2006). 
 
As seen previously (see section 5.1.2.4 - NLRP2), maternal-effect mutation in 
NLRP2 was previously reported to be associated with the BWS phenotype and MLID 
(Meyer et al. 2009). Hence sequencing of parental samples would be indicated to 
determine if the variants were of paternal or maternal inheritance and if the mother 




Further studies, including sequencing of the parents of the probands, are necessary 
to determine a more precise role of these variants in the molecular aetiology of MLID 
and BWS. 
5.4.4 Trans-mechanism involving imprinting gene network 
disruption 
The complex co-regulation of multiple imprinted genes and the existence of 
imprinted gene networks (Varrault et al. 2006; Patten et al. 2016; Soellner et al. 2016) 
suggested that the genetic insults of a member of a network might have dramatic 
consequences on not only the imprinted gene itself but also on the other imprinted 
gene members of the network. I hypothesised this may act at the methylation level 
and may be involved in the abnormal imprinted epigenotype seen in BWS patients 
with MLID. 
 
The exons of 37 out of the 76 imprinting genes were not sequenced or had a poor 
coverage. This can be explained by the fact that a majority of these genes are non-
protein coding genes. The library preparation method used for WES was not 
designed to capture these non-protein coding regions. However, despite the lack of 
sequencing coverage I identified one stop-gain (not reported in ESP and ExAC) and 
one non-synonymous (ESP: T=77/G=11847; ExAC: T=756/G=118228) rare variants 
in the ZDBF2 imprinted gene and one rare non-synonymous (not reported in ESP 
and ExAC) variant in the KCNQ1 imprinted gene (KCNQ1 variant did not overlap 
with KCNQ1OT1 genomic region). Mutations in KCNQ1 have been associated with 
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hereditary long QT syndrome 1 (Q Wang et al. 1996), short QT syndrome 2 (Bellocq 
et al. 2004) and familial atrial fibrillation (heart conditions) (Y.-H. Chen et al. 2003), 
and Jervell and Lange-Nielsen syndrome (a hearing loss condition) (Neyroud et al. 
1997) but not with an imprinting disorder. The three variants were reported as rare 
and were predicted to be damaging for the protein by several scoring databases, 
hence suggesting they might be pathogenic. 
 
In placental tissue, the imprinted expression of ZDBF2 is expressed from the 
paternal allele, although stochastic maternal expression of ZDBF2 is detected. In 
somatic tissue, ZDBF2 paternal expression is maintained whilst maternal ZDBF2 is 
silenced. I hypothesised that the stop-gain and the non-synonymous dominant 
variant could affect the ZDBF2 paternal gene expression, which in return would (i) 
induce aberrant methylation at other imprinting regions through trans-imprinting 
mechanism and (ii) result in aberrant embryonic development. To support my 
hypothesis, the author of a recent study has found that the knockout of Liz (Long 
isoform of Zdbf2) in mice results in the absence of ZDBF2 expression and in an 
abnormal growth phenotype (methylation profiling at other imprinting DMRs was not 
performed) (Greenberg et al. 2017). However, the authors found that the lack of 
ZDBF2 activation was associated with growth restriction rather than growth 
promotion, which in fine was not compatible with my hypothesis. 
 
KCNQ1 is located within KCNQ1OT1:TSS-DMR region, which is the main locus 
involved in BWS aetiology. I hypothesised that the non-synonymous variant could 
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be a dominant maternally-inherited mutation affecting a regulatory sequence 
required for the cis methylation of the maternal KCNQ1OT1:TSS-DMR IC. 
Consequently, this would primarly result in maternal KCNQ1OT1:TSS-DMR 
hypomethylation, biallelic expression of KCNQ1OT1, bisilencing of CDKN1C and, in 
fine, to BWS phenotype. Furthermore, through a mechanism that would by-pass the 
KCNQ1OT1-mediated transcriptional repression activity, the non-synonymous 
mutation could result in the translation of an altered KCNQ1 protein that would 
disrupt genomic imprinting methylation at other loci. Although it was an interesting 
hypothesis, several lines of evidence contradicted this hypothesis. Firstly, it seems 
that the variant does not affect a regulatory element required for the methylation of 
the IC. Secondly, the mechanisms that would explain the by-pass of KCNQ1OT1-
mediated gene silencing are yet to be identified. Finally, there is a lack of evidence 
suggesting that KCNQ1 (as opposed to KCNQ1OT1) has a role in imprinting. 
 
In conclusion, further investigations are required to further characterise these 
variants. However, the current line of evidence suggests that the ZDBF2 and KCNQ1 
variants are non-pathogenic and consequently are not involved in the molecular 








6.1.1 UHRF1, a critical epigenetic modifier 
Ubiquitin-like with PHD and RING finger domains 1 (UHRF1), also known as inverted 
CCAAT box protein of 90 kDa (ICBP90) in human and NP95 in mouse, is a nuclear 
multi-structural domain and functional protein. UHRF1 has been shown to promote 
cell proliferation in various cancers, including breast, colon, prostate, and lung 
cancer (Bronner et al. 2013). In these, it was demonstrated that the over expression 
of UHRF1 contributed to the silencing of tumour suppressor genes, the inhibition of 
the DNA repair pathway, the tumour growth and metastasis (Bronner et al. 2013). 
The down-regulation of UHRF1 in human colon colorectal carcinoma cells was 
shown to induce cell cycle to arrest at the G1/S transition, hence suggesting that 
UHRF1 is required for progression in the cell cycle (Y. Arima et al. 2004). UHRF1 is 
also known to be essential for the maintenance of DNA methylation through 
recruiting DNMT1 to the replication fork in S phase of the cell cycle (Bostick et al. 
2007; Sharif et al. 2007). The depletion of UHRF1 in human cells, mouse embryonic 
stem cells and in zebrafish results in the reduction of global DNA methylation and at 
locus specific DNA methylation, including IGS-rDNA (intergenic spacer of ribosomal 
DNA) and imprinted loci such as H19, Kcnq1ot1, Nnat, Igf2r, Dlk1 (Bostick et al. 
2007; Sharif et al. 2007; Tittle et al. 2011; Rothbart et al. 2012; Qi et al. 2015). 
However, the transient expression of wild-type UHRF1 in knockdown UHRF1 human 
cells, or in Uhrf1 null embryonic stem cells, was reported to restore the loss-of-
methylation associated with UHRF1 knockdown (Rothbart et al. 2012; X. Liu et al. 
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2013). This also includes methylation rescue in only a small subset of mouse 
imprinted loci, H19, Nnat, Dlk1 (Qi et al. 2015). Consequently, this line of evidences 
demonstrated that UHRF1 is a key epigenetic modifier. 
 
UHRF1 harbours at least five functional domains: a N-terminal ubiquitin-like domain 
(UBL), followed by a tandem tudor domain (TTD), a plant homeodomain (PHD), a 
SET and RING-associated (SRA) domain, and a C-terminal really interesting new 
gene (RING) domain (Figure 6.1). The SRA domain preferentially binds to hemi-
methylated CpG, which during semiconservative replication of DNA recruits DNMT1 
at the replication fork to copy the methylation pattern onto the daughter strand (Sharif 
et al. 2007). This process may also involve the RING domain through the 
ubiquitylation of H3K23 and H3K18, which creates ubiquitylated docking sites for 
DNMT1 (Nishiyama et al. 2013; Qin et al. 2015). The isolated TTD domain was 
shown to recognise and bind preferentially to H3K9me3 (Nady et al. 2011) whilst the 
isolated PHD domain binds to the unmodified extreme H3 N terminus, and more 
particularly to unmodified histone H3 arginine residue 2 (Hu et al. 2011; Rajakumara 
et al. 2011). Through the existence of functional cooperation in reading histone 
modifications, both TTD and PHD domains were suggested to play a role in the DNA 
methylation maintenance mechanism. Interestingly, whilst some studies suggested 
that these domains were essential for the maintenance of DNA methylation (Rothbart 
et al. 2012; Rothbart et al. 2013), others suggested that both domains promoted DNA 
methylation maintenance but were not essential to it (X. Liu et al. 2013; Zhao et al. 
2016). The crosstalk between both epigenetic marks (i.e. DNA methylation and 
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histone modifications) is to date not well understood. However, a few recent studies 
had started to decipher possible mechanisms that might link both epigenetic marks. 
In a recent report, the existence of a poly basic region (PBR) between the SRA and 
RING domains was suggested. The PBR was shown to facilitate the recognition of 
semi-methylated DNA by the SRA (Fang et al. 2016) and to mediate the interaction 
of the TTD domain with H3K9me3 and the interaction of the PHD domain with 
H3K4me0 (Gelato et al. 2014; Fang et al. 2016). This mechanism was dependant 
on the presence or absence of phosphatidylinositol 5-phosphate (PIP5). The binding 
of PIP5 to the PBR was shown help to stabilise UHRF1 and then DNMT1 to genomic 
regions containing H3K9me3 and undergoing replication. In the absence of PIP5, 
UHRF1 and then DNMT1 stabilise at genomic regions undergoing replication that 




Figure 6.1: Domain structure of UHRF1. 
UBL, ubiquitin-like domain; TTD, tandem tudor domain; PHD, plant homeodomain; 
SRA, SET and RING-associated; RING, really interesting new gene; PBR, polybasic 




6.1.2 Case Report 
Two siblings born to consanguineous parents were diagnosed with BWS. Previous 
molecular genetic analysis had demonstrated that both siblings had loss-of-
methylation at KCNQ1OT1:TSS-DMR. The methylation profiling at imprinted loci 
other than KCNQ1OT1:TSS-DMR was not performed and is currently under 
investigation. Whole-exome sequencing was performed prior to my study and the 
data was inspected to identify candidate mutations that might cause a trans-
imprinting defect. No candidate mutations were identified in NLRP2, NLRP5 (a 
heterozygous candidate mutation would be present in the siblings if the mother was 
a homozygote or compound heterozygote for mutations in these genes) or in ZFP57. 
In view of the parental consanguinity a candidate mutation would be predicted to be 
homozygous in both siblings and therefore rare homozygous variants were identified 
in the exome data and evaluated as potential candidate mutations. 
 
It was noted that both siblings had a novel homozygous missense variant in UHRF1 
(Figure 6.2-a) (the variant was not present in ESP nor in ExAC databases). The 
guanine to cytosine substitution at position 4954693 of chromosome 19 (Build 
GRCh38) resulted in an amino acid substitution of lysine to asparagine at position 
667 (NM_001048201.2, c.2237G>C, p.K667N). The rare non synonymous missense 
variant was predicted to be protein damaging by Mutation Taster (score: 0.999) and 
SIFT (score: 0.015) and probably damaging by PolyPhen-2 (score: 0.991) (Figure 
6.2-b). Additionally, the affected amino acid was found to be conserved across 
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species including mice, zebrafish and Xenopus tropicalis (Figure 6.2-c). Finally, the 
variant is located near to the polybasic region (PBR) within UHRF1. As discussed 
previously, this region may also be involved in the faithful DNMT1-mediated DNA 
methylation maintenance mechanism during replication. 
 
 
Figure 6.2: Case report of two siblings with BWS_IC2 and a homozygous 
mutation in the UHRF1 gene. 
(a) Family pedigree of the two affected siblings. Both siblings have a novel 
homozygous missense variant affecting UHRF1 (g.49544693G>C, GRCh38). (b) 
Deleterious scores obtained with Mutation taster, PolyPhen-2, SIFT and PROVEAN. 




To date several trans-acting factors have been described in the molecular aetiology 
of familial MLID disorders including KHDC3L (also known as C6ORF221), NLRP2, 
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NLRP5, NLRP7 and ZFP57 (see section 5.1.2 - Trans-imprinting defect and MLID). 
However, an underlying genetic defect responsible for MLID in BWS is very rare and 
only two of these genes have been linked to MLID in BWS (NLRP2 and NLRP5) 
(Meyer et al. 2009; Docherty et al. 2015). In this chapter I describe investigations 
into the potential pathogenicity of a homozygous variant in the UHRF1 gene found 
in two siblings with BWS_IC2. It was suggested that the missense substitution in 
UHRF1 p.K667N might partially or fully disturb the function of the protein and 
compromise normal DNA methylation maintenance mechanisms at imprinted DMRs. 
If this hypothesis was correct then UHRF1 would be the third described trans-acting 
factor responsible for methylation disturbances associated with BWS. However in 
the absence of additional families with a similar phenotype the candidacy of UHRF1 
remained unproven. Therefore it was decided to investigate, in vitro, whether the 
missense substitution could be shown to compromise UHRF1 function. I therefore 
proceeded to assess whether wild-type and mutant UHRF1 could rescue methylation 
abnormalities in  human HeLa cells in which UHRF1 gene expression had been 
knocked down by shRNA lentiviral transduction. 
 
6.2 Materials and methods 
6.2.1 Cells 
HeLa cells knockdown for UHRF1 (HeLa shUHRF1) and control HeLa cells (HeLa 
shLuc) were a generous gift from Dr. Scott Rothbart (Rothbart et al. 2012). The 
shRNA were designed to target the 3’ UTR region of the UHRF1 and Luciferase 
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gene, hence allowing subsequent rescue experiments. The shRNA used to 
knockdown targeted genes were obtained from the RNAi Consortium and were used 
following standard TRC lentivirus production and infection protocols (Table 6.16). 
 
Table 6.16: shRNA clones used in HeLa cells. 




The plasmids pRP+EV (i.e. empty vector) and pRP+WT (i.e. full-length human cDNA 
of wild-type UHRF1) were designed and ordered from Vector Builder. The pRP 
expression vector contains a cytomegalovirus (CMV) promoter, a cDNA sequence 
coding for the enhanced green fluorescent protein (EGFP) marker, and the C-
terminus of the protein of interest (UHRF1) has a dual FLAG and HA tags. 
 
The plasmids pTag-2C+EV (i.e. empty vector), pTag-2C+WT (i.e full-length human 
cDNA of wild-type UHRF1) and pTag-2C+Y188A (i.e full-length human cDNA of 
UHRF1 Y188A mutant) were a generous gift from Dr. Scott Rothbart (Rothbart et al. 
2012). The pTag-2C expression vector contains a CMV promoter and the N-terminus 
of the protein of interest (UHRF1) has a FLAG tag. 
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6.2.3 Maintenance of adherent cells 
Complete growth medium, PBS 1X and Trypsin 1X solutions were warmed up at 
37°C in water bath for approximatively 30 minutes prior starting procedure. In a class 
II cabinet growth medium was removed from cells container (i.e. Flasks (StarLab)/ 
Petri Dishes (Corning)). In order to completely remove growth medium the cells were 
rapidly washed by adding a small quantity of sterile PBS 1X and by gently rocking 
the container. Supernatant was then discard from container. To detach adherent cells 
from the bottom of the container a small amount of Trypsin 1X - EDTA 0.02% solution 
was added to the container. Cells were then placed into CO2 incubator at 37 °C until 
they start to detach. Once the cells are detached the container was transferred back 
to class II cabinet and complete growth medium was added to the cells to stop the 
reaction of the Trypsin. To remove dead cells and Trypsin the cell suspension was 
transferred in a falcon tube and then centrifuged for 5 minutes at 2000 rpm. 
Supernatant was removed and cell pellet was resuspended carefully but thoroughly 
in an appropriate volume of complete growth medium. Cell counting was performed 
on LUNA™ Automated Cell Counter (logos biosystems). 10 µl of sample was mixed 
with 10 µl of 0.4% trypan blue stain. 10~12 µl of the mixture was loaded into the 
chamber port on the LUNA™ counting slide, slide was inserted into slide port of the 
counter, focus was done if necessary and live cells (i.e. bright centres and dark 
edges while dead cells have blue colour with no bright centres) were counted. Once 
the cell concentration was determined, the required volume of cell suspension was 
transferred into a new container and an appropriate volume of fresh complete growth 
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medium was added to the container. The new container was then placed into CO2 
incubator at 37 °C. 
 
6.2.4 Transient transfection 
One day prior to transfection HeLa shLuc and HeLa shUHRF1 cells were seeded in 
sterile 6 cm Petri Dish (Corning) (see section 6.2.3 - Maintenance of adherent cells) 
in normal growth medium for an expected cells at confluence of 70-80% the next 
day. At the day of transfection, growth medium was removed from Petri Dish and 9 
ml of fresh antibiotic free growth medium was gently added to the plate. For 1 Petri 
Dish plate, transfection reagents were prepared as followed: TransIT-LT1 Reagent 
(Mirus) was put at room temperature and vortexed gently before using. In a 1.5 ml 
sterile tube (Eppendorf), 250 µl of Opti-MEM I Reduced-Serum Medium (Thermo 
Fisher Scientific) was mixed gently with 1.5 µl of 1 µg/µl plasmid DNA (one of 
pRP+EV; pRP+WT; pTag-2C+EV; pTag-2C+WT; pTag-2C+Y188A). 3-9 µl of TransIT-
LT1 Reagent was added to the tube and mixed completely by pipetting. The diluted 
TransIT-LT1 Reagent was incubated at room temperature for 15-30 minutes. The 
resultingTransIT-LT1 Reagent:DNA complexes were added drop-wise at different 
area of the plate. The Petri Dish was rocked gently to distribute the TransIT-LT1 
Reagent:DNA complexes evenly and then put into CO2 incubator at 37 °C. 





6.2.5 Quantitative PCR 
6.2.5.1 RNA extraction from adherent cells 
Total RNA of adherent cells was extracted using RNeasy Mini Kit (Qiagen). Cells 
were trypsinized (see section 6.2.3 - Maintenance of adherent cells) and pelleted in 
falcon tube by centrifugation at 500 x g for 5 minutes. The cells were washed with 
1.5 ml of PBS 1X and centrifuged at 500 x g for 5 minutes at 4 °C. To lyse the cells, 
supernatant was removed and 350 µl of Buffer RLT was added directly to the cells 
pellet. Pellet was resuspended by vortexing 4-6 seconds and the lysate was directly 
pipet into a QIAshredder spin column in a 2 ml collection tube and centrifuge at 
10,000 x g during 2 minutes for homogenisation. 350 µl of freshly prepared 70% 
ethanol was added to the homogenised lysate and the mixture was mixed well by 
pipetting. Up to 700 µl of sample, including any precipitate that may have formed, to 
an RNeasy spin column placed in a 2 ml collection tube. The lid was close gently 
and the tube was centrifuged at 10,000 x g for 15 seconds. The flow-through was 
discarded from collection tube. 700 µl of Buffer RW1 was added to the RNeasy spin 
column in a 2 ml collection tube. The lid was closed gently and the tube was 
centrifuged at 10,000 g for 15 seconds. The flow-through was discarded and the 
collection tube was reuse. To wash the spin column membrane, 500 µl of Buffer RPE 
was added to the RNeasy spin column in a 2 ml collection tube. The lid was closed 
gently and the tube was centrifuged at 10,000 g for 15 seconds. The flow-through 
was discarded and the collection tube was reuse. To wash the spin column 
membrane, 500 µl of Buffer RPE was added to the RNeasy spin column in a 2 ml 
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collection tube. The lid was closed gently and the tube was centrifuged at 10,000 g 
for 2 minutes. To eliminate any carryover of buffers, the RNeasy spin column (with 
lid close) was then placed in a new 2 ml collection tube and was centrifuge at 10,000 
x g for 1 minute. To elute the RNA, the RNeasy spin column was put in a new 1.5 ml 
collection tube and 30-50 µl of RNase-free water was directly added to the spin 
column membrane and the tube was centrifuged at 10,000 x g for 1 minute. The 
eluted RNA was used immediately or stored at -20 °C for future use. 
 
6.2.5.2 DNase treatment 
DNase treatment of freshly extracted RNA was done using the TURBO DNA-free™ 
Kit (Thermo Fisher Scientific). 0.1 volume of 10X TURBO DNase Buffer and 1 µl of 
TURBO DNase were added to the RNA and mixed gently. The mixture was incubated 
for 20-30 minutes at 37 °C. 0.1 volume of resuspended DNase Inactivation Reagent 
was added to the sample and mixed well. With occasional mixing, the mixture was 
incubated for 5 minutes at room temperature. Finally, the tube was centrifuged at 
10,000 x g for 1.5 minutes and the treated RNA was transferred to a fresh tube. The 
DNase treated RNA was used immediately or stored at -20 °C for future use. 
 
6.2.5.3 Bioanalyzer RNA 6000 Nano Kit quality check and quantification 






6.2.5.3.1 Setting up the chip priming station 
A new syringe was placed in the chip priming station, the plate base was inserted in 
position C and the syringe clip was positioned at the top position. 
 
6.2.5.3.2 Loading the gel dye mix 
Protected from light, the gel-dye mix was put at room temperature for 30 minutes 
before use. After equilibration at room temperature, 9 µl of gel-dye mix was pipetted 
at the bottom of the well located on the fourth column and third row of the RNA chip. 
The RNA chip was then placed into the chip priming station. The chip priming station 
was closed and the plunger of the syringe that was previously positioned at 1 ml was 
pressed down until held by the clip. The plunger was kept down for exactly 30 
seconds and then released. Finally, the plunger was inspected that it moved back to 
the 0.3 ml mark and after 5 seconds it was slowly pull back to the 1 ml position. After 
waiting 5 seconds, the plunger was gently pull back and 9 µl of gel-dye mix was 
pipetted in the wells located at the fourth column and first and second row. 
 
6.2.5.3.3 Loading the marker 
5 µl of RNA 6000 Nano marker was pipetted into the wells with a ladder symbol and 
into each of the 12 sample wells. 
 
6.2.5.3.4 Loading the ladder and the samples 
Before use, the ladder aliquots were thaw and kept on ice. Before loading, the 
samples were heat denatured at 70 °C for 2 minutes, hence minimising the formation 
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of secondary structure. 1 µl of the RNA ladder was pipetted in the well marked with 
the ladder symbol. 1 µl of sample was pipetted in each of the 21 sample wells. The 
chip was then placed horizontally in the adapter of the IKA vortex mixer and vortex 
for 60 seconds at 2400 rpm. Finally, the RNA chip was placed into the Agilent 2100 
Bioanalyzer (with chip selector was set to position (1)). 
 
6.2.5.3.5 Starting the chip run 
Using the 2100 Expert software, the appropriate assay was selected from the Assay 
menu located in the instrument context tab. Then the sample informations were 
inserted into the sample name table. Finally, the button start was pressed to start the 
run. 
 
6.2.5.3.6 Data analysis 
RNA integrity and concentration were assessed directly using the 2100 Expert 
software built-in analysis module. 
 
6.2.5.4 cDNA synthesis 
Complementary DNA (cDNA) was synthesised using the High Capacity cDNA 
Reverse Transcription kit (Thermo Fisher Scientific). In a PCR tube on ice, 10 µl of 
RNA (equivalent to 1µg; see section 6.2.5.3 - Bioanalyzer RNA 6000 Nano Kit quality 
check and quantification) was mixed with 10 µl of 2X RT Master mix (2 µl of 10X RT 
Buffer; 0.8 µl of 25X dNTP mix (100 mM); 2 µl of10X RT random primers; 1 µl of 
MultiScribe Reverse Transcriptase; 1 µl of RNase inhibitor; and 3.2 µl of nuclease-
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free water). The mixture was mixed by pipetting up and down several times and kept 
on ice. The mixture was then placed in a thermocycler and incubated at 25 °C for 10 
minutes, 37 °C for 120 minutes, 85 °C for 5 minutes and then hold at 4 °C. The 
synthesised cDNA was used immediately or stored at -20 °C for future use. 
 
6.2.5.5 Quantitative PCR 
6.2.5.5.1 Samples preparation 
10 µl of sample cDNA (i.e. from untransfected HeLa shUHRF1, untransfected HeLa 
shLuc) was mixed with 90 µl of RNase free water, hence resulting in a diluted sample 
cDNA at 5 ng/µl. 
 
6.2.5.5.2 Serial dilution preparation for standard curve 
A mixture of both untransfected HeLa shLuc and untransfected HeLa shUHRF1 
cDNA was used to generate the standard curve. 
 
5 µl of 50 ng/µl of untransfected HeLa shLuc cDNA was mixed with 5 µl of 50 ng/µl 
of untransfected HeLa shUHRF1 cDNA and 90 µl of RNase free water, hence 
resulting in a diluted mixture of cDNA ‘D1’ at 5 ng/µl. 4 µl of D1 was mixed with 16 µl 
of RNase free water hence resulting in a diluted cDNA ‘D2’ at 1 ng/µl. 4 µl of D2 was 
mixed with 16 µl of RNase free water hence resulting in a diluted cDNA ‘D3’ at 200 
pg/µl. 4 µl of D3 was mixed with 16 µl of RNase free water hence resulting in a diluted 




6.2.5.5.3 Reaction set-up and PCR amplification 
All the following reactions were done in triplicate to ensure accuracy. In a 
MicroAmp™ Fast Optical 96-Well Reaction Plate (Thermo Fisher Scientific), 
• 4 µl of diluted samples was mixed with 10 µl of SYBR Select 2X Mix (Thermo 
Fisher Scientific), 0.4 µl of each 10 µM forward and reverse primers (Table 
6.17) and 5.2 µl of water. 
• 4 µl of each of D1, D2, D3 and D4 was mixed with 10 µl of SYBR Select 2X Mix, 
0.4 µl of each 10 µM forward and reverse primers (Table 6.17) and 5.2 µl of 
water. 
• 4 µl of negative controls (i.e. water) was mixed with 10 µl of SYBR Select 2X Mix, 
0.4 µl of each 10 µM forward and reverse primers (Table 6.17) and 5.2 µl of 
water. 
The plate was sealed using MicroAmp™ Optical Adhesive Film (Thermo Fisher 
Scientific) and centrifuged at 1,500 rpm for 30 seconds. The plate was then placed 
in StepOne Plus system (Thermo Fisher Scientific) and incubated at 50 °C for 2 
minutes, 95 °C for 5 minutes and 40 cycles of 95 °C for 15 seconds; 60 °C for 1 





Table 6.17: List of primers used to quantify relative UHRF1 mRNA level. 
UHRF1 and GAPDH primers were chosen from PrimerBank database (X Wang 
2003; Xiaowei Wang et al. 2012). 
 
 
6.2.5.5.4 Data analysis using the relative standard curve 
Relative standard curve method was used to determine the relative target quantity 
in samples. The StepOne software (Thermo Fisher Scientific) measures 
amplification of the target (UHRF1) and of the endogenous control (GAPDH) in 
sample (i.e. HeLa shUHRF1), in a reference sample (i.e. HeLa shLuc), and in a 
standard dilution series (i.e. D1, D2, D3 and D4). Measurements are normalised 
using the endogenous control GAPDH. Data from the standard dilution series are 
used to generate the standard curve. Using the standard curve, the software 
interpolates UHRF1 quantity in the sample HeLa shUHRF1 and in the reference 
sample HeLa shLuc. The software determines the relative quantity of UHRF1 in 






6.2.6 Protein assay 
6.2.6.1 Protein extraction from adherent cells 
Cells were trypsinized (see section 6.2.3 - Maintenance of adherent cells) and 
pelleted in falcon tube by centrifugation at 500 x g for 5 minutes. The cells were 
washed with 1.5 ml of PBS 1X and centrifuged at 500 x g for 5 minutes at 4 °C. To 
lyse the cells and extract proteins, 150 µl of ice-cold RIPA buffer (see section 2.1.5 - 
RIPA) was added to the pellet and the mixture was mixed thoroughly by vortexing 
for 10 seconds. The mixture was placed on ice for 15 minutes with vortexing every 
5 minutes for 10 seconds. Tubes were then centrifuged at 16,000 x g for 15 minutes 
at 4 °C. The supernatant was collected and transferred to ice-cold 1.5 ml tube 
(Eppendorf). Protein lysates were used immediately or stored at -20 °C for later use. 
 
6.2.6.2 Protein quantification 
Proteins were quantified using Quick Start™ Bradford Protein Assay (Bio-Rad). 
Before starting, the 1x dye reagent were removed from 4 °C storage, let to warm at 
ambient temperature and inverted few times before use. Bovine serum albumin was 
diluted into RIPA buffer to make a series of 8 protein standards ranging from 0 to 
2000 µg/ml. In triplicate, 5 µl of each standards and samples were added to 
FLUOTRAC 200 microplate (Greiner Bio-One) and mixed with 250 µl of 1x dye 
reagent. The microplate was incubated for 5 min at room temperature and then 
placed into a microplate reader (PHERAstar® FS, BMG LABTECH). The 
absorbance at 595 nm was measured for each standards and samples. To determine 
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samples concentration, absorbance of each triplicate was averaged and the blank 
(i.e. 0 µg/mL of protein) value was subtracted from all standards and samples. Linear 
equation was generated by finding the line of best fit of the absorbance of each 
standard and their respective protein concentration. Samples protein concentration 
were estimated by solving 𝑥 in the linear equation 𝑦 = 𝑎𝑥＋𝑏, where 𝑦 is the 
absorbance, 𝑥 is the protein concentration, 𝑎 is the slope of the line and 𝑏 is the 𝑦-
intercept. 
 
6.2.6.3 Western Blot 
6.2.6.3.1 SDS-PAGE 
20 µg of protein lysate (see section 6.2.6.1 - Protein extraction from adherent cells 
and 6.2.6.2 - Protein quantification) was mixed with 5 µl of 4X Laemmli sample buffer 
(see section 2.1.4 - 4X Laemmli sample buffer) and, if needed, deionized water for 
a total volume of 20 µl. Samples were then heated at 100 °C for 10 minutes, vortexed 
and quickly centrifuged. NuPAGE™ Novex™ 4-12% Bis-Tris Protein Gels (Thermo 
Fisher Scientific) was put into XCell SureLock™ Mini-Cell Electrophoresis System 
(Thermo Fisher Scientific). Upper chamber of the electrophoresis system was filled 
with 200 ml of 1X NuPAGE® MOPS SDS Running Buffer (Thermo Fisher Scientific) 
with 500 µl NuPAGE® Antioxidant (Thermo Fisher Scientific) and the lower chamber 
was filled with 600 ml of 1X NuPAGE® MOPS SDS Running Buffer only. Samples 




Proteins were transferred onto a membrane of nitrocellulose (GE Healthcare Life 
Sciences). Sponges, Whatman papers (Thermo Fisher Scientific), nitrocellulose 
membrane and protein gel were incubated for 5 minutes in pre-cooled 1X transfer 
buffer (see section 2.1.1 - 1X Transfer buffer). They were then assembled into a 
“sandwich” making sure no bubbles were present between layers in the following 
order: black side transfer - sponge - Whatman paper - gel - membrane - Whatman 
paper - sponge - red side transfer. The ‘sandwich’ was then loaded into a transfer 
apparatus filled with pre-cooled 1X transfer buffer. Transfer was performed for 90 
minutes at 100 V constant and at 4 °C. After transfer, the nitrocellulose membrane 
was incubated in blocking buffer (see section 2.1.3 - Blocking buffer) for 1 hour at 
room temperature and on a rocking platform for gentle agitation. 
 
6.2.6.3.3 Immunoblotting 
The blocked nitrocellulose membrane was incubated with primary antibody against 
UHRF1 (mouse monoclonal; 1:1,000 in blocking buffer; BD Biosciences) or beta-
actin (goat polyclonal; 1,2000 in blocking buffer, Santa Cruz Biotechnology) 
overnight at 4 °C and on rocking platform. Membrane was then washed with 1X 
PBST (see section 2.1.2 - 1X PBS-Tween 20 (PBST)) 3 times for 10 minutes and 
incubated in HRP-conjugated secondary antibody for 1 hour at room temperature 
and on rocking platform. Membrane was washed again 3 times for 10 minutes with 




6.2.6.3.4 Membrane revelation 
The chemiluminescence reaction was done by incubating for 1 minute and gentle 
agitation the nitrocellulose membrane with an equal mixed volumes of the Enhanced 
Luminol Reagent and the Oxidizing Reagent included in the Western Lightning Plus 
ECL kit (Perkin Elmer). Excess of chemiluminescence reagent was removed by 
draining and the membrane was placed in plastic sheet protector. Protein 
visualisation was done by chemiluminescence imaging using an automatic image 
capture GeneGnome XRQ (Syngene). 
 
6.2.6.3.5 Gel analysis 
ImageJ (http://imagej.nih.gov) was used to compare protein band densities. Density 
of protein of interest (i.e. UHRF1) was measured using ImageJ gel analysis module 
(top menu: Analyze>Gels), normalised to the measured loading control density (i.e. 
beta-actin) and scaled between 0 and 1. 
 
6.2.7 Methylation assay 
6.2.7.1 DNA extraction from adherent cells 
Genomic DNA of adherent cells was extracted using Quick-DNA™ Miniprep Kit 
(Zymo Research). Cells were trypsinized (see section 6.2.3 - Maintenance of 
adherent cells) and pelleted in a falcon tube by centrifugation at 500 x g for 5 
minutes. To lyse the cells, supernatant was removed and 500 µl of Genomic Lysis 
Buffer was added directly to the cells pellet. Pellet was resuspended by vortexing 4-
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6 seconds and let stand for 5-10 minutes at room temperature. After lysis, the mixture 
was transferred to a Zymo-Spin™ Column in a Collection Tube and centrifuged at 
10,000 x g for 1 minute. Zymo-Spin™ Column was transferred to a new Collection 
Tube, 200 µl of DNA Pre-Wash Buffer was added to the spin column and centrifuged 
at 10,000 x g for 1 minute. 500 µl of g-DNA Wash Buffer was added to the spin 
column and centrifuged at 10,000 x g for 1 minute. For elution, the spin column was 
transferred to a clean micro centrifuge tube, 50 µl of DNA Elution Buffer was added 
to the spin column and let incubated for 2-5 minutes at room temperature. The spin 
column was centrifuged at 10,000 x g for 30 seconds. The eluted DNA was quantified 
by Nanodrop (see section 2.3 - DNA quantification) and immediately used or stored 
at -20 °C for future use. 
 
6.2.7.2 Methylation-sensitive restriction digestion assay 
The genomic DNA was extracted from the different cell lines (see section DNA 
extraction from adherent cells) and digested with Msp I and Hpa II (New England 
Biolabs). Restriction digestion reaction was prepared as followed: in 2 different tubes 
2 units of Msp I or 2 units of Hpa II were mixed with 1 µg of gDNA, 1X CutSmart® 
Buffer (New England Biolabs) and deionized water if needed for a total final volume 
of 50 µl. Both tubes reactions were incubated at 37 °C for 2 hours. The digested 
DNA samples were resolved on a 1% (w/v) agarose gel (1 g agarose dissolved in 
100 ml 1X TAE buffer (see section 2.1.7 - 1X TAE) containing SYBR® Safe DNA gel 
staining (Thermo Fisher Scientific) for 30 min at 100 V constant. The gel was then 
placed into Gel Doc XR+ System (Bio-Rad) for UV exposition and image capture. 
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ImageJ was used to determine the top gel band density and the associated level of 
enzymatic digestion. HpaII cuts at unmethylated sites (bright band) whilst methylated 
sites remain protected to the enzyme (darker band). 
 
6.2.7.3 Manual DNA dot-blot 
6.2.7.3.1 DNA spotting 
In 6 µl final volume reaction, 100 ng of sample genomic DNA (see section 2.3 - DNA 
quantification) or a set of calibrated human methylated DNA (Zymo Research; 
standard curve at 0%, 25%, 50%, 75%, 100% methylated DNA) was mixed with 0.6 
µl of 0.1 M EDTA, 0.48 µl of 5 M NaOH and, if necessary, dH₂O. Samples were 
denatured at 99 °C for 10 minutes and let cool down at room temperature without 
snap-cooling. Charged nylon membrane (Zeta-Probe Membranes, Bio-Rad) was wet 
in autoclaved dH₂O, and placed face-up on Whatman paper (Thermo Fisher 
Scientific) to remove the excess of water. Denatured DNA samples were quickly but 
carefully manually spotted on the membrane whilst the latter was still wet. Nylon 
membrane was let air-dried for at least 10 minutes and rinsed face down in a clean 
box containing 100-200 ml of 2x SSC buffer (see section 2.1.6 - 2X SSC) for 1–2 
minutes at room temperature and gentle agitation. The membrane was oven baked 
at 80 °C for 1 hour to immobilise the DNA onto it and then blocked in blocking buffer 





6.2.7.3.2 5-mC visualisation 
The blocked nylon membrane was incubated with primary monoclonal antibody 
against 5-mC (Eurogentec) diluted at 1:1,000 in blocking buffer (see section 2.1.3 - 
Blocking buffer) overnight at 4 °C and on rocking platform. Membrane was then 
washed with 1X PBST (see section 2.1.2 - 1X PBS-Tween 20 (PBST)) 3 times for 
10 minutes and incubated in HRP-conjugated secondary antibody (1:2,000 in 1X 
PBS-T) for 1 hour at room temperature and on rocking platform. Membrane was 
washed again 3 times for 10 minutes with 1X PBST on rocking platform. The 
chemiluminescence reaction was done by incubating for 1 minute and gentle 
agitation the nylon membrane with an equal mixed volume of the Enhanced Luminol 
Reagent and the Oxidizing Reagent included in the Western Lightning Plus ECL kit 
(Perkin Elmer). Excess of chemiluminescence reagent was removed by draining and 
the membrane was placed in plastic sheet protector. Protein visualisation was done 
by chemiluminescence imaging using an automatic image capture GeneGnome 
XRQ (Syngene). 
 
6.2.7.3.3 DNA quantity assessment 
Following 5-mC detection, the nylon membrane was washed 2 times 1 minute in 1x 
PBST. DNA staining was done by incubating the membrane in 1x SYBR® Gold 
(Thermo Fisher Scientific) in 1x TAE (see section 2.1.7 - 1X TAE) for 5-10 minutes 
and gentle agitation. Membrane was quickly washed 2-3 times in 1X PBST to remove 
the excess of SYBR® Gold and then placed into Gel Doc XR+ System (Bio-Rad) for 
UV exposition and image capture. 
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6.2.7.3.4 Membrane analysis 
ImageJ (http://imagej.nih.gov) and the MicroArray Profile plugin (Bob Dougherty and 
Wayne Rasband, http://www.optinav.info/MicroArray_Profile.htm) were used to 
analyse the membrane. The measured 5-mC density of the standard curve and of 
the samples was normalised to their corresponding measured DNA loading control 
density. The methylation level in the samples was calculated by resolving 𝑥 in the 
linear equation 𝑦 = 𝑎𝑥＋b derived from the methylated standard points regression 
analysis. 
 
6.2.7.4 Targeted bisulfite sequencing assay 
6.2.7.4.1 Library preparation and sequencing 
The following library preparation method was developed by Dr. Eguzkine Ochoa. 
The data were generated by Dr France Docquier. The data processing and analysis 
were performed by me. 
 
6.2.7.4.1.1 First round PCR: target capture 
500 ng (see section 2.3 - DNA quantification) of gDNA or a set of calibrated human 
methylated DNA (Zymo Research; standard curve at 0%, 25%, 50%, 75%, 100% 
methylated DNA) was bisulfite treated (see section 2.4 - Sodium bisulfite treatment). 
1 µl of bisulfite converted DNA was mixed with 8.5 µl of ZymoTaqTM PreMix (Zymo 
Research), 0.85 µl of each 10 µM forward and reverse primers (Table 6.18) and 5.8 
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µl of distilled water. The mixture was placed in a thermocycler and incubated at 95 
°C for 10 min, 40 cycles of 95 °C for 30 sec; 58 °C for 40 sec and 72 °C for 1 min, 
72 °C for 7 min and then hold at 4 °C. PCR reaction was loaded on a 1.5% agarose 
gel electrophoresis (1.5 g agarose dissolved in 100 ml 1X TAE (see section 2.1.7 - 
1X TAE), 1X SYBR Safe) and the gel was run for 40 minutes at 100 V. Once finished, 
the gel was placed into Gel Doc XR+ System (Bio-Rad) for UV exposition. The size 
of amplicons was compared to the 1 kb DNA ladder. The PCR products were used 
immediately after or stored at -20 °C for later use. 
 
Table 6.18: List of primers used for targeted bisulfite sequencing. 
KvDMR1 primers amplify a region within the imprinting centre KCNQ1OT1:TSS-
DMR. H19 primers amplify a region within the imprinting centre H19/IGF2:IG-DMR. 
KvDMR1 and H19 primers were designed by Dr. Eguzkine Ochoa. IGS-rDNA 





6.2.7.4.1.2 Purification of PCR products 
The PCR products were purified using QIAquick PCR purification kit and eluted in 
50 µl of double distilled water (see section 2.2 - DNA purification). The purified PCR 
products were used immediately after or stored at -20 °C for later use. 
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6.2.7.4.1.3 Second round PCR: adaptor tagging and indexing 
5 µl of purified PCR products was mixed with 25 µl of 2X KAPA HiFi HotStart 
ReadyMix (Kapa Biosystems), 5 µl of each Nextera XT Index forward and reverse 
primers (Nextera XT Index Kit v2 Set A, Illumina) and 10 µl of distilled water. The 
mixture was placed in a thermocycler and incubated at 95 °C for 3 min, 8 cycles of 
95 °C for 30 sec; 55 °C for 30 sec and 75 °C for 30 sec, 72 °C for 5 min and then 
hold at 4 °C. The PCR products were used immediately after or stored at -20 °C for 
later use. 
 
6.2.7.4.1.4 Purification of PCR products 
The resulting adaptor-tagged and indexed PCR product was purified and size 
selected using AGENCOURT® AMPURE® XP (Beckman Coulter). The PCR 
product was transferred to a 300 µl round bottom plate (Thermo Fisher Scientific). 
The AMPure XP bottle was gently mixed to resuspend the magnetic particles that 
may have settled. 90 µl of AMPure XP was added to the PCR reaction and then 
mixed thoroughly by pipetting up and down 10 times. The mixed sample was 
incubated for 5 minutes at room temperature. To separate the beads from the 
solution, the plate was placed onto an Agencourt SPRIPlate 96 Super Magnet Plate 
(Beckman Coulter) for 2 minutes. The cleared solution was aspirated from the 
reaction plate and discarded. With the plate still on the magnetic stand, the beads 
were washed by adding carefully (i.e. without disturbing the separated magnetic 
beads) 200 µl of freshly prepared 70% ethanol to the well of the reaction plate and 
let to incubate for 30 seconds at room temperature. The ethanol was carefully 
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removed and the wash step was repeated for a total of two washes. Once the ethanol 
removed, the plate was let to air dry for 3 minutes. The plate was then removed from 
the magnetic stand and the sequencing libraries were eluted by adding 56 µl of 
distilled water to it and mixing by pipetting up and down 10 times. The eluted DNA 
was used immediately after or stored at -20 °C for later use. 
 
6.2.7.4.1.5 Sequencing libraries quality assessment 
The resulting purified sequencing libraries were quantified using Qubit® dsDNA HS 
Assay Kit (see section 2.3 - DNA quantification) and their size were checked using 
Bioanalyzer High Sensitivity DNA Kit (see section 2.7 - Fragment analysis of DNA 
libraries). The sequencing libraries were then diluted to 4 nM, pooled if necessary 
(i.e. in case of sample multiplexing) and stored at -20 °C until sequencing. 
 
6.2.7.4.1.6 Sequencing 
The sequencing of the libraries was performed by the Stratified Medicine Core 
Laboratory (SMCL) Next Generation Sequencing facility. A MiSeq sequencer was 
used for the sequencing. 
 
6.2.7.4.2 Processing and analysis of NGS data 
Trim Galore v0.4.0 was used to remove and trim low-quality sequences and 
sequencer adaptors from bisulfite converted reads. Bismark v0.14.4 (Krueger and 
Andrews 2011) was used to align the trimmed sequencing reads to an in silico 
bisulfite converted human genome (GRCh38.p6). Bismark Methylation Extractor 
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v0.14.4 was used for cytosine methylation calling. The shell code used to trim, align 
and extract 5-mC level from the sequencing reads is available in Appendix 5. 
 
6.2.7.4.3 5-mC quantification 
The resulting methylation called file was used to assess the methylation level for 
each amplicons (i.e. H19/IGF2:IG-DMR; KCNQ1OT1:TSS-DMR and IGS-rDNA). 
The level of 5-mC in each locus was estimated by calculating the average of 5-mC 
level reported at each CpG sites within each locus. The R script used for 5-mC 
quantification is available in Appendix 6. 
 
6.2.7.4.4 PCR bias correction for 5-mC methylation level 
To account for the PCR amplification bias, the degree of experimental methylation 
measured in each samples at each loci was corrected by resolving 𝑥 in the cubic 
polynomial equation 𝑦 = 𝑎𝑥＋c𝑥2＋dx3＋e derived from the methylated standard 
points regression analysis (Moskalev et al. 2011). The R script used to adjust the 
methylation data is available in Appendix 7. 
 
6.3 Results 
6.3.1 Transfection optimisation 
The following data were generated by Dr France Docquier and further analysed by 
myself. Optimal transfection efficiency was evaluated on parental non-knocked down 
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HeLa cells. Different concentrations of transfecting reagents were mixed with a 
constant amount of plasmid DNA (plasmid pRP, 1.5 µg) and transfection efficiency 
was evaluated by visual estimation of GFP positive cells using fluorescent 
microscope. The best condition of transfection was achieved using 1.5 µg of plasmid 
DNA and 9 µl of transfecting reagents (Figure 6.3). This condition was used to 




Figure 6.3: HeLa cells transfection optimisation using pRP plasmid. 
For the transfection of the pRP plasmid into HeLa cells, different concentration of 
transfection reagent was used as indicated and transfection efficiency (level of GFP 
positive cells) was visually evaluated by fluorescent cell imager. Top, brightfield; 
bottom, green channel. (Data were generated by Dr France Docquier and analysed 
by myself). 
 
6.3.2 Low level of UHRF1 mRNA and protein in HeLa shUHRF1 
The following data were generated by Dr France Docquier and further analysed by 
myself. Quantitative PCR measuring UHRF1 mRNA level showed efficient 
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knockdown of more than 80 % of UHRF1 between control HeLa cells (i.e. HeLa 
shLuc) and HeLa UHRF1 knockdown cells (i.e. HeLa shUHRF1) (Figure 6.4-a). This 
result was further confirmed by Western-blot. Compared to HeLa shLuc, UHRF1 
protein level in HeLa shUHRF1 decreased by more than 80 %, thus indicating 




Figure 6.4: Efficient knockdown of UHRF1 in HeLa cells. 
UHRF1 shRNA knockdown efficiency was compared to a control luciferase shRNA 
in HeLa cells (a) by qPCR and (b) by Western blot (top: Western blot, bottom: UHRF1 
gel band relative density obtained with ImageJ). HeLa shLuc, HeLa cells transduced 
with shRNA targeting luciferase; HeLa shUHRF1, HeLa cells transduced with shRNA 




6.3.3 Transfection of UHRF1 does not rescue global methylation 
The following data were generated by Dr France Docquier and further analysed by 
myself. In comparison to the control cells HeLa shLuc, the digestion of HeLa 
shUHRF1 cells by the methylation-sensitive restriction enzyme HpaII suggested that 
the knockdown of UHRF1 induced a global reduction of DNA methylation. However, 
the transient expression of wild-type UHRF1 seemed to fail to restore the methylation 
to a similar level than observed in the control cells (Figure 6.5-a). These qualitative 
observations provided unexpected suggestions as a methylation rescue was 
expected following the transient expression of wild-type UHRF1. DNA dot-blots 
assays were carried out to confirm this trend. In comparison to the control cell HeLa 
shLuc, in which the methylation level was 60.3%, the UHRF1 knockdown in HeLa 
shUHRF1 induced the global methylation to drop to 23%. However, although the 
transient expression of wild-type UHRF1 in HeLa shUHRF1 cells seemed to induce 
the methylation to increase slightly to 27.4%, it seemed to fail to restore the 
methylation to a similar level than observed in the control cells (Figure 6.5-b). UHRF1 
protein level was assessed by Western-blot and significant UHRF1 over expression 
was observed after transient transfection of wild-type UHRF1 in both HeLa shLuc 
and HeLa shUHRF1 (Figure 6.5-c). Altogether, these results suggested that although 
it was expressed in cells, the exogenous UHRF1 might have been non-functional. I 
hypothesised that this could be linked to the pRP vector backbone or the FLAG and 
HA protein tags. To address these issues, a plasmid construct identical to the one 
used in previous studies (Rothbart et al. 2012; Rothbart et al. 2013) was tested on 
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control and UHRF1 knockdown cells for DNA methylation rescue. In comparison to 
the control cells HeLa shLuc in which the methylation level was 70.7%, the 
knockdown of UHRF1 in HeLa shUHRF1 seemed to reduce the global methylation 
level to 37.9%. However, similar to experiments using the plasmid pRP, the transient 
expression of wild-type UHRF1 expressed from the new vector backbone pTag-2C 
seemed to fail to rescue the methylation to the level seen in the control cells. 
Interestingly, the transient expression of wild-type UHRF1 seemed to induce a small 
loss-of-methylation (drop to 60.8%) in the control cells HeLa shLuc. As expected, 
the transient expression of the mutant UHRF1 Y188A, used here as a positive control 
for loss of protein function (Rothbart et al. 2012), seemed to have no effect on DNA 
methylation in HeLa shUHRF1 cells (Figure 6.6-a). UHRF1 wild-type and UHRF1 
Y188A protein levels were assessed by Western-blot in HeLa shUHRF1 cells and 
significant over expression was observed for both constructs (Figure 6.6-b). It has to 
be noted that in this set of experiment, the level of repeatability between my 
biological replicates was very low, hence the necessity to draw careful interpretations 






Figure 6.5: Transfection of pRP UHRF1 WT does not rescue global 
methylation. 
The global methylation level in HeLa shLuc and HeLa shUHRF1 transfected with 
different pRP plasmid (as indicated) was assessed by (a) digestion using 
methylation-sensitive restriction enzymes (n=1) and by (b) DNA dot-blot (n=2). (c) 
UHRF1 protein level in HeLa shLuc and HeLa shUHRF1 transfected with indicated 
plasmid was assessed by Western-blot. +NT, not transfected; +EV, empty vector; 








Figure 6.6: Transfection of pTag-2C UHRF1 WT does not rescue global 
methylation. 
(a) The global methylation level in HeLa shLuc and HeLa shUHRF1 transfected with 
different pTag-2C plasmids (as indicated) was assessed by DNA dot-blot (n=2). (b) 
UHRF1 protein level in HeLa shLuc and HeLa shUHRF1 transfected with indicated 
plasmids was assessed by Western-blot. +NT, not transfected; +EV , empty vector; 
+WT, UHRF1-WT; +Y188A, UHRF1-Y188A. (Data were generated by Dr France 
Docquier and analysed by myself). 
 
6.3.4 Transfection of UHRF1 does not rescue methylation at 
IGS-rDNA 
The following data were generated by Dr France Docquier and further analysed by 
myself. Targeted bisulfite sequencing was used to measure methylation levels at a 
CpG island within the intergenic spacer of ribosomal DNA (IGS-rDNA), a known 
target of UHRF1 (Bostick et al. 2007; Rothbart et al. 2012; Rothbart et al. 2013), and 
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at the imprinted locus KCNQ1OT1:TSS-DMR. Both targets were amplified by 
bisulfite-PCR followed by next-generation sequencing on an Illumina sequencing 
platform (MiSeq). Using calibrated DNA standards, preferential amplification of the 
methylated alleles (4.41 fold at IGS-rDNA and 3.02 fold at KCNQ1OT1:TSS-DMR) 
was observed at both loci (Figure 6.7). Consequently, the degree of experimental 
methylation measured in each samples was corrected for PCR amplification bias 
(Moskalev et al. 2011). The interpretation of the adjusted values showed that in 
agreement with previous studies (Bostick et al. 2007; Rothbart et al. 2012; Rothbart 
et al. 2013), UHRF1 knockdown seemed to induce a loss-of-methylation (~ 57-59%) 
at IGS-rDNA. However, and similar to our findings on global methylation (Figure 6.5 
and Figure 6.6), the transient expression of wild-type UHRF1 expressed from the 
pRP and pTag-2C expression vector seemed to fail to restore the DNA methylation 
at IGS-rDNA (~ 57-58% LOM compare to control cells) (Figure 6.8-a). Similarly, DNA 
methylation at the imprinted locus KCNQ1OT1:TSS-DMR seemed to decrease by 
approximatively 48-50% in UHRF1 knockdown cells but the transient expression of 
wild-type UHRF1 seemed to failt to restore the DNA methylation (~ 46-53% LOM 






Figure 6.7: Degree of bias introduced by PCR amplification. 
IGS-rDNA and KCNQ1OT1:TSS-DMR amplification bias was calculated from 
calibrated methylated DNA standards (0%, 25%, 50%, 75%, 100% methylated). The 
experimental degree of methylation observed after amplification (y-axis) was plotted 
as a function of the actual methylation percentage (x-axis). The value of b, equivalent 
to the PCR bias, was calculated by averaging individual b values calculated for each 
curve point with the following equation: b = [y × (100 - x)]/[x × (100 - y)] where y is 
the uncorrected experimental and x is the real value. Red line, cubic polynomial 
regression line derived from calibrated DNA standards; black dotted line, derived 
theoretical regression line derived from un-bias amplification. (Data were generated 




Figure 6.8: Transfection of pTag-2C UHRF1 WT does not rescue methylation 
at KCNQ1OT1:TSS-DMR and IGS-rDNA. 
Methylation at IGS-rDNA and at KCNQ1OT1:TSS-DMR loci were obtained by 
bisulfite-PCR followed by next-generation sequencing. Corrected methylation 
estimated in HeLa shLuc and HeLa shUHRF1 cells transfected with the indicated 
construct at (a) IGS-rDNA and (b) KCNQ1OT1:TSS-DMR. +NT, not transfected; 
+EV, empty vector; +WT, wild-type UHRF1; +Y188A, UHRF1 Y188A mutant. (Data 




I hypothesised that the novel homozygous missense variant in the UHRF1 gene 
(NM_001048201.2, c.2237G>C, p.K667N) found in the two siblings with BWS_IC2 
would affect the maintenance of DNA methylation at imprinted DMRs such as 
KCNQ1OT1:TSS-DMR without disrupting global DNA methylation. To test this 
hypothesis I undertook DNA methylation rescue assays in HeLa cells knockdown for 
UHRF1 (HeLa shUHRF1). Those cells were a generous gift from Dr. Scott Rothbart 
and they were previously shown to have decreased DNA methylation genome-wide 
and at IGS-rDNA compared to control HeLa cells (i.e. HeLa shLuc). Additionally, it 
was shown that transient expression of wild-type UHRF1 in those cells should rescue 
the loss of DNA methylation resulting from the knockdown of UHRF1 (Rothbart et al. 
2012).  
 
Before evaluating the effects that the UHRF1 variant may have on DNA methylation, 
experiments were undertaken to assess the effects of the transient expression of 
wild-type UHRF1 using pRB expression vector in HeLa shUHRF1 cells. However, 
the choice of assessing the global level of methylation by DNA digestion using 
methylation-sensitive restriction enzymes was not indicated for my objectives. This 
method only provided the qualitative, and not quantitative, assessment of the global 
level of DNA methylation. The use of manual DNA dot-blot assays revealed to be 
more quantitative and appropriate for my objectives. However, the second set of 
experiments using the pTag-2C plasmid achieved a very low level of repeatability, 
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hence indicating the lack of both biological and technical replicates. Therefore, 
additional biological and technical replicates were required to gain more accuracy 
and confidence in the results. Consequently, the conclusions I drawn from these 
experiments are limited to the suggestion of possible changes in DNA methylation. 
 
Global and targeted DNA loss-of-methylation associated with UHRF1 knockdown 
seemed not to be rescued following the transient expression of wild-type UHRF1. 
This result was unexpected as it appeared to contradict the previous published 
results reported by Dr. Scott Rothbart and colleagues (Rothbart et al. 2012). I 
hypothesised that the presence of a dual FLAG and HA protein tags in C-terminus 
may prevent the exogenous UHRF1 from rescuing the DNA methylation defect. To 
test this hypothesis, Dr. France Docquier performed experiments using wild-type 
UHRF1 expressed from pTag-2C expression vectors. This plasmid construct, a 
generous gift from Dr. Scott Rothbart, displayed a single FLAG tag in N-terminus and 
was previously shown to be efficient in rescuing DNA methylation abnormality 
(Rothbart et al. 2012). Similar to the results obtained using pRB, the transient 
expression of wild-type UHRF1 using pTag-2C seemed to fail to rescue the global 
loss-of-methylation associated with UHRF1 knockdown. Additionally, no DNA 
methylation rescue was observed at IGS-rDNA and KCNQ1OT1:TSS-DMR whilst it 
was expected that both loci would re-gain DNA methylation after transient expression 
of wild-type UHRF1. 
 
Following these failed attempts to rescue the DNA methylation associated with 
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UHRF1 knockdown by expressing wild-type UHRF1 with both the pRB and pTag-2C 
expression vector, I did not continue with the analysis of the UHRF1 missense variant 
found in the siblings with BWS. After carefully reviewing the experimental procedures 
and discussion with Dr. Scott Rothbarts’ collaborators, I hypothesised that in my 
experiments UHRF1 was too overexpressed and this may have deregulated UHRF1 
function, ultimately leading to a loss of DNA methylation. To support this hypothesis, 
a small loss-of-methylation was observed in HeLa controls cells following the 
transient expression of wild-type UHRF1 whilst no DNA methylation change was 
expected. Additionally, UHRF1 overexpression had been associated with DNA 
hypomethylation in cancer such as hepatocellular carcinoma and esophageal 
squamous cell carcinoma (Mudbhary et al. 2014; K. Nakamura et al. 2016). 
However, although these observations would be compatible with my hypothesis, 
further studies would be required to confirm these. 
 
The potential causal link between the mutant UHRF1_K667N and the DNA 
methylation maintenance failure at KCNQ1OT1:TSS-DMR is still under 
investigation. Further DNA methylation rescue experiments involving the use of an 
expression vector including a tag free protein and a weak promoter, such as the 
human ubiquitin C promoter, for gene expression is considered. Another approach 
using gene knockin in mice is currently being discussed. The CRISPR/Cas9 system 
could be used to generate a NP95 p.K662N (NP_035061) mouse line (p.K662N in 
mice is equivalent to p.K667N in human). Using this model would have the 
advantages of being able to investigate in more detail the effects of the mutant in the 
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maintenance of DNA methylation. Furthermore, although UHRF1 has mainly been 
described as a DNA methylation maintenance protein, the genome-edited mouse 
line may provide potential insights on the role of the protein (and the mutant) in the 







7.1 Multilocus imprinting disturbances in imprinting 
disorders, a need for standardisation 
Aberrant DNA methylation at imprinting control regions plays a critical role in the 
molecular aetiology of imprinting disorders (IDs) such as BWS and SRS. In the 
current report, I combined the use of a reliable and robust genome-wide methylation 
array and an accurate and efficient bioinformatic pipeline to identify widespread 
methylation disturbances across multiple imprinting control regions in a subset of 
BWS and SRS cohorts. Though my findings were consistent with previously 
published reports (Rossignol et al. 2006; Bliek et al. 2008; Azzi et al. 2009; Court et 
al. 2013; Poole et al. 2013; Tee et al. 2013; Maeda et al. 2014), they also highlighted 
a current need to harmonise the way in which aberrant DNA methylation in ID 
individuals is defined, analysed and reported. Indeed, the variability in (i) the loci 
investigated, (ii) the platform used to perform the methylation profiling and (iii) the 
methodology used to identify methylation change complicated comparisons with 
other studies (discussed below). To address these issues, the research community 
has begun adopting different measures that would help standardisation of results 
and consequently leading to better comparison between studies (Monk et al. 2016). 
 
7.1.1 Where to look? 
To define the frequency of multilocus imprinting disturbances (MLIDs) in ID cohort 
researchers focused on a subset of arbitrary loci. In the current study I analysed DNA 
methylation at 46 imprinted differentially methylated regions (DMRs), which 
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contrasts with the limited number of loci that were assessed in others (e.g. 7 in Azzi 
et al. 2009; 4 in Tee et al. 2013). As discussed in Chapter 4, it seems that the more 
loci being investigated, the higher the reported MLID frequency. Therefore, whilst 
assessing all imprinted DMRs might not be possible in all cases (e.g. technical 
constrains associated with the used platform), it will be beneficial to define a core 
set of imprinted DMRs that would need to be included in all reports. 
 
7.1.2 Too many platforms might lead to confusion 
The use of different platforms to assess methylation may also hamper comparison 
between studies. Whilst some studies, including mine, used high-throughput 
genome-wide methylation array, others relied on combined bisulphite restriction 
analysis and methylation-specific PCR (Bliek et al. 2008), allele-specific methylated 
multiplex real time quantitative PCR (Azzi et al. 2009), or pyrosequencing (Poole et 
al. 2013). The sensitivity to detect subtle changes in DNA methylation and low-level 
mosaicism may differ between platforms, hence leading to the identification, or 
exclusion, of findings that may be relevant to the research question and to diagnostic 
testing. 
 
7.1.3 A common informatic approach to detect epimutations 
A standardised method to define a loss- or a gain-of-methylation should be defined. 
Should the method rely on a cut-off threshold calculated from normal control 
individuals? How many normal control individuals should be used for the 
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comparison? In the current study, I developed a method relying on a cut-off threshold 
of ± three standard deviations calculated from the mean of a cohort of more than 
1400 normal control individuals. Whilst this is an impressive number that should 
increase the robustness of statistical analysis, it is unlikely that such large amounts 
of data would be available to all laboratories. To overcome this issue, alternative 
informatics methodologies have been developed, such as a single case-control 
comparison test that requires 20 normal control individuals only and which is based 
on Crawford-Howell t-test (Rezwan et al. 2015). 
 
7.1.4 Need to find a better alternative for diagnostic services 
With the scope to address these issues, I originally undertook the development of a 
novel NGS strategy for the genomic imprinting methylation profiling of individual with 
BWS and SRS, and more globally with a clinically diagnosed ID. The methodology 
was based on bisulfite padlock probes, a potentially reliable and sensitive method 
that was previously used to characterise 66,000 CpG sites within 2,020 CpG islands 
on human chromosome 12, chromosome 20, and 34 selected regions (Deng et al. 
2009), and 500,000 CpG sites within genomic regions known to contain differentially 
methylated regions or sites, CTCF binding sites, DNase I hypersensitive regions, all 
microRNA genes and all promoters for human NCBI Reference Sequence genes 
(Diep et al. 2012). Although the development of the method was not successful, it 
could have offered a highly sensitive method to characterise at a single base pair 
resolution the majority of CpGs within all the currently known imprinted DMRs (Court 
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et al. 2014) in a single multiplex reaction. The method was intended to allow the 
sequencing of a large number of samples using the bench top MiSeq sequencer 
whilst maintaining great depth of sequencing coverage (>150 samples at >500x). 
Consequently, this could have resulted in very precise detection of DNA methylation 
change at a given region and CpG site level, hence improving accuracy in 
epimutation identification rate even in samples with low level mosaicism. Finally, the 
method could have been used for the genomic imprinting methylation profiling in 
several tissues, hence leading to the characterisation of the nature and frequency of 
MLID in these. 
 
In conclusion another NGS-based method, if successfully developed and applied, 
might be part of the answer to standardise findings in the scope of better comparison 
of findings between studies. In the meantime, until such NGS-based method is 
successfully developed, I would recommend the use of HM450K for the clinical 
diagnostic of individuals with suspected ID. Despite some limiting factors, such as 
low probe coverage at some loci or presence of technical and biological batch 
effects, it provided 100% sensitivity and >99% specificity in identifying all of my BWS 
and SRS patients and similar efficiency has been seen in other studies focussing on 
other ID (Court et al. 2013; Docherty et al. 2014; Maeda et al. 2014; Prickett et al. 
2015; Rochtus et al. 2016). Finally, the HM450K allows in a single analytic procedure 
the comprehensive and simultaneous assessment of DNA methylation at not only 
the disease-causing loci but also at other regions not known to be involved in the 
molecular aetiology of the disease which allows potential new discovery. 
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7.2 The possible underlying causes of BWS and MLID 
The underlying causes of MLID in BWS, and more globally in most ID, remain to 
date unknown. However, several hypothesises that could explain the aberrant 
epigenotype have been formulated. 
 
7.2.1 Environmental pressure 
It is well established that assisted-reproductive technology (ART) is associated with 
the LOM of KCNQ1OT1:TSS-DMR in BWS individuals (DeBaun et al. 2003; Gicquel 
et al. 2003; Maher et al. 2003; Halliday et al. 2004; Weksberg et al. 2010). 
Consequently, it was natural to suggest that ART might also be implicated in the 
MLID epigenotype. To that end, several studies, including the current one, undertook 
the characterisation of MLID in BWS_IC2 individuals conceived with ART. Whilst I 
and others found an association (Lim et al. 2009; Hiura et al. 2012; Tee et al. 2013), 
others reported the opposite (Rossignol et al. 2006; Azzi et al. 2009). The 
discrepancy between reports might be explained by several factors that might 
include (i) the platform/methodology used to identify the epimutation (which could 
relate to the discussion above), (ii) the overlap between cohort used for the different 
studies (the current one may overlap with Lim et al. 2009 and Tee et al. 2013) and 
therefore the possible bias in the findings and (iii) differences between the ART 
procedures themselves. For the latter, it is conceivable that the techniques used to 
perform the ART may differ to some degree between hospitals and countries. 
Consequently, some aspects of a procedure may interfere with DNA methylation 
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differently, hence resulting in different epigenotype. 
 
Overall, although it is not a universal finding, cohort studies suggested that ART 
might be associated with MLID epigenotype. However, it is yet to be determined if 
the methylation disturbances result directly from the ART procedures themselves, 
other factors such as the infertility or the age of the parents, or a combination of all. 
Furthermore, there is a need to identify which step of the ART procedures is involved 
in this mechanism. Therefore, the study of more extensive cohort will bring some 
clarity in the characterisation of ART in MLID epigenotype. 
 
7.2.2 Genetic component 
Recently, the identification of MLID in a subset of individuals with IDs has triggered 
a particular interest in performing WES screening to determine if there might be 
potential underlying genetic causes that are responsible for MLID. However, despite 
much effort, only a few causative trans-acting mutations have been found. These 
include the maternal-zygotic gene ZFP57 and the maternal genes NLRP7, KHDC3L, 
NLRP2 and NLRP5 (Murdoch et al. 2006; Mackay et al. 2008; Meyer et al. 2009; 
Parry et al. 2011; Docherty et al. 2015). In the current study I undertook WES with 
the scope to identify new pathogenic mutations that might explain BWS and MLID 
phenotype. In addition to a homozygous missense variant in the UHRF1 gene for 
which the potential pathogenicity is currently being assessed through functional 
studies within our group, I report additional potential candidate gene mutations that 
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affect maternal-effect genes (BNC1, CTCF, NLRP2) and could be implicated in BWS 
phenotype and MLID epigenotype. However, the potential pathogenicity of these still 
require further validation. Overall, taking into consideration the current study and 
previous reports (Begemann et al. 2011; Azzi et al. 2014; Caliebe et al. 2014) it 
appears that the number of disease-causing mutations found by targeted exome and 
WES is very rare in individuals with an ID. Alternatively, it is possible that the potential 
pathological variants may have been missed due to the complexity that poses the 
analysis and interpretation of WES. The filtering and prioritisation criteria are critical 
in WES analysis such as using wrong parameters might result in either too many 
variants left for interpretation (resulting in false positives) or in losing the pathogenic 
disease-causing ones (resulting in false negatives). 
 
On the other hand, it is possible that the underlying genetic causes reside elsewhere 
in the genome (e.g. intronic or other genomic material such as non-coding RNA) or 
is not well detected by WES (e.g. internal exon deletion, copy number variation, 
chromosomal rearrangement, repeats variations). Consequently, it is worth 
considering performing whole-genome sequencing (WGS) to obtain the most 
comprehensive view of the genomic informations. However, using such approach 
also comes with some limitations. (i) Whilst the WGS of a very small subset of 
carefully selected individuals is financially possible, the processing of large sample 
size cohort is unlikely. Hence the notion of carefully selected individuals. Under which 
criteria should a patient have his genome sequenced? Should the ones with more 
severe phenotype, a family history or a negative WES be prioritised? (ii) If WES is 
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challenging to interpret WGS will be prove even more so since the process is 
expected to yield millions of variants. Consequently, appropriate filtering and 
prioritisation criteria will be the key to remove false-positive variants without filtering-
out the pathogenic ones. 
 
7.2.3 Methylation abnormalities outside of imprinted DMRs 
Finally, it is possible that the underlying causes of BWS and MLID are not of a genetic 
nature but an epigenetic origin. Besides methylation disturbances at imprinted 
DMRs, it is conceivable that other genomic regions might also present a pathogenic 
methylation profile that could participate to the BWS phenotype and MLID 
epigenotype. In the current study, using a genome-wide approach, I identified three 
additional regions outside of imprinted DMRs, SLC12A9, LTA, and KCNAB3, that 
display aberrant DNA methylation. However, the clinical significance of these 
findings is currently unknown and further investigations are needed to define their 
role in BWS and MLID aetiology. It should be noted that my analysis was restricted 
to the captured sequences on the arrays. Indeed, the Infinium HumanMethylation 
450K BeadChips allows the characterisation of more than 485,000 CpG sites, which 
is equivalent to approximatively 2% of the human CpG content. Consequently, it is 
possible that pathologic methylation changes at an undocumented important locus 
might be associated with BWS and MLID but remain unidentified due to the lack of 
coverage by the array. The use of a more comprehensive method such as whole-
genome bisulfite sequencing (WGBS), reduced-representation-bisulphite-
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sequencing (RRBS) (Meissner et al. 2008; Z.D. Smith et al. 2009; Gu et al. 2011; 
Boyle et al. 2012) or methylated DNA immunoprecipitation sequencing (MeDIP-seq) 
could be an answer to alleviate this issue. Although they are more costly, especially 
to process large sample size cohorts, they will undoubtedly cover greater amount of 
CpG sites (WGBS, >90% of human CpG content; RRBS, 10-20%; MeDIP-seq, 60-
90% (Plongthongkum et al. 2014)), hence allowing new discoveries that were not 
possible with methylation array alone. 
 
7.2.4 5-hydroxymethylation, a hot topic for the future? 
5-hydroxymethylcytosine (5-hmC) is a cytosine modification recently described to be 
an intermediate in the DNA demethylation pathway (see section 1.1.1.2.3 - DNA 
demethylation). The modification results from the oxidation of 5-methylcytosine (5-
mC) by the ten-eleven translocation enzymes, TET1 and TET2 (He et al. 2011; Inoue 
et al. 2011; Ito et al. 2011; Hackett et al. 2013). The levels of 5-hmC varied in different 
organs with highest content found in the brain, followed by the rectum, liver and 
colon. In contrast, the level of 5-hmC is very low in the heart, breast and placenta 
(W. Li and M. Liu 2011). In mouse embryonic stem cells, 5-hmC was found to be 
mostly associated with euchromatin and, unlike 5-mC, was particularly enriched at 
CpG islands, gene promoters, particularly the ones marked with H3K4me3 and 
H3K27me3, and enhancers, particularly the ones marked with H3K4me1 and 
H3K27ac (Ficz et al. 2011; Pastor et al. 2011). Consequently, it was suggested that 
5-hmC has functional significance in gene expression regulation. Since the recent 
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development of methods that allow the discrimination of 5-mC to 5-hmC (oxidative 
bisulfite sequencing), several studies undertook the characterisation of the impact of 
5-hmC in diseases. Subsequently, multiple suggestive data indicated that 5-hmC 
might potentially be involved in the pathophysiology of diseases (Jingyu Wang et al. 
2014) such as Rett syndrome (Szulwach et al. 2011), Huntington diseases (Fengli 
Wang et al. 2013), melanoma (Lian et al. 2012; Gambichler et al. 2013), 
gastrointestinal stromal tumours (Mason and Hornick 2013) and hepatocellular 
carcinoma (M.-L. Chen et al. 2013). 
As an epigenetic regulator, it was natural to think that aberrant change in 5-hmC 
level might be implicated in the molecular aetiology of imprinting disorders via either 
directly deregulating imprinted DMRs or indirectly through the silencing or activation 
of a trans-acting factor. Accordingly, a report exploring the relationship between 5-
hmC and Kagami-Ogata syndrome has recently been published (Matsubara et al. 
2015). The authors concluded that the hypermethylation of the two imprinting control 
regions MEG3/DLK1:IG-DMR and MEG3:TSS-DMR was not due to an increased 
level of 5-hmC. Additionally, the analysis of blood taken from the patients did not 
revealed conclusive evidence of global changes of the levels of 5-hmC that could 
explain the disease phenotype. However, although inconclusive this report was the 
very first one to explore the relationship between 5-hmC and ID. The analysis of 
more individuals with an ID, including BWS, will surely help deciphering the potential 





7.3 Final conclusions 
Genomic imprinting is a fascinating but incompletely understood process. Whilst 
breakthrough discoveries have been made via in-depth molecular investigation of 
model organisms, particularly mice, the study of imprinting disorders has provided 
additional critical insights into both the pathogenesis and associated phenotypic 
consequences of aberrant imprinting. Application of high-throughput NGS-based 
techniques to large cohorts of ID patients has the potential to provide further insights 
and this would be further facilitated by data-sharing and international collaborative 









R code used for methylation data preprocessing. 
 
> library("RnBeads") 
# Set and create result directory folder 
> resultDir <- "/path/to/result/directory/" 
> dir.create(resultDir, showWarnings = FALSE, recursive = 
TRUE) 
# Set data directory (idat and sample sheet files need to be 
both located in that folder) 
> data.source <- "/path/to/data/directory/" 
# Set directory where the output should be written to 
> analysis.dir <- file.path(resultDir) 
# Set directory where the report files should be written to 
> report.dir <- file.path(analysis.dir, "reports") 
# Initialising reports 
> rnb.initialize.reports(report.dir) 
# Enable multicore 
> logger.start(fname = NA) 
> num.cores <- 20 
> parallel.setup(num.cores) 
# Loading raw methylation data (idat file format) in R 
> result.raw <- rnb.run.import(data.source = data.source, 
data.type = "infinium.idat.dir", dir.reports = report.dir) 
> rnb.set.raw <- result.raw$rnb.set 
# Generate quality check report 
> rnb.run.qc(rnb.set.raw, report.dir) 
# Set options for filtering and normalisation 
> rnb.options(disk.dump.big.matrices = FALSE, 
  identifiers.column = "Sample_Name", 
  filtering.context.removal = c("CC", "CAG", "CAH", "CTG", 
"CTH", "Other"), 
  filtering.snp = "5", filtering.greedycut = TRUE, 
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  filtering.greedycut.pvalue.threshold = 0.01, 
  filtering.sex.chromosomes.removal = TRUE, 
  filtering.cross.reactive = TRUE, 
  filtering.coverage.threshold = 0, 
  filtering.low.coverage.masking = FALSE, 
  filtering.missing.value.quantile = 0, 
  normalization = TRUE, 
  normalization.method = "bmiq", 
  normalization.background.method = "methylumi.noob", 
  normalization.plot.shifts = TRUE, 
  qc.snp.boxplot = TRUE) 
# Perform normalisation with BMIQ method 
> result.norm.filt <- rnb.run.preprocessing(rnb.set.raw, 
dir.reports = report.dir) 
> rnb.set.norm.filt <- result.norm.filt$rnb.set 
# Extract normalised methylation data (M-value) 
> datMval <- as.data.frame(mval(rnb.set.norm.filt, row.names 
= TRUE, epsilon = 1e-05)) 
# Remove CpG probes with missing data in all samples 
> datMval <- datMval[complete.cases(datMval), ] 
# Save normalised methylation data 
> write.csv(datMval, paste(resultDir, "mval_norm.csv", 





R code used for batch effect correction. 
 
# Import data in CSV file format 
> library("sqldf") 
# Set and create result directory folder 
> resultDir <- "/path/to/result/directory/" 
> dir.create(resultDir, showWarnings = FALSE, recursive = 
TRUE) 
# Import data (in .csv format) 
> Data = read.csv.sql("/path/to/data.csv", header = T) 
rownames(Data) <- gsub("\"", "", Data$X) 
> Data[1] <- NULL 
# Batch effect correction with ComBat 
> library("sva") 
# Import phenotype file (tab separated file format) Phenotype 
file is in general the same as the samplesheet provided for 
the 450K 
> Pheno <- read.table("/path/to/phenotype.txt", header = T, 
sep = "\t") 
# Batch correction step 1 (Sentrix_ID correction) 
> DataBat.1 <- ComBat(dat = Data, batch = Pheno$Sentrix_ID, 
mod = model.matrix(~as.factor(Sample_Group) + 
as.factor(Sentrix_Position) + as.factor(Age), data = Pheno)) 
# Batch correction step 2 (Sentrix_Position correction) 
> DataBat.2 <- ComBat(dat = DataBat.1, batch = 
Pheno$Sentrix_Position, mod = 
model.matrix(~as.factor(Sample_Group) + as.factor(Age), data 
= Pheno)) 
# Batch correction step 3 (age correction) 
> DataBat.3 <- ComBat(dat = DataBat.2, batch = Pheno$Age, mod 
= model.matrix(~as.factor(Sample_Group), data = Pheno)) 
# Save normalised and batch effect corrected methylation data 
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> write.csv(DataBat.3, paste(resultDir, 






R code used for genomic imprinting methylation profiling. 
 
#### Set variables below #### 
# Need to be edited Character vector indicated group of 
interest. It has to match with the "Disease" column in 
phenotype file (i.e. Pheno$Disease) 
GroupOfInterest <- c("Patient") 
# Character vector indicated from what standard deviation 
will be calculated from. It has to match with the "Disease" 
column in phenotype file (i.e. Pheno$Disease) 
GroupOfControl <- "Control" 
# Indicate standard deviation threshold 
nbSd <- 3 
# Fill with target names to remove from analysis. Can be 
empty 
TargetToRemove <- c("MEG3-DLK1_IG-DMR") 
# Indicate where results should be saved 
resultDir <- "/path/to/result/directory/" 
# Indicate where methylation data is located (CSV file 
format, row: CpG probes, column: samples) 
dataFile <- "/path/to/data.csv" 
# Indicate where phenotype file is located (tab separated 
file) 
phenoFile <- "/path/to/phenotype.txt" 
# Indicate where target file (i.e. region of interests) is 
located (bed file format with .txt file extension). Column 
names need to include 'chr', 'start', 'end' 
targetFile <- "/path/to/target.file.txt" 
#### Set variables above #### 
 
 
#### Import files Create result directory folder 
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dir.create(resultDir, showWarnings = FALSE, recursive = TRUE) 
# Import phenotype file 
Pheno <- read.table(phenoFile, header = T, sep = "\t") 
# Import target file 
target <- read.table(targetFile, header = TRUE, sep = "\t") 
target$chr <- paste("chr", target$chr, sep = "") 
library("GenomicRanges") 
grTarget <- makeGRangesFromDataFrame(target, seqnames.field = 
"chr", start.field = "start", end.field = "end", 
keep.extra.columns = TRUE, ignore.strand = TRUE, seqinfo = 
NULL) 
# Set final target specify 
FinalTarget <- as.character(grTarget$Name[!grTarget$Name %in% 
TargetToRemove]) 
FinalTarget <- factor(FinalTarget, levels = 
unique(FinalTarget)) 
# Import data file 
library("sqldf") 
Data = read.csv.sql(dataFile, header = T) 
rownames(Data) <- gsub("\"", "", Data$X) 
Data[1] <- NULL 
# Convert data in Beta value if necessary 
library("lumi") 
Data <- as.data.frame(m2beta(Data)) 
 
##### Convert methylation data into GenomicRanges object 
library("FDb.InfiniumMethylation.hg19") 
library("GenomicRanges") 
hm450 <- as.data.frame(get450k()) 
hm450 <- hm450[rownames(hm450) %in% rownames(Data), ] 
hm450 <- hm450[order(hm450$seqnames, hm450$probeTarget), ] 
Data.2 <- as.data.frame(Data[match(rownames(Data), 
rownames(hm450)), ]) 
Data.2$chr <- hm450$seqnames 
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# Df.2$chr <- gsub('chr', '', Data.2$chr) #Need to un-comment 
if chromosome is indicated as 1,2,3,... and not chr1, chr2, 
chr3 in target file 
Data.2$start <- hm450$probeTarget 
grData.2 <- makeGRangesFromDataFrame(df = Data.2, 
seqnames.field = "chr", start.field = "start", end.field = 
"start", keep.extra.columns = TRUE, ignore.strand = TRUE, 
seqinfo = NULL) 
 
##### Subset data regarding target files 
dir.create(paste(resultDir, 
"Methylation.analysis/meth.score/", sep = ""), showWarnings = 
FALSE, recursive = TRUE) 
setwd(paste(resultDir, "Methylation.analysis/meth.score/", 
sep = "")) 
# Extract and save CpG beta value for all samples within 
regions of interest 
meth.score <- list() 
for (i in seq(grTarget)) { 
    x <- as.data.frame(subsetByOverlaps(grData.2, 
grTarget[i])) 
    x <- x[, -(1:5)] 
    write.table(x, paste(resultDir, 
"Methylation.analysis/meth.score/", grTarget[i]$Name, sep = 
""), sep = "\t", row.names = FALSE, quote = FALSE) 
    meth.score[[i]] <- x 
} 




##### Compute methylation index at target loci in all 
individuals (patients and controls). 





# For GroupOfInterest (i.e. Patient) Put a list in a list 
GroupPatient <- list() 
for (j in seq(GroupOfInterest)) { 
    y <- list() 
    for (i in seq(grTarget)) { 
        x <- meth.score[[i]][Pheno$Disease %in% 
GroupOfInterest[j]] 
        y[[i]] <- x 
    } 
    names(y) <- grTarget$Name 
    y[TargetToRemove] <- NULL 
    GroupPatient[[j]] <- y 
} 
names(GroupPatient) <- GroupOfInterest 
 
# Calculate mean for all patients 
GroupPatientMean <- list() 
for (j in seq(GroupOfInterest)) { 
    x <- as.data.frame(lapply(GroupPatient[[j]], colMeans)) 
    GroupPatientMean[[j]] <- x 
} 
 
# Calculate standard error for all patients 
GroupPatientStdError <- list() 
for (j in seq(GroupOfInterest)) { 
    for (i in 1:nrow(Pheno[Pheno$Disease %in% 
GroupOfInterest, ])) x <- lapply(GroupPatient[[j]], 
std.error) 
    x <- do.call(cbind, x) 
    x[is.na(x)] <- 0 
    GroupPatientStdError[[j]] <- x 
} 




# For GroupOfControl (i.e. Control) 
GroupControl <- list() 
for (i in seq(grTarget)) { 
    x <- meth.score[[i]][Pheno$Disease %in% GroupOfControl] 
    GroupControl[[i]] <- x 
} 
names(GroupControl) <- grTarget$Name 
GroupControl[TargetToRemove] <- NULL 
 
# Compute mean of control group, grand mean of control group 
and standard deviation 
GroupControlMean <- lapply(GroupControl, colMeans) 
 
GroupControlMean <- do.call(cbind, GroupControlMean) 
GroupControlGrandMean <- 
as.data.frame(colMeans(GroupControlMean)) 
rownames(GroupControlGrandMean) <- FinalTarget 
 
library("matrixStats") 
GroupControlSd <- as.data.frame(colSds(GroupControlMean)) 
rownames(GroupControlSd) <- FinalTarget 
 
# Create data.list table with 'patient.Mean', 
'patient.StdError', 'control.GrandMean' and 
'control.Stdeviation' 
DataMI.P <- list() 
for (j in seq(GroupOfInterest)) { 
    for (i in 1:length(FinalTarget)) { 
        y <- cbind(GroupPatientMean[[j]][, i], 
GroupPatientStdError[[j]][, i], GroupControlGrandMean[i, ], 
GroupControlSd[i, ]) 
        colnames(y) <- c("patient.Mean", "patient.StdError", 
"control.GrandMean", "control.Stdeviation") 
        DataMI.P[[i]] <- as.data.frame(y) 




names(DataMI.P) <- FinalTarget 
 
#### Compute hypomethylation (i.e. LOM) and hypermethylation 
(i.e. GOM) in patient group. 
#### Standard deviation threshold: cf. nbSd variable above. 
#### 60% of interrogated probes need to be over or below Sdev 
threshold 
dir.create(paste(resultDir, 
"Methylation.analysis/epimutation/", sep = ""), showWarnings 
= FALSE, recursive = TRUE) 
setwd(paste(resultDir, "Methylation.analysis/epimutation/", 
sep = "")) 
 
PatientEpimut <- list() 
y <- data.frame(matrix(NA, nrow = nrow(Pheno[Pheno$Disease 
%in% GroupOfInterest, ]), ncol = 1)) 
for (i in 1:length(FinalTarget)) { 
    for (j in 1:nrow(Pheno[Pheno$Disease %in% 
GroupOfInterest, ])) { 
        for (k in 1:length(GroupOfInterest)) y[j, 1] <- 
ifelse((DataMI.P[[i]][j, 1] > DataMI.P[[i]][j, 3] + 
DataMI.P[[i]][j, 4] * nbSd & sum(GroupPatient[[k]][[i]][, j] 
> DataMI.P[[i]][j, 3] + DataMI.P[[i]][j, 
            4] * nbSd) * 100/length(GroupPatient[[k]][[i]][, 
j]) > 60), 1, ifelse((DataMI.P[[i]][j, 1] < DataMI.P[[i]][j, 
3] - DataMI.P[[i]][j, 4] * nbSd & 
sum(GroupPatient[[k]][[i]][, j] < 
            DataMI.P[[i]][j, 3] - DataMI.P[[i]][j, 4] * nbSd) 
* 100/length(GroupPatient[[k]][[i]][, j]) > 60), -1, 0)) 
        PatientEpimut[[i]] <- as.data.frame(y) 
    } 
} 




PatientEpimut <- do.call(cbind, PatientEpimut) 
rownames(PatientEpimut) <- rownames(DataMI.P[[1]]) 
colnames(PatientEpimut) <- FinalTarget 
tmpPatientMap <- PatientEpimut 
tmpPatientMap[tmpPatientMap == -1] <- "LOM" 
tmpPatientMap[tmpPatientMap == 1] <- "GOM" 
tmpPatientMap[tmpPatientMap == 0] <- "." 
write.table(tmpPatientMap, paste(resultDir, 
"Methylation.analysis/epimutation/", "Patient_epimut.txt", 




# Subset control group and define hypo/hypermethylated loci 
in control group For GroupOfControl (ie. Control) 
GroupControl <- list() 
for (i in seq(grTarget)) { 
    x <- meth.score[[i]][Pheno$Disease %in% GroupOfControl] 
    GroupControl[[i]] <- x 
} 
names(GroupControl) <- grTarget$Name 
GroupControl[TargetToRemove] <- NULL 
 
# Compute mean of control group, grand mean of control group 
and standard deviation 
GroupControlMean <- lapply(GroupControl, colMeans) 
GroupControlMean <- do.call(cbind, GroupControlMean) 











GroupControlStdError <- lapply(GroupControl, std.error) 
GroupControlStdError <- do.call(cbind, GroupControlStdError) 
GroupControlStdError <- as.data.frame(GroupControlStdError) 
GroupControlStdError[is.na(GroupControlStdError)] <- 0 
 
# Create data.list table to compute 3 standard deviations 
DataMI.C <- list() 
for (j in seq(GroupOfControl)) { 
    for (i in 1:length(FinalTarget)) { 
        y <- cbind(GroupControlMean[, i], 
GroupControlStdError[, i], GroupControlGrandMean[i, ], 
GroupControlSd[i, ]) 
        colnames(y) <- c("control.Mean", "control.StdError", 
"control.GrandMean", "control.Stdeviation") 
        DataMI.C[[i]] <- as.data.frame(y) 
    } 
} 
names(DataMI.C) <- FinalTarget 
 
#### Create list to store data 
#### Determine if Control individual are epimutated 
ControlEpimut <- list() 
y <- data.frame(matrix(NA, nrow = nrow(Pheno[Pheno$Disease 
%in% GroupOfControl, ]), ncol = 1)) 
for (i in 1:length(FinalTarget)) { 
    for (j in 1:nrow(Pheno[Pheno$Disease %in% GroupOfControl, 
])) { 
        y[j, 1] <- ifelse((DataMI.C[[i]][j, 1] > 
DataMI.C[[i]][j, 3] + DataMI.C[[i]][j, 4] * nbSd & 
sum(GroupControl[[i]][, j] > DataMI.C[[i]][j, 3] + 
DataMI.C[[i]][j, 4] * nbSd) * 100/length(GroupControl[[i]][, 
            j]) > 60), 1, ifelse((DataMI.C[[i]][j, 1] < 
DataMI.C[[i]][j, 3] - DataMI.C[[i]][j, 4] * nbSd & 
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sum(GroupControl[[i]][, j] < DataMI.C[[i]][j, 3] - 
DataMI.C[[i]][j, 4] * nbSd) * 
            100/length(GroupControl[[i]][, j]) > 60), -1, 0)) 
        ControlEpimut[[i]] <- y 
    } 
} 
names(ControlEpimut) <- FinalTarget 
 
ControlEpimut <- do.call(cbind, ControlEpimut) 
rownames(ControlEpimut) <- rownames(DataMI.C[[1]]) 
colnames(ControlEpimut) <- FinalTarget 
tmpControltMap <- ControlEpimut 
tmpControltMap[tmpControltMap == -1] <- "LOM" 
tmpControltMap[tmpControltMap == 1] <- "GOM" 
tmpControltMap[tmpControltMap == 0] <- "." 
write.table(tmpControltMap, paste(resultDir, 
"Methylation.analysis/epimutation/", "Control_epimut.txt", 
sep = ""), sep = "\t", quote = FALSE) 
rm(tmpControltMap) 
 
#### Create contingency table (2x2) for hypomethylated and 
hypermethylated loci in cases versus controls 
#### Calculate Fisher's exact test P-value and FDR P-value 
# Create hypomethylation contingency table 
hypo <- list() 
 
for (i in 1:length(PatientEpimut)) { 
    case.hypo <- data.frame(Hypo = sum(PatientEpimut[, i] == 
-1), Other = sum(PatientEpimut[, i] != -1)) 
    control.hypo <- data.frame(Hypo = sum(ControlEpimut[, i] 
== -1), Other = sum(ControlEpimut[, i] != -1)) 
    o <- rbind(case.hypo, control.hypo) 
    rownames(o) <- c("Cases", "Controls") 




    hypo[[i]] <- o 
} 
names(hypo) <- FinalTarget 
rm(case.hypo, control.hypo, o) 
 
# Perform Fisher's exact test and FDR correction for 
hypomethylation observations 
hypoFisherTest <- data.frame(matrix(NA, nrow = 
length(FinalTarget), ncol = 1)) 
for (i in 1:length(hypo)) { 
    x <- fisher.test(hypo[[i]]) 
    hypoFisherTest[i, ] <- x 
} 
colnames(hypoFisherTest) <- "p.value" 
rownames(hypoFisherTest) <- names(hypo) 
 
hypoFisherTest <- cbind(hypoFisherTest, 
p.adjust(hypoFisherTest$p.value, method = "BH")) 




sep = ""), sep = "\t", quote = FALSE) 
 
# Create hypermethylation contingency table 
hyper <- list() 
 
for (i in 1:length(PatientEpimut)) { 
    case.hyper <- data.frame(Hypo = sum(PatientEpimut[, i] == 
1), Other = sum(PatientEpimut[, i] != 1)) 
    control.hyper <- data.frame(Hypo = sum(ControlEpimut[, i] 
== 1), Other = sum(ControlEpimut[, i] != 1)) 
    o <- rbind(case.hyper, control.hyper) 
    rownames(o) <- c("Cases", "Controls") 




    hyper[[i]] <- o 
} 
names(hyper) <- FinalTarget 
rm(case.hyper, control.hyper, o) 
 
# Perform Fisher's exact test and FDR correction for 
hypermathylation observations 
hyperFisherTest <- data.frame(matrix(NA, nrow = 
length(FinalTarget), ncol = 1)) 
for (i in 1:length(hyper)) { 
    x <- fisher.test(hyper[[i]]) 
    hyperFisherTest[i, ] <- x 
} 
colnames(hyperFisherTest) <- "p.value" 
rownames(hyperFisherTest) <- names(hyper) 
 
hyperFisherTest <- cbind(hyperFisherTest, 
p.adjust(hyperFisherTest$p.value, method = "BH")) 




sep = ""), sep = "\t", quote = FALSE) 
 
##### Correct epimutation following hypo/hyper FDR p.value 
PatientEpimutCorrected <- list() 
for (i in 1:length(PatientEpimut)) { 
    h <- ifelse((PatientEpimut[i] == -1 & hypoFisherTest[i, 
2] < 0.05), -1, ifelse((PatientEpimut[i] == 1 & 
hyperFisherTest[i, 2] < 0.05), 1, 0)) 





PatientEpimutCorrected <- as.data.frame(do.call(cbind, 
PatientEpimutCorrected)) 
colnames(PatientEpimutCorrected) <- FinalTarget 





R code used for bump hunting in BWS_IC1. Similar code was used for other 
disease group. 
 
# Import data in CSV file format 
> library("sqldf") 
> Data = read.csv.sql("/path/to/data.csv", header = T) 
rownames(Data) <- gsub("\"", "", Data$X) 
> Data[1] <- NULL 
# Convert data in Beta value if necessary 
> library("lumi") 
> Data <- as.data.frame(m2beta(Data))  #Comment this line if 
data is b-value and not m-value 
# Import phenotype file in tab separated file format) 
> Pheno <- read.table("/path/to/phenotype.txt", header = T, 
sep="\t") 
# Set and create result directory folder 
> resultDir <- "/path/to/result/directory/" 
> dir.create(resultDir, showWarnings = FALSE, recursive = 
TRUE) 
# Import 450K annotation file and reorder methylation data 
> library("FDb.InfiniumMethylation.hg19") 
> hm450 <- as.data.frame(get450k()) 
> hm450 <- hm450[rownames(hm450) %in% rownames(Data), ] 
> hm450 <- hm450[order(hm450$seqnames, hm450$probeTarget), ] 
> Data.2 <- as.data.frame(Data[match(rownames(Data), 
rownames(hm450)), ]) 
# Subset data for bumphunting: cases (e.g. BWS_IC1 patients) 
versus controls (e.g. normal indivuals) 
> DataSubset <- Data.2[colnames(Data.2) %in% 




# Subset phenotype for bumphunting: cases (e.g. BWS_IC1
 patients) versus controls (e.g. normal indivuals) 
> PhenoSubset <- Pheno[Pheno$Sample_Group %in% c("BWS_IC1",
 "Control"), ] 
> PhenoSubset <- PhenoSubset[, -c(6, 5, 4, 2)] 
> PhenoSubset$Sample_Name <- factor(PhenoSubset$Sample_Name,
 levels = unique(PhenoSubset$Sample_Name)) 
> PhenoSubset$Sample_Group <- 
factor(PhenoSubset$Sample_Group, levels = 
unique(PhenoSubset$Sample_Group)) 
# DMR hunting 
> library("bumphunter") 
# Create cluster for bumphunting 
> cl <- clusterMaker(hm450$seqnames, hm450$probeTarget, 
maxGap = 300) 
# Enable multicore 
> library("doParallel") 
> registerDoParallel(cores = 10) 
# Create design matrix for bumphunter 
> designMatrix <- model.matrix(~as.factor(Sample_Group), data 
= PhenoSubset) 
# Perform bump hunting with multicores enabled, cutoff 
difference: 15%, permutation: 1000, smooth function enabled) 
> bumps <- bumphunter(object = as.matrix(DataSubset), design 
= > designMatrix, chr = hm450$seqnames, pos = 
hm450$probeTarget, cluster = cl, coef = 2, cutoff = 0.15, B = 
1000, maxGap = 300, permutations = TRUE, smooth = TRUE, 
smoothFunction = loessByCluster, useWeights = TRUE) 
# Save bumps 
> bumps <- bumps$table 
> write.table(bumps, paste(resultDir, "Bumps.txt", sep=""), 





Shell script used for the trimming, alignment and methylation calling of bisulfite 





### Script for trimming, alignment (hg38, hg38, rDNA) and 
methylation calling ### 
### Need to be executed in RAW folder ### 
#############################################################
#################### 
#create samples.txt file 
> echo create samples name file 
> ls *_L001_R1_001.fastq.gz > samples.txt 
> vim -c "%s/_L001_R1_001.fastq.gz//g|wq" samples.txt 
#Trimming, alignment and non-directional BS-seq library 
> echo trimming 
> mkdir ../trimmed &> /dev/null 
> for i in `cat samples.txt`; do trim_galore --paired --
clip_R2 3 ${i}_L001_R1_001.fastq.gz ${i}_L001_R2_001.fastq.gz 




#Align to hg38 
> echo align to hg38 
> mkdir -p ../hg38/hg38_aligned &> /dev/null 
> for i in `cat samples.txt`; do bismark --bowtie2 --
non_directional --bam --output_dir ../hg38/hg38_aligned --
temp_dir ../temp --multicore 10 /media/Sasha/Resources/hg38/ 
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-1 ../trimmed/${i}_L001_R1_001_val_1.fq.gz -2 
../trimmed/${i}_L001_R2_001_val_2.fq.gz &> /dev/null 
> done 
 
> echo methylation call 
> mkdir -p ../hg38/hg38_methCall &> /dev/null 
> for i in `cat samples.txt`; do 
bismark_methylation_extractor --bedGraph --p --merge_non_CpG 
--report --output ../hg38/hg38_methCall --multicore 10 --gzip 
../hg38/hg38_aligned/${i}_L001_R1_001_val_1.fq.gz_bismark_bt2







R code used for the quantification of 5-mC at H19/IGF2:IG-DMR; 
KCNQ1OT1:TSS-DMR and IGS-rDNA in each sample. 
 
## Script to quantify methylation in target regions (ie. DMRs 
or IGS-rDNA) 
## 












temp = list.files(pattern="*bismark.cov") 
#get sample name 
sample_name <- sapply(strsplit(temp, "_"), "[", 1) 
sample_name <- as.factor(sample_name) 
#read all table in the folder and store them in a list 




#Convert methylation call file into GenomicRanges 
for (i in 1:length(methCall)) { 







names(methCall) <- sample_name 
 
#Import target file and convert to GenomicRanges 
target <- read.table("../hg38_target", sep="\t", header=F) 
target <- GRanges(target$V1, IRanges(target$V2, target$V3, 
names=target$V4)) 
 
#Find overlap between methylation call file and target file 
for all samples and convert into data frame object 
methSubset <- list() 
for (i in 1:length(methCall)) { 
  methSubset[[i]] <- subsetByOverlaps(methCall[[i]], target) 
  #Add DMRs names in overlap object 
  overlaps_tmp <- findOverlaps(methCall[[i]],target) 
  match_hit <- 
data.frame(names(target)[subjectHits(overlaps_tmp)], 
stringsAsFactors=F) 
  names(match_hit) <- "DMR" 
  mcols(methSubset[[i]]) <- c(mcols(methSubset[[i]]), 
match_hit) 
  methSubset[[i]] <- as.data.frame(methSubset[[i]]) 
  methSubset[[i]] <- 
methSubset[[i]][!rowSums(data.frame(methSubset[[i]]$countMeth
, methSubset[[i]]$countUnmeth)) < 1000,] 
} 
names(methSubset) <- sample_name 
 
#Calculate mean and std.error for samples at DMRs 
x <- data.frame(matrix(ncol = 4, nrow = length(target))) 
y <- list() 
for (i in 1:length(methSubset)) { 
  for (j in 1:length(target)) { 
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  y[[i]] <- x 
}} 
 
methAnalysis <- do.call(rbind,y) 
methAnalysis <- data.frame(as.factor(methAnalysis[,1]), 
as.factor(methAnalysis[,2]), as.numeric(methAnalysis[,3]), 
as.numeric(methAnalysis[,4])) 
colnames(methAnalysis) <- c("sample", "locus", "mean", 
"std.error") 
 
sample.order <- c("0meth", "25meth", "50meth", "75meth", 
"100meth", "sample01", " sample02", " sample03", "sample04") 
 
#Barplot methylation level 
dir.create("result", showWarnings = FALSE, recursive = TRUE) 
setwd("result") 
for (i in 1:length(target)) { 
q <- ggplot(methAnalysis[methAnalysis$locus == 
names(target[i]),], aes(x=sample, y=mean)) + 
  geom_bar(position=position_dodge(), stat="identity", 
fill="#FF9999", colour="black", size=.3) + 
  geom_errorbar(aes(ymin=mean-std.error, 
ymax=mean+std.error), size=1, width=.2, 
position=position_dodge(.9)) + 
  ggtitle(paste("Methylation index at", 
names(target[i]),"\nAverage nb CpG:",round(sum(do.call(rbind, 
methSubset)$locus== 
names(target[i]))/length(sample_name),0))) + 
  ylab('Methylation level (%)') + 
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  theme(panel.grid.minor.y = element_blank()) + 
  theme(plot.title=element_text(face="bold", hjust=0.5)) + 
  theme(axis.text.x = element_text(angle = 45, hjust=1, face 
= "bold", colour = "black")) + 
  theme(axis.text.y = element_text(face = "bold", colour = 
"black")) + 
  theme(axis.title.x = element_blank()) + 
  scale_y_continuous(limits=c(0,110), expand = c(0, 0)) + 
  scale_x_discrete(limits = sample.order) 
ggsave(filename=paste("MI at_", names(target[i]), ".tiff", 
sep=""), plot=q, dpi=600, compression="lzw") 
} 
############################# 
## FOR IGS-rDNA anaylsis ONLY 
############################# 
#import file folder 
setwd("rDNA/rDNA_methCall") 
temp = list.files(pattern="*bismark.cov") 
#get sample name 
sample_name <- sapply(strsplit(temp, "_"), "[", 1) 
sample_name <- as.factor(sample_name) 
#read all table in the folder and store them in a list 




#Re-name column name in methCall object and remove CpG with 
low count reads (ie. total < 1000) 
for (i in 1:length(methCall)) { 
  colnames(methCall[[i]]) <- c("chr", "start", "end", "meth", 
"countMeth", "countUnmeth") 
  methCall[[i]] <- 
methCall[[i]][!rowSums(data.frame(methCall[[i]]$countMeth, 




names(methCall) <- sample_name 
 
 
#Calculate mean and std.error for samples at DMRs 
x <- data.frame(matrix(ncol = 4, nrow = 1)) 
y <- list() 
for (i in 1:length(methCall)) { 
  x <- c(sample=names(methCall[i]), locus="IGS-rDNA", 
mean=mean(methCall[[i]]$meth), 
std.error=std.error(methCall[[i]]$meth)) 
  y[[i]] <- x 
} 
 
methAnalysis <- do.call(rbind,y) 
methAnalysis <- data.frame(as.factor(methAnalysis[,1]), 
as.factor(methAnalysis[,2]), as.numeric(methAnalysis[,3]), 
as.numeric(methAnalysis[,4])) 
colnames(methAnalysis) <- c("sample", "locus", "mean", 
"std.error") 
 
sample.order <- c("0meth", "25meth", "50meth", "75meth", 
"100meth", "sample01", " sample02", " sample03", "sample04") 
#Barplot methylation level 
dir.create("result", showWarnings = FALSE, recursive = TRUE) 
setwd("result") 
q <- ggplot(methAnalysis, aes(x=sample, y=mean)) + 
  geom_bar(position=position_dodge(), stat="identity", 
fill="#FF9999", colour="black", size=.3) + 
  geom_errorbar(aes(ymin=mean-std.error, 
ymax=mean+std.error), size=1, width=.2, 
position=position_dodge(.9)) + 
  ggtitle(paste("Methylation index at IGS-rDNA", "\nAverage 
nb CpG:",round(nrow(do.call(rbind, 
methCall))/length(sample_name),0))) + 
  ylab('Methylation level (%)') + 
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  theme(panel.grid.minor.y = element_blank()) + 
  theme(plot.title=element_text(face="bold", hjust=0.5)) + 
  theme(axis.text.x = element_text(angle = 45, hjust=1, face 
= "bold", colour = "black")) + 
  theme(axis.text.y = element_text(face = "bold", colour = 
"black")) + 
  theme(axis.title.x = element_blank()) + 
  scale_y_continuous(limits=c(0,110), expand = c(0, 0)) + 
  scale_x_discrete(limits = sample.order) 
ggsave(filename=paste("MI at IGS-rDNA", ".tiff", sep=""), 
plot=q, dpi=600, compression="lzw") 
 






R code used for the PCR amplification bias correction. 
 
#Import data 
Data <- read.table("/Users/NoName/Desktop/test.txt", 
sep='\t', header=T, row.names = 1) 
 
#Create empty DataCorrected object 
DataCorrected <- data.frame(matrix(ncol = length(Data), nrow= 
nrow(Data))) 
rownames(DataCorrected) <- rownames(Data) 
colnames(DataCorrected) <- colnames(Data) 
 
#Theoric values 
ytheo <- c(0, 25, 50, 75, 100) 
xtheo <- c(0, 25, 50, 75, 100) 
 
for (i in 1:nrow(Data)){ 
#Standard Curve 
yobserved <- as.numeric(Data[i,1:5]) 
xexpected <- c(0, 25, 50, 75, 100) 
 
### Methylation correction with cubic polynomiale regression 
#Model 
fit1 <- lm(xexpected ~ poly(yobserved,3, raw = TRUE)) 
#Correct standard curve 
SCcorrected <- predict(fit1,data.frame(yobserved)) 
#Correct Samples 
Samples <- as.numeric(Data[i,6:length(Data)]) 
SamplesCorrected <- predict(fit1, 
data.frame(yobserved=Samples)) 
SamplesCorrected[SamplesCorrected<0] <- 0 
#Store corrected values 
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DataCorrected[i,] <- c(SCcorrected,SamplesCorrected) 
### 
 
### Plot standard curve before and after correction 
###BEFORE correction 
#bias 
bias <- (yobserved * (100 - xexpected))/(xexpected * (100 - 
yobserved)) 
bias[bias==Inf] <- 0 
bias[bias==-Inf] <- 0 
bias[is.na(bias)] <- 0 
bias <- bias[!bias==0] 
MeanBias1 <- mean(bias) 
#predicted curve for uncorrected standard curve 
q <- seq(from=0, to=100, by=0.1) 
fit2 <- lm(yobserved ~ poly(xexpected,3, raw = TRUE)) 
R.SQUARE1 <- summary(fit2)$r.squared 




bias <- (SCcorrected * (100 - xexpected))/(xexpected * (100 - 
SCcorrected)) 
bias[bias==Inf] <- 0 
bias[bias==-Inf] <- 0 
bias[is.na(bias)] <- 0 
bias <- bias[!bias==0] 
MeanBias2 <- mean(bias) 
#predicted curve for uncorrected standard curve 
q <- seq(from=0, to=100, by=0.1) 
fit3 <- lm(SCcorrected ~ poly(xexpected,3, raw = TRUE)) 
R.SQUARE2 <- summary(fit3)$r.squared 





pdf(paste(rownames(Data)[i],"_bias.pdf", sep=""), height = 5, 
width = 10) 
par(mfrow=c(1,2)) 
plot(yobserved~xexpected, col="red", ylim=c(0,100), 
xlim=c(0,100), xlab="Actual methylation 
(%)",ylab="Uncorrected estimated methylation (%)", 
main="Standard curve before correction") 
lines(x=q, y=pred1, col="red") 
lines(ytheo~xtheo, lty=2) 
text(x=10,y=98,labels = paste("b=", 
round(MeanBias1,digits=2), sep=""), col="red") 
text(x=80,y=0, labels= bquote(R^2 == 
.(round(R.SQUARE1,digits=3)))) 
 
plot(SCcorrected~xexpected, col="red", ylim=c(0,100), 
xlim=c(0,100), xlab="Actual methylation (%)",ylab="Corrected 
estimated methylation (%)",  main="Standard curve after 
correction") 
lines(x=q, y=pred2, col="red") 
lines(ytheo~xtheo, lty=2) 
text(x=10,y=98,labels = paste("b=", 
round(MeanBias2,digits=2), sep=""), col="red") 
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Unmethylated cytosine residues are deaminated to uracil whereas methylated 
cytosine residues are unaffected. After polymerase chain reaction and sequencing, 
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